0000014272-14-000172.txt : 20140429 0000014272-14-000172.hdr.sgml : 20140429 20140429085058 ACCESSION NUMBER: 0000014272-14-000172 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 4 CONFORMED PERIOD OF REPORT: 20140429 ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20140429 DATE AS OF CHANGE: 20140429 FILER: COMPANY DATA: COMPANY CONFORMED NAME: BRISTOL MYERS SQUIBB CO CENTRAL INDEX KEY: 0000014272 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 220790350 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-01136 FILM NUMBER: 14791434 BUSINESS ADDRESS: STREET 1: 345 PARK AVE CITY: NEW YORK STATE: NY ZIP: 10154 BUSINESS PHONE: 2125464000 MAIL ADDRESS: STREET 1: 345 PARK AVE CITY: NEW YORK STATE: NY ZIP: 10154 FORMER COMPANY: FORMER CONFORMED NAME: BRISTOL MYERS CO DATE OF NAME CHANGE: 19891012 8-K 1 q12014earningsrelease8-k.htm 8-K Q1 2014 Earnings Release 8-K


 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
 
FORM 8-K
 
 
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act Of 1934
Date of Report (Date of earliest event reported): April 29, 2014
 
 
BRISTOL-MYERS SQUIBB COMPANY
(Exact Name of Registrant as Specified in its Charter)
 
 
 
 
 
 
 
 
Delaware
 
1-1136
 
22-0790350
(State or Other
Jurisdiction of
Incorporation)
 
(Commission File
Number)
 
(IRS Employer
Identification
Number)
345 Park Avenue
New York, NY, 10154
(Address of Principal Executive Office)
Registrant’s telephone number, including area code: (212) 546-4000
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
 
¨
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
¨
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
¨
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
¨
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
 
 









Item 2.02.
Results of Operations and Financial Condition.

On April 29, 2014, Bristol-Myers Squibb Company (the “Company”) issued a press release announcing its financial results for the first quarter of 2014. A copy of the press release is furnished as Exhibit 99.1 to this report and incorporated herein by reference. Also furnished and incorporated by reference as Exhibit 99.2 is certain supplemental information posted on the Company’s website at www.bms.com.

 
Item 9.01.
Financial Statements and Exhibits.

(d) Exhibits.
 
 
99.1
  
Press release of Bristol-Myers Squibb Company dated April 29, 2014.
 
 
99.2
  
Certain supplemental information posted on Bristol-Myers Squibb Company’s website at www.bms.com not included in the press release.








































SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 


BRISTOL-MYERS SQUIBB COMPANY


Dated: April 29, 2014                By:       /s/Sandra Leung________________    
Name: Sandra Leung
Title: General Counsel and Corporate Secretary



















































EXHIBIT INDEX
 
 
 
 
Exhibit No.
  
Description
 
 
99.1
  
Press release of Bristol-Myers Squibb Company dated April 29, 2014.
 
 
99.2
  
Certain supplemental information posted on Bristol-Myers Squibb Company’s website at www.bms.com not included in the press release.




 EX-99.1 2 q12014ex991.htm PRESS RELEASE OF BRISTOL-MYERS SQUIBB COMPANY DATED APRIL 29, 2014 Q1 2014 Ex. 99.1

Exhibit 99.1

Bristol-Myers Squibb Reports First Quarter 2014 Financial Results

•
Posts First Quarter GAAP EPS of $0.56 and Non-GAAP EPS of $0.46
•
Announces Plans to Initiate a Rolling Submission for nivolumab in Third-Line Squamous Cell Non-Small Cell Lung Cancer Based on Study 063, to be Completed by Year-end
•
Achieved Important Regulatory Milestones for Eliquis, daclatasvir/asunaprevir and Diabetes Franchise
•
Acquires iPierian, Inc., a privately held biotechnology company
•
Adjusts 2014 GAAP EPS and Non-GAAP EPS Guidance Ranges to $1.70 - $1.80

(NEW YORK, April 29, 2014) - Bristol-Myers Squibb Company (NYSE: BMY) today reported financial results for the first quarter of 2014 and adjusted GAAP and non-GAAP guidance for 2014. The first quarter was highlighted by the achievement of important regulatory milestones for Eliquis, daclatasvir/asunaprevir and the diabetes franchise. The company also completed the sale of its diabetes business to AstraZeneca, receiving $3.3 billion in closing and milestone payments during the quarter. In addition, the company announced that it plans to initiate a rolling submission for nivolumab in third-line
squamous cell non-small cell lung cancer based on Study 063, which it expects to complete by year-end.

“In the first quarter, we again delivered strong financial results, demonstrating the strength of our core brands and our focus on operational execution,” said Lamberto Andreotti, chief executive officer, Bristol-Myers Squibb. “We continue to build a foundation for long-term success by investing across our portfolio, developing our innovative pipeline and advancing our evolution to a diversified specialty care BioPharma leader.”
 
First Quarter
$ amounts in millions, except per share amounts
2014
 
2013
 
Change
Total Revenues
$
3,811

 
$
3,831

 
(1)%
GAAP Diluted EPS
0.56

 
0.37

 
51%
Non-GAAP Diluted EPS
0.46

 
0.41

 
12%




1


FIRST QUARTER FINANCIAL RESULTS
•
Bristol-Myers Squibb posted first quarter 2014 revenues of $3.8 billion, a decrease of 1% compared to the same period a year ago. Excluding the recently divested Diabetes Alliance, global revenues increased 5% to $3.6 billion.

•
U.S. revenues decreased 10% to $1.8 billion in the quarter compared to the same period a year ago. International revenues increased 10% to $2.0 billion.

•
Gross margin as a percentage of revenues was 74.6% in the quarter compared to 72.3% in the same period a year ago.

•
Marketing, selling and administrative expenses decreased 4% to $957 million in the quarter.

•
Advertising and product promotion spending decreased 14% to $163 million in the quarter.

•
Research and development expenses increased 2% to $946 million in the quarter.

•
The effective tax rate on earnings before income taxes was 5.0% in the quarter, compared to 7.6% in the first quarter last year. 

•
The company reported net earnings attributable to Bristol-Myers Squibb of $937 million, or $0.56 per share, in the quarter compared to $609 million, or $0.37 per share, a year ago.

•
The company reported non-GAAP net earnings attributable to Bristol-Myers Squibb of $766 million, or $0.46 per share, in the first quarter, compared to $679 million, or $0.41 per share, for the same period in 2013. An overview of specified items is discussed under the “Use of Non-GAAP Financial Information” section.

•
Cash, cash equivalents and marketable securities were $10.6 billion, with a net cash position of $3.0 billion, as of March 31, 2014.


2



FIRST QUARTER STRATEGIC UPDATE

In February, the company completed the sale of its global diabetes business, excluding China, to AstraZeneca. Bristol-Myers Squibb received from AstraZeneca a payment of approximately $2.7 billion at closing and a subsequent milestone payment of $600 million for the U.S. approval of Farxiga™ (dapagliflozin). The company also received $100 million in the second quarter for the approval of dapagliflozin in Japan. Under terms of the agreement, Bristol-Myers Squibb will potentially receive additional regulatory- and sales-based milestone payments from AstraZeneca of up to $700 million, royalty payments based on net sales through 2025 and additional payments if and when certain assets are subsequently transferred.
The closing of the transaction as it relates to China remains subject to the satisfaction of certain conditions in the Sino-American Shanghai Squibb Pharmaceutical Company joint venture agreement between Bristol-Myers Squibb China and its joint venture partners.

FIRST QUARTER PRODUCT AND PIPELINE UPDATE
Bristol-Myers Squibb’s global revenues in the first quarter included Sprycel, which grew 19%, Yervoy, which grew 18%, Orencia, which grew 13%, and Baraclude, which grew 11%. Global revenues for Eliquis were $106 million.

Nivolumab
•
In April, the company met with the U.S. Food and Drug Administration (FDA) regarding the results of Study 063, which evaluated nivolumab in third-line squamous cell non-small cell lung cancer, and plans to initiate a rolling submission for this indication based on Study 063 in the coming days. The company expects to complete the rolling submission by year-end.

Eliquis
•
In March, the company and its partner, Pfizer, announced that the FDA approved a Supplemental New Drug Application for Eliquis to reduce the risk of deep vein thrombosis (DVT), which may lead to pulmonary embolism (PE), in patients who have undergone hip or knee replacement surgery. DVT is a blood clot that forms in a large vein, usually in the lower leg, thigh or pelvis and can lead to a PE when a portion or all of a blood clot breaks off and travels to the lungs, blocking one or more blood vessels. A PE can lead to sudden death.


3


•
In March, the company and its partner, Pfizer, announced the results of a pre-specified subanalysis of the Phase III ARISTOTLE trial assessing the effect of blood pressure control on outcomes. The study showed that the results for stroke risk reduction for Eliquis versus warfarin were consistent with the overall ARISTOTLE study results, demonstrating that Eliquis reduced stroke or systemic embolism, caused fewer major bleeding events and reduced all-cause mortality as compared to warfarin, regardless of blood pressure control. The results also showed that poor blood pressure control was associated with a substantially higher risk of stroke or systemic embolism, independent of Eliquis or warfarin treatment. The data were presented at the American College of Cardiology’s 63rd Annual Scientific Session in Washington, D.C.

•
In February, the company and its partner, Pfizer, announced that results of a pre-specified subanalysis of the Phase III ARISTOTLE trial in relation to patient age were published in the European Heart Journal. The subanalysis found consistent results across age groups for reducing the risk of stroke and systemic embolism and reducing the risk of all-cause death with fewer bleeding events for Eliquis versus warfarin. Owing to the higher risk in older age (75 and older), the absolute benefit to patients with nonvalvular atrial fibrillation was greater with Eliquis in the older population.

Hepatitis C
•
In April, the company announced that it submitted New Drug Applications (NDAs) to the FDA for the investigational products daclatasvir (DCV), an NS5A replication complex inhibitor, and asunaprevir (ASV), an NS3 protease inhibitor. The data submitted in the NDAs support the use of DCV+ASV in patients with genotype 1b hepatitis C (HCV). The DCV NDA also seeks approval for use of this compound in combination with other agents for multiple genotypes. The submissions are subject to FDA review for acceptance for filing.

•
In April, at The International Liver Congress in London, the company announced the first Phase III results from the global HALLMARK Dual study investigating the all-oral, interferon- and ribavirin-free regimen of DCV+ASV among genotype 1b HCV patients. Results showed that the 24-week regimen achieved an overall sustained virologic response (a functional cure) 12 weeks after the end of treatment (SVR12) among treatment naïve (90%), peginterferon/ribavirin non-responder (82%), and peginterferon/ribavirin ineligible/intolerant (82%) patients, including

4


cirrhotic and non-cirrhotic patients (84% and 85%, respectively). In the study, the DCV+ASV regimen was generally well-tolerated.

•
In February, the company announced that the FDA has granted its investigational DCV+ASV dual regimen Breakthrough Therapy Designation for use as a combination therapy in the treatment of genotype 1b chronic HCV infection. The designation is based on data from the company’s ongoing Phase III clinical trial program evaluating the all-oral combination regimen of DCV+ASV without ribavirin.

HIV
•
In April, the company announced the submission of an NDA to the FDA for a fixed-dose combination of atazanavir sulfate, a protease inhibitor marketed as Reyataz, and cobicistat, an investigational pharmacokinetic enhancer, or boosting agent, that can increase the level of certain HIV-1 medicines in the blood and make them more effective. The company is seeking approval of the fixed-dose combination tablet for use in combination with other antiretroviral agents for the treatment of HIV-1 infection. Cobicistat is being developed by Gilead Sciences, Inc.

•
In March, at the 21st Conference on Retroviruses and Opportunistic Infections in Boston, the company presented 24-week Phase IIb data for its investigational compound, BMS-663068, that demonstrated similar response rates (HIV-1 RNA <50 c/mL) when compared to a boosted protease inhibitor, Reyataz, with ritonavir. Among HIV-1 infected treatment-experienced patients receiving BMS-663068, 69% to 80% had HIV-1 RNA levels of <50 c/mL (a measure indicating virus replication is undetectable), compared to 75% of patients taking Reyataz with ritonavir.

Diabetes
•
In March, following the company’s sale of its global diabetes business to AstraZeneca, the Japanese Ministry of Health, Labor and Welfare (MHLW) approved Forxiga® as a once-daily oral treatment for type 2 diabetes in Japan. The Forxiga® application was submitted to MHLW by Bristol-Myers Squibb K.K.
•
Also in March, the FDA approved the Bydureon® pen (exenatide extended-release for injectable suspension) 2 mg as an adjunct to diet and exercise to improve glycemic control in adults with

5


type 2 diabetes. The Bydureon® pen was developed by Amylin Pharmaceuticals as part of the company’s prior global diabetes collaboration with AstraZeneca.

•
In February, the FDA approved orphan drug Myalept™ (metreleptin for injection) as an adjunct to diet as replacement therapy for the treatment of complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy. Myalept™ was being developed by the Bristol-Myers Squibb-AstraZeneca collaboration at the time of the company’s sale of its global diabetes business to AstraZeneca and was among the products included in that sale. Bristol-Myers Squibb continues to provide AstraZeneca with development and regulatory support for Myalept™ pursuant to the company’s development agreement with AstraZeneca.

•
In January, the company and its partner, AstraZeneca, announced that the FDA approved Farxiga™ (dapagliflozin), a once-daily oral treatment indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Farxiga™ is marketed by AstraZeneca as Forxiga® outside the United States.

FIRST QUARTER BUSINESS DEVELOPMENT UPDATE

•
In April, the company announced its acquisition of iPierian, Inc., a privately held biotechnology company focused on the discovery and development of new treatments for Tauopathies, a class of neurodegenerative diseases associated with the pathological aggregation of Tau protein in the human brain. The acquisition of iPierian advances the company’s discovery strategy to pursue therapeutics for genetically defined diseases. The acquisition gives Bristol-Myers Squibb full rights to iPierian’s lead asset IPN007, an innovative preclinical monoclonal antibody that represents a promising new approach to treat progressive supranuclear palsy (PSP) and other Tauopathies, and has the potential to commence Phase 1 clinical trials by early 2015.
•
In April, the company and Samsung BioLogics increased the scope of their existing manufacturing agreement to have Samsung manufacture commercial drug substances and drug product for several Bristol-Myers Squibb biologic medicines at its manufacturing site in Incheon, South Korea.
•
In March, the company signed a collaboration agreement with Five Prime Therapeutics for the discovery, development and commercialization of immuno-oncology (I-O) therapies directed at targets identified in two undisclosed immune checkpoint pathways using Five Prime’s proprietary

6


target discovery platform. Bristol-Myers Squibb will leverage Five Prime’s platform to advance its existing I-O programs by identifying the most viable drug targets for continued research and development. Drug candidates developed against these new and existing targets may be studied either as single agents or in combination with existing or potential Bristol-Myers Squibb I-O therapies.

2014 FINANCIAL GUIDANCE

Bristol-Myers Squibb is adjusting its 2014 GAAP EPS guidance range to $1.70 - $1.80 from $1.75 - $1.90 and its non-GAAP EPS guidance range to $1.70 - $1.80 from $1.65 - $1.80. Both GAAP and non-GAAP guidance assume current exchange rates. Key 2014 non-GAAP guidance assumptions include:

•
Worldwide revenues between $15.2 billion and $15.8 billion.
•
Full-year gross margin as a percentage of revenues between 75% and 76%.
•
Advertising and promotion expense decreasing in the mid-teen-digit range.
•
Marketing, sales and administrative expenses decreasing in the mid-single-digit range.
•
Research and development expenses growing in the mid-single-digit range.
•
An effective tax rate of approximately 18%.

The financial guidance for 2014 excludes the impact of any potential future strategic acquisitions and divestitures, and any specified items that have not yet been identified and quantified. The non-GAAP 2014 guidance also excludes other specified items as discussed under “Use of Non-GAAP Financial Information.” Details reconciling adjusted non-GAAP amounts with the amounts reflecting specified items are provided in supplemental materials available on the company’s website.

Use of Non-GAAP Financial Information

This press release contains non-GAAP financial measures, including non-GAAP earnings and related earnings per share information. These measures are adjusted to exclude certain costs, expenses, significant gains and losses and other specified items. Among the items in GAAP measures but excluded for purposes of determining adjusted earnings and other adjusted measures are: restructuring and other exit costs; accelerated depreciation charges; IPRD and asset impairments; charges and recoveries
relating to significant legal proceedings; upfront, milestone and other licensing payments for in-licensing of products that have not achieved regulatory approval which are immediately expensed; net amortization of acquired intangible assets and deferred income related to Amylin; pension settlement charges; and significant tax events. This information is intended to enhance an investor’s overall understanding of the company’s past financial performance and prospects for the future. Non-GAAP financial measures

7


provide the company and its investors with an indication of the company’s baseline performance before items that are considered by the company not to be reflective of the company’s ongoing results. The company uses non-GAAP gross profit, non-GAAP marketing, selling and administrative expense, non-GAAP research and development expense, and non-GAAP other income and expense measures to set internal budgets, manage costs, allocate resources, and plan and forecast future periods. Non-GAAP effective tax rate measures are primarily used to plan and forecast future periods. Non-GAAP earnings and earnings per share measures are primary indicators the company uses as a basis for evaluating company performance, setting incentive compensation targets, and planning and forecasting of future periods. This information is not intended to be considered in isolation or as a substitute for financial measures prepared in accordance with GAAP.

Statement on Cautionary Factors

This press release contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 regarding, among other things, statements relating to goals, plans and projections regarding the company’s financial position, results of operations, market position, product development and business strategy. These statements may be identified by the fact that they use words such as "anticipate", "estimates", "should", "expect", "guidance", "project", "intend", "plan", "believe" and other words and terms of similar meaning in connection with any discussion of future operating or financial performance. Such forward-looking statements are based on current expectations and involve inherent risks and uncertainties, including factors that could delay, divert or change any of them, and could cause actual outcomes and results to differ materially from current expectations. These factors include, among other things, effects of the continuing implementation of governmental laws and regulations related to Medicare, Medicaid, Medicaid managed care organizations and entities under the Public Health Service 340B program, pharmaceutical rebates and reimbursement, market factors, competitive product development and approvals, pricing controls and pressures (including changes in rules and practices of managed care groups and institutional and governmental purchasers), economic conditions such as interest rate and currency exchange rate fluctuations, judicial decisions, claims and concerns that may arise regarding the safety and efficacy of in-line products and product candidates, changes to wholesaler inventory levels, variability in data provided by third parties, changes in, and interpretation of, governmental regulations and legislation affecting domestic or foreign operations, including tax obligations, changes to business or tax planning strategies, difficulties and delays in product development, manufacturing or sales including any potential future recalls, patent positions and the ultimate outcome of any litigation matter. These factors also include the company’s ability to execute successfully its strategic plans, including its business development strategy, the expiration of patents or data protection on certain products, and the impact and result of governmental investigations. There can be no guarantees with respect to pipeline compounds that future clinical studies will support the data described in this release, that the compounds will receive necessary regulatory approvals, or that they will prove to be commercially successful; nor are there guarantees that regulatory approvals will be sought, or sought within currently expected timeframes, or that contractual milestones will be achieved. For further details and a discussion of these and other risks and uncertainties, see the company's periodic reports, including the annual report on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K, filed with or furnished to the Securities and Exchange Commission. The company
undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.


8


Company and Conference Call Information

Bristol-Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. For more information, please visit http://www.bms.com or follow us on Twitter at http://twitter.com/bmsnews.

There will be a conference call on April 29, 2014, at 9 a.m. EDT during which company executives will review financial information and address inquiries from investors and analysts. Investors and the general public are invited to listen to a live webcast of the call at http://investor.bms.com or by dialing: 719-325-2331, confirmation code: 9920668. Materials related to the call will be available at the same website prior to the call.

For more information, contact: Laura Hortas, 609-252-4587, laura.hortas@bms.com, Communications; John Elicker, 609-252-4611, john.elicker@bms.com, Ranya Dajani, 609-252-5330, ranya.dajani@bms.com or Ryan Asay, 609-252-5020, ryan.asay@bms.com, Investor Relations.

Abilify is a trademark of Otsuka Pharmaceutical Co., Ltd.
Byetta®, Bydureon® and Myalept™ are trademarks of Amylin Pharmaceuticals, LLC and AstraZeneca Pharmaceuticals LP.
Erbitux is a trademark of ImClone LLC. ImClone Systems is a wholly-owned subsidiary of Eli Lilly and Company.
Farxiga™ and Forxiga® are trademarks of AstraZeneca AB.
All other brand names are registered trademarks of the company and/or one of its subsidiaries.



9





BRISTOL-MYERS SQUIBB COMPANY
SELECTED PRODUCTS
FOR THE THREE MONTHS ENDED MARCH 31, 2014 AND 2013
(Unaudited, dollars in millions)
 
 
Worldwide Revenues
 
U.S. Revenues
 
 
2014
 
2013
 
%
Change
 
2014
 
2013
 
%
Change
Three Months Ended March 31,
 
 
 
 
 
 
 
 
 
 
 
 
Key Products
 
 
 
 
 
 
 
 
 
 
 
 
Virology
 
 
 
 
 
 
 
 
 
 
 
 
Baraclude
 
$
406

 
$
366

 
11
 %
 
$
70

 
$
68

 
3
 %
Reyataz
 
344

 
361

 
(5
)%
 
176

 
193

 
(9
)%
Sustiva Franchise
 
319

 
387

 
(18
)%
 
228

 
251

 
(9
)%
Oncology
 
 
 
 
 
 
 
 
 
 
 
 
Erbitux
 
169

 
162

 
4
 %
 
158

 
158

 
—

Sprycel
 
342

 
287

 
19
 %
 
145

 
115

 
26
 %
Yervoy
 
271

 
229

 
18
 %
 
146

 
159

 
(8
)%
Neuroscience
 
 
 
 
 
 
 
 
 
 
 
 
Abilify
 
540

 
522

 
3
 %
 
325

 
328

 
(1
)%
Immunoscience
 
 
 
 
 
 
 
 
 
 
 
 
Orencia
 
363

 
320

 
13
 %
 
229

 
214

 
7
 %
Cardiovascular
 
 
 
 
 
 
 
 
 
 
 
 
Eliquis
 
106

 
22

 
**

 
61

 
17

 
**

 
 
 
 
 
 
 
 
 
 
 
 
 
Diabetes Alliance
 
179

 
358

 
(50
)%
 
114

 
292

 
(61
)%
 
 
 
 
 
 
 
 
 
 
 
 
 
Mature Products and All Other
 
772

 
817

 
(6
)%
 
113

 
176

 
(36
)%
 
 
 
 
 
 
 
 
 
 
 
 
 
Total
 
3,811

 
3,831

 
(1
)%
 
1,765

 
1,971

 
(10
)%
 
 
 
 
 
 
 
 
 
 
 
 
 
Total Excluding Diabetes Alliance
 
3,632

 
3,473

 
5
 %
 
1,651

 
1,679

 
(2
)%
 
**
In excess of 100%




10





BRISTOL-MYERS SQUIBB COMPANY
CONSOLIDATED STATEMENTS OF EARNINGS
FOR THE THREE MONTHS ENDED MARCH 31, 2014 AND 2013
(Unaudited, dollars and shares in millions except per share data)
 
 
 
Three Months Ended 
 March 31,
 
 
2014
 
2013
Net product sales
 
$
2,807

 
$
2,957

Alliance and other revenues
 
1,004

 
874

Total Revenues
 
3,811

 
3,831

 
 
 
 
 
Cost of products sold
 
968

 
1,063

Marketing, selling and administrative
 
957

 
994

Advertising and product promotion
 
163

 
189

Research and development
 
946

 
930

Other (income)/expense
 
(208
)
 
(19
)
Total Expenses
 
2,826

 
3,157

 
 
 
 
 
Earnings Before Income Taxes
 
985

 
674

Provision for income taxes
 
49

 
51

 
 
 
 
 
Net Earnings
 
936

 
623

Net Earnings/(Loss) Attributable to Noncontrolling Interest
 
(1
)
 
14

Net Earnings Attributable to BMS
 
$
937

 
$
609

 
 
 
 
 
Earnings per Common Share
 
 
 
 
Basic
 
$
0.57

 
$
0.37

Diluted
 
$
0.56

 
$
0.37

 
 
 
 
 
Average Common Shares Outstanding:
 
 
 
 
Basic
 
1,652

 
1,638

Diluted
 
1,666

 
1,655

 
 
 
 
 
Other (Income)/Expense
 
 
 
 
 
 
 
 
 
Interest expense
 
$
54

 
$
50

Investment income
 
(23
)
 
(25
)
Provision for restructuring
 
21

 
33

Litigation charges
 
29

 
—

Equity in net income of affiliates
 
(36
)
 
(36
)
Gain on sale of product lines, businesses and assets
 
(259
)
 
(1
)
Other alliance and licensing income
 
(108
)
 
(57
)
Pension curtailments, settlements and special termination benefits
 
64

 
—

Other
 
50

 
17

Other (income)/expense
 
$
(208
)
 
$
(19
)
 
 
 
 
 


11





BRISTOL-MYERS SQUIBB COMPANY
SPECIFIED ITEMS
FOR THE THREE MONTHS ENDED MARCH 31, 2014 AND 2013
(Unaudited, dollars in millions)
 
 
 
Three Months Ended 
 March 31,
 
 
2014
 
2013
Accelerated depreciation, asset impairment and other shutdown costs
 
$
45

 
$
—

Amortization of acquired Amylin intangible assets
 
—

 
138

Amortization of Amylin collaboration proceeds
 
—

 
(67
)
Amortization of Amylin inventory adjustment
 
—

 
14

Cost of products sold
 
45

 
85

 
 
 
 
 
Marketing, selling and administrative*
 
3

 
1

 
 
 
 
 
Upfront, milestone and other licensing payments
 
15

 
—

IPRD impairment
 
33

 
—

Research and development
 
48

 
—

 
 
 
 
 
Provision for restructuring
 
21

 
33

Gain on sale of product lines, businesses and assets
 
(259
)
 
—

Acquisition and alliance related items
 
16

 
—

Litigation charges
 
25

 
—

Loss on debt redemption
 
45

 
—

Upfront, milestone and other licensing receipts
 
—

 
(14
)
Pension curtailments, settlements and special termination benefits
 
64

 
—

Other (income)/expense
 
(88
)
 
19

 
 
 
 
 
Increase to pretax income
 
8

 
105

Income tax on items above
 
(179
)
 
(35
)
Increase/(decrease) to net earnings
 
$
(171
)
 
$
70


* Specified items in marketing, selling and administrative are process standardization implementation costs.


12





BRISTOL-MYERS SQUIBB COMPANY
RECONCILIATION OF CERTAIN NON-GAAP LINE ITEMS TO CERTAIN GAAP LINE ITEMS
FOR THE THREE MONTHS ENDED MARCH 31, 2014 AND 2013
(Unaudited, dollars in millions)

Three months ended March 31, 2014
 
GAAP
 
Specified
Items*
 
Non
GAAP
Gross Profit
 
$
2,843

 
45

 
$
2,888

Marketing, selling and administrative
 
957

 
(3
)
 
954

Research and development
 
946

 
(48
)
 
898

Other (income)/expense
 
(208
)
 
88

 
(120
)
Effective Tax Rate
 
5.0
%
 
18.0
%
 
23.0
%
 
 
 
 
 
 
 
Three months ended March 31, 2013
 
GAAP
 
Specified
Items*
 
Non
GAAP
Gross Profit
 
$
2,768

 
85

 
$
2,853

Marketing, selling and administrative
 
994

 
(1
)
 
993

Research and development
 
930

 
—

 
930

Other (income)/expense
 
(19
)
 
(19
)
 
(38
)
Effective Tax Rate
 
7.6
%
 
3.4
%
 
11.0
%
*
Refer to the Specified Items schedule for further details. Effective tax rate on the Specified Items represents the difference between the GAAP and Non-GAAP effective tax rate.


13





BRISTOL-MYERS SQUIBB COMPANY
RECONCILIATION OF NON-GAAP EPS TO GAAP EPS
FOR THE THREE MONTHS ENDED MARCH 31, 2014 AND 2013
(Unaudited, dollars and shares in millions except per share data)
 
 
 
Three Months Ended March 31,
 
 
2014
 
2013
Net Earnings Attributable to BMS – GAAP
 
$
937

 
$
609

Earnings attributable to unvested restricted shares
 
—

 
—

Net Earnings used for Diluted EPS Calculation – GAAP
 
$
937

 
$
609

 
 
 
 
 
Net Earnings Attributable to BMS – GAAP
 
$
937

 
$
609

Less Specified Items*
 
(171
)
 
70

Net Earnings Attributable to BMS – Non-GAAP
 
766

 
679

Earnings attributable to unvested restricted shares
 
—

 
—

Net Earnings used for Diluted EPS Calculation – Non-GAAP
 
$
766

 
$
679

 
 
 
 
 
Average Common Shares Outstanding – Diluted
 
1,666

 
1,655

 
 
 
 
 
Diluted Earnings Per Share — GAAP
 
$
0.56

 
$
0.37

Diluted EPS Attributable to Specified Items
 
(0.10
)
 
0.04

Diluted Earnings Per Share — Non-GAAP
 
$
0.46

 
$
0.41

*
Refer to the Specified Items schedule for further details.


14





BRISTOL-MYERS SQUIBB COMPANY
NET CASH/(DEBT) CALCULATION
AS OF MARCH 31, 2014 AND DECEMBER 31, 2013
(Unaudited, dollars in millions)
 
 
 
March 31, 2014
 
December 31, 2013
Cash and cash equivalents
 
$
5,225

 
$
3,586

Marketable securities - current
 
1,834

 
939

Marketable securities - long term
 
3,558

 
3,747

     Cash, cash equivalents and marketable securities
 
10,617

 
8,272

Short-term borrowings and current portion of long-term debt
 
(281
)
 
(359
)
Long-term debt
 
(7,367
)
 
(7,981
)
     Net cash/(debt) position
 
$
2,969

 
$
(68
)


15

 EX-99.2 3 q12014ex992.htm CERTAIN SUPPLEMENTAL INFORMATON POSTED ON BRISTOL-MYERS SQUIBB COMPANY'S WEBSITE Q1 2014 Ex. 99.2

Exhibit 99.2

BRISTOL-MYERS SQUIBB COMPANY
QUARTERLY TREND ANALYSIS OF REVENUES
(Unaudited, dollars in millions)
Revenues
 
2013
 
2014
 
% Change
 
FX Impact
 
 
1st Qtr
 
2nd Qtr
 
6 Months
 
3rd Qtr
 
9 Months
 
4th Qtr
 
Year
 
1st Qtr
 
2nd Qtr
 
6 Months
 
3rd Qtr
 
9 Months
 
4th Qtr
 
Year
 
Qtr vs. Qtr
 
YTD vs. YTD
 
Qtr vs. Qtr
 
YTD vs. YTD
Total
 
$
3,831

 
$
4,048

 
$
7,879

 
$
4,065

 
$
11,944

 
$
4,441

 
$
16,385

 
$
3,811

 
 
 
 
 
 
 
 
 
 
 
 
 
(1)%
 
(1)%
 
(1)%
 
(1)%
    US and Puerto Rico
 
1,971

 
2,045

 
4,016

 
2,037

 
6,053

 
2,265

 
8,318

 
1,765

 
 
 
 
 
 
 
 
 
 
 
 
 
(10)%
 
(10)%
 
—
 
—
    Europe
 
946

 
950

 
1,896

 
985

 
2,881

 
1,049

 
3,930

 
948

 
 
 
 
 
 
 
 
 
 
 
 
 
—
 
—
 
2%
 
2%
    Rest of the World
 
765

 
835

 
1,600

 
805

 
2,405

 
890

 
3,295

 
830

 
 
 
 
 
 
 
 
 
 
 
 
 
8%
 
8%
 
(7)%
 
(7)%
    Other
 
149

 
218

 
367

 
238

 
605

 
237

 
842

 
268

 
 
 
 
 
 
 
 
 
 
 
 
 
80%
 
80%
 
N/A
 
N/A
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
% of Revenues
 
2013
 
2014
 
 
 
 
 
 
 
 
 
 
1st Qtr
 
2nd Qtr
 
6 Months
 
3rd Qtr
 
9 Months
 
4th Qtr
 
Year
 
1st Qtr
 
2nd Qtr
 
6 Months
 
3rd Qtr
 
9 Months
 
4th Qtr
 
Year
 
 
 
 
 
 
 
 
Total
 
100.0
%
 
100.0
%
 
100.0
%
 
100.0
%
 
100.0
%
 
100.0
%
 
100.0
%
 
100.0
%
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
    US and Puerto Rico
 
51.4
%
 
50.5
%
 
51.0
%
 
50.1
%
 
50.7
%
 
51.0
%
 
50.8
%
 
46.3
%
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
    Europe
 
24.7
%
 
23.5
%
 
24.1
%
 
24.2
%
 
24.1
%
 
23.6
%
 
24.0
%
 
24.9
%
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
    Rest of the World
 
20.0
%
 
20.6
%
 
20.3
%
 
19.8
%
 
20.1
%
 
20.0
%
 
20.1
%
 
21.8
%
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
    Other
 
3.9
%
 
5.4
%
 
4.6
%
 
5.9
%
 
5.1
%
 
5.4
%
 
5.1
%
 
7.0
%
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 


1

BRISTOL-MYERS SQUIBB COMPANY
REVENUES AND COMPOSITION OF CHANGE IN REVENUES
FOR THE PERIOD ENDED MARCH 31, 2014
(Unaudited, dollars in millions)
QUARTER-TO-DATE
 
Revenues
 
Analysis of % Change
 
 
2014
 
2013
 
Total Change
 
Volume
 
Price
 
Foreign Exchange
US and Puerto Rico
 
$
1,765

 
$
1,971

 
(10
)%
 
(12
)%
 
2
 %
 
—

Europe
 
948

 
946

 
—

 
3
 %
 
(5
)%
 
2
 %
Rest of the World
 
830

 
765

 
8
 %
 
18
 %
 
(3
)%
 
(7
)%
Other
 
268

 
149

 
80
 %
 
N/A

 
N/A

 
N/A

Total
 
$
3,811

 
$
3,831

 
(1
)%
 
1
 %
 
(1
)%
 
(1
)%


2

Exhibit 99.2

BRISTOL-MYERS SQUIBB COMPANY
EARNINGS FROM OPERATIONS
(Unaudited, dollars and shares in millions except per share data)
 
 
2013
 
2014
 
% Change
 
 
1st Qtr
 
2nd Qtr
 
6 Months
 
3rd Qtr
 
9 Months
 
4th Qtr
 
Year
 
1st Qtr
 
2nd Qtr
 
6 Months
 
3rd Qtr
 
9 Months
 
4th Qtr
 
Year
 
Qtr vs. Qtr
 
YTD vs. YTD
Net product sales
 
$
2,957

 
$
3,024

 
$
5,981

 
$
3,025

 
$
9,006

 
$
3,298

 
$
12,304

 
$
2,807

 
 
 
 
 
 
 
 
 
 
 
 
 
(5)%
 
(5)%
Alliance and other revenues
 
874

 
1,024

 
1,898

 
1,040

 
2,938

 
1,143

 
4,081

 
1,004

 
 
 
 
 
 
 
 
 
 
 
 
 
15%
 
15%
Total Revenues
 
$
3,831

 
$
4,048

 
$
7,879

 
$
4,065

 
$
11,944

 
$
4,441

 
$
16,385

 
$
3,811

 
 
 
 
 
 
 
 
 
 
 
 
 
(1)%
 
(1)%
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cost of products sold
 
1,063

 
1,108

 
2,171

 
1,175

 
3,346

 
1,273

 
4,619

 
968

 
 
 
 
 
 
 
 
 
 
 
 
 
(9)%
 
(9)%
Marketing, selling and administrative
 
994

 
1,042

 
2,036

 
980

 
3,016

 
1,068

 
4,084

 
957

 
 
 
 
 
 
 
 
 
 
 
 
 
(4)%
 
(4)%
Advertising and product promotion
 
189

 
218

 
407

 
194

 
601

 
254

 
855

 
163

 
 
 
 
 
 
 
 
 
 
 
 
 
(14)%
 
(14)%
Research and development
 
930

 
951

 
1,881

 
893

 
2,774

 
957

 
3,731

 
946

 
 
 
 
 
 
 
 
 
 
 
 
 
2%
 
2%
Other (income)/expense
 
(19
)
 
199

 
180

 
5

 
185

 
20

 
205

 
(208
)
 
 
 
 
 
 
 
 
 
 
 
 
 
**
 
**
Total Expenses
 
3,157

 
3,518

 
6,675

 
3,247

 
9,922

 
3,572

 
13,494

 
2,826

 
 
 
 
 
 
 
 
 
 
 
 
 
(10)%
 
(10)%
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Earnings Before Income Taxes
 
$
674

 
$
530

 
$
1,204

 
$
818

 
$
2,022

 
$
869

 
$
2,891

 
$
985

 
 
 
 
 
 
 
 
 
 
 
 
 
46%
 
46%
Provision for income taxes
 
51

 
—

 
51

 
126

 
177

 
134

 
311

 
49

 
 
 
 
 
 
 
 
 
 
 
 
 
(4)%
 
(4)%
Net Earnings
 
$
623

 
$
530

 
$
1,153

 
$
692

 
$
1,845

 
$
735

 
$
2,580

 
$
936

 
 
 
 
 
 
 
 
 
 
 
 
 
50%
 
50%
Net Earnings/(Loss) Attributable to Noncontrolling Interest
 
14

 
(6
)
 
8

 
—

 
8

 
9

 
17

 
(1
)
 
 
 
 
 
 
 
 
 
 
 
 
 
**
 
**
Net Earnings Attributable to BMS
 
$
609

 
$
536

 
$
1,145

 
$
692

 
$
1,837

 
$
726

 
$
2,563

 
$
937

 
 
 
 
 
 
 
 
 
 
 
 
 
54%
 
54%
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Earnings attributable to unvested restricted shares
 
—

 
—

 
—

 
—

 
—

 
—

 
—

 
—

 
 
 
 
 
 
 
 
 
 
 
 
 
—
 
—
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Net Earnings used for Diluted EPS Calculation
 
$
609

 
$
536

 
$
1,145

 
$
692

 
$
1,837

 
$
726

 
$
2,563

 
$
937

 
 
 
 
 
 
 
 
 
 
 
 
 
54%
 
54%
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Diluted Earnings per Common Share*
 
$
0.37

 
$
0.32

 
$
0.69

 
$
0.42

 
$
1.11

 
$
0.44

 
$
1.54

 
$
0.56

 
 
 
 
 
 
 
 
 
 
 
 
 
51%
 
51%
Average Common Shares Outstanding - Diluted
 
1,655

 
1,660

 
1,658

 
1,662

 
1,659

 
1,666

 
1,662

 
1,666

 
 
 
 
 
 
 
 
 
 
 
 
 
1%
 
1%
Dividends declared per common share
 
$
0.35

 
$
0.35

 
$
0.70

 
$
0.35

 
$
1.05

 
$
0.36

 
$
1.41

 
$
0.36

 
 
 
 
 
 
 
 
 
 
 
 
 
3%
 
3%
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2013
 
2014
 
 
 
 
% of Total Revenues
 
1st Qtr
 
2nd Qtr
 
6 Months
 
3rd Qtr
 
9 Months
 
4th Qtr
 
Year
 
1st Qtr
 
2nd Qtr
 
6 Months
 
3rd Qtr
 
9 Months
 
4th Qtr
 
Year
 
 
 
 
Gross Margin
 
72.3
%
 
72.6
%
 
72.4
%
 
71.1
%
 
72.0
%
 
71.3
%
 
71.8
%
 
74.6
%
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Other Ratios
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Effective tax rate
 
7.6
%
 
—

 
4.2
%
 
15.4
%
 
8.8
%
 
15.4
%
 
10.8
%
 
5.0
%
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Other (Income)/Expense
 
2013
 
2014
 
% Change
 
 
1st Qtr
 
2nd Qtr
 
6 Months
 
3rd Qtr
 
9 Months
 
4th Qtr
 
Year
 
1st Qtr
 
2nd Qtr
 
6 Months
 
3rd Qtr
 
9 Months
 
4th Qtr
 
Year
 
Qtr vs. Qtr
 
YTD vs. YTD
Interest expense
 
$
50

 
$
50

 
$
100

 
$
46

 
$
146

 
$
53

 
$
199

 
$
54

 
 
 
 
 
 
 
 
 
 
 
 
 
8%
 
8%
Investment income
 
(25
)
 
(28
)
 
(53
)
 
(23
)
 
(76
)
 
(28
)
 
(104
)
 
(23
)
 
 
 
 
 
 
 
 
 
 
 
 
 
(8)%
 
(8)%
Provision for restructuring
 
33

 
173

 
206

 
6

 
212

 
14

 
226

 
21

 
 
 
 
 
 
 
 
 
 
 
 
 
(36)%
 
(36)%
Litigation charges/(recoveries)
 
—

 
(22
)
 
(22
)
 
17

 
(5
)
 
25

 
20

 
29

 
 
 
 
 
 
 
 
 
 
 
 
 
N/A
 
N/A
Equity in net income of affiliates
 
(36
)
 
(50
)
 
(86
)
 
(42
)
 
(128
)
 
(38
)
 
(166
)
 
(36
)
 
 
 
 
 
 
 
 
 
 
 
 
 
—
 
—
Gain on sale of product lines, businesses and assets
 
(1
)
 
—

 
(1
)
 
—

 
(1
)
 
(1
)
 
(2
)
 
(259
)
 
 
 
 
 
 
 
 
 
 
 
 
 
**
 
**
Other alliance and licensing income
 
(57
)
 
(32
)
 
(89
)
 
(31
)
 
(120
)
 
(28
)
 
(148
)
 
(108
)
 
 
 
 
 
 
 
 
 
 
 
 
 
89%
 
89%
Pension curtailments, settlements and special termination benefits
 
—

 
101

 
101

 
37

 
138

 
27

 
165

 
64

 
 
 
 
 
 
 
 
 
 
 
 
 
N/A
 
N/A
Other
 
17

 
7

 
24

 
(5
)
 
19

 
(4
)
 
15

 
50

 
 
 
 
 
 
 
 
 
 
 
 
 
**
 
**
 
 
$
(19
)
 
$
199

 
$
180

 
$
5

 
$
185

 
$
20

 
$
205

 
$
(208
)
 
 
 
 
 
 
 
 
 
 
 
 
 
**
 
**
* Quarterly amounts may not add to the year-to-date totals due to rounding of individual calculations.
** In excess of 100%


3

BRISTOL-MYERS SQUIBB COMPANY
RECONCILIATION OF GAAP AND NON-GAAP GROWTH DOLLARS AND PERCENTAGES EXCLUDING FOREIGN EXCHANGE IMPACT
FOR THE PERIOD ENDED MARCH 31, 2014
(Unaudited, dollars in millions)
QUARTER-TO-DATE
 
 
2014
 
2013
 
Growth $
 
Growth %
 
Favorable /
(Unfavorable)
FX Impact $ *
 
2014
Excluding FX
 
Favorable /
(Unfavorable)
FX Impact % *
 
Growth %
Excluding FX
Revenues
 
$
3,811

 
$
3,831

 
(20
)
 
(1
)%
 
$
(27
)
 
$
3,838

 
(1
)%
 
—

Gross profit
 
2,843

 
2,768

 
75

 
3
 %
 
N/A

 
N/A

 
N/A

 
N/A

Gross profit excluding specified items (a)
 
2,888

 
2,853

 
35

 
1
 %
 
N/A

 
N/A

 
N/A

 
N/A

          Gross profit excluding specified items as a % of revenues
 
75.8
%
 
74.5
%
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Marketing, selling and administrative
 
957

 
994

 
(37
)
 
(4
)%
 
9

 
966

 
1
 %
 
(3
)%
Marketing, selling and administrative excluding specified items (a)
 
954

 
993

 
(39
)
 
(4
)%
 
9

 
963

 
1
 %
 
(3
)%
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Advertising and product promotion
 
163

 
189

 
(26
)
 
(14
)%
 
1

 
164

 
1
 %
 
(13
)%
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
         SG&A excluding specified items as a % of revenues
 
29.3
%
 
30.9
%
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Research and development
 
946

 
930

 
16

 
2
 %
 
1

 
947

 
—

 
2
 %
Research and development excluding specified items (a)
 
898

 
930

 
(32
)
 
(3
)%
 
1

 
899

 
—

 
(3
)%
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
         Research and development excluding specified items as a % of revenues
 
23.6
%
 
24.3
%
 
 
 
 
 
 
 
 
 
 
 
 

(a) Refer to the Specified Items schedule for further details.
* Foreign exchange (FX) impact determined by the change in a line item's current and prior period results at a common exchange rate and comparing this change to the actual reported change from the same period. This difference is determined to be the FX impact.


4

BRISTOL-MYERS SQUIBB COMPANY
WORLDWIDE REVENUES FROM OPERATIONS BY PRODUCT
QUARTERLY REVENUES TREND ANALYSIS AND RECONCILIATION OF GAAP AND NON-GAAP GROWTH DOLLARS AND PERCENTAGES EXCLUDING FOREIGN EXCHANGE IMPACT
(Unaudited, dollars in millions)
 
 
2013
 
2014
 
Growth $
 
% Change
 
EX-FX
 
FX Impact
 
 
1st Qtr
 
2nd Qtr
 
6 Months
 
3rd Qtr
 
9 Months
 
4th Qtr
 
Year
 
1st Qtr
 
2nd 
Qtr
 
6 
Months
 
3rd Qtr
 
9 
Months
 
4th 
Qtr
 
Year
 
Qtr vs. Qtr
 
YTD vs. YTD
 
Qtr vs. Qtr
 
YTD vs. YTD
 
QTD EX-FX $
 
YTD EX-FX $
 
Qtr vs. Qtr %
 
YTD vs. YTD %
 
Qtr vs. Qtr
 
YTD vs. YTD
TOTAL
 
$
3,831

 
$
4,048

 
$
7,879

 
$
4,065

 
$
11,944

 
$
4,441

 
$
16,385

 
$
3,811

 
 
 
 
 
 
 
 
 
 
 
 
 
$
(20
)
 
$
(20
)
 
(1)%
 
(1)%
 
$
3,838

 
$
3,838

 
—
 
—
 
(1)%
 
(1)%
Virology (a)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Baraclude
 
366

 
371

 
737

 
378

 
1,115

 
412

 
1,527

 
406

 
 
 
 
 
 
 
 
 
 
 
 
 
40

 
40

 
11%
 
11%
 
412

 
412

 
13%
 
13%
 
(2)%
 
(2)%
Reyataz
 
361

 
431

 
792

 
375

 
1,167

 
384

 
1,551

 
344

 
 
 
 
 
 
 
 
 
 
 
 
 
(17
)
 
(17
)
 
(5)%
 
(5)%
 
348

 
348

 
(4)%
 
(4)%
 
(1)%
 
(1)%
Sustiva Franchise (b)
 
387

 
411

 
798

 
389

 
1,187

 
427

 
1,614

 
319

 
 
 
 
 
 
 
 
 
 
 
 
 
(68
)
 
(68
)
 
(18)%
 
(18)%
 
316

 
316

 
(18)%
 
(18)%
 
—
 
—
Oncology (a)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Erbitux
 
162

 
171

 
333

 
183

 
516

 
180

 
696

 
169

 
 
 
 
 
 
 
 
 
 
 
 
 
7

 
7

 
4%
 
4%
 
169

 
169

 
4%
 
4%
 
N/A
 
N/A
Sprycel
 
287

 
312

 
599

 
316

 
915

 
365

 
1,280

 
342

 
 
 
 
 
 
 
 
 
 
 
 
 
55

 
55

 
19%
 
19%
 
351

 
351

 
22%
 
22%
 
(3)%
 
(3)%
Yervoy
 
229

 
233

 
462

 
238

 
700

 
260

 
960

 
271

 
 
 
 
 
 
 
 
 
 
 
 
 
42

 
42

 
18%
 
18%
 
270

 
270

 
18%
 
18%
 
—
 
—
Neuroscience (a)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
     Abilify (c)
 
522

 
563

 
1,085

 
569

 
1,654

 
635

 
2,289

 
540

 
 
 
 
 
 
 
 
 
 
 
 
 
18

 
18

 
3%
 
3%
 
538

 
538

 
3%
 
3%
 
—
 
—
Immunoscience (a)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
     Orencia (d)
 
320

 
352

 
672

 
375

 
1,047

 
397

 
1,444

 
363

 
 
 
 
 
 
 
 
 
 
 
 
 
43

 
43

 
13%
 
13%
 
370

 
370

 
16%
 
16%
 
(3)%
 
(3)%
Cardiovascular (a)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Eliquis
 
22

 
12

 
34

 
41

 
75

 
71

 
146

 
106

 
 
 
 
 
 
 
 
 
 
 
 
 
84

 
84

 
**
 
**
 
107

 
107

 
**
 
**
 
N/A
 
N/A
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Diabetes Alliance (e)
 
358

 
438

 
796

 
432

 
1,228

 
455

 
1,683

 
179

 
 
 
 
 
 
 
 
 
 
 
 
 
(179
)
 
(179
)
 
(50)%
 
(50)%
 
179

 
179

 
(50)%
 
(50)%
 
—
 
—
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Mature Products and All Other (f)
 
817

 
754

 
1,571

 
769

 
2,340

 
855

 
3,195

 
772

 
 
 
 
 
 
 
 
 
 
 
 
 
(45
)
 
(45
)
 
(6)%
 
(6)%
 
778

 
778

 
(5)%
 
(5)%
 
(1)%
 
(1)%
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Total Excluding Diabetes Alliance
 
3,473

 
3,610

 
7,083

 
3,633

 
10,716

 
3,986

 
14,702

 
3,632

 
 
 
 
 
 
 
 
 
 
 
 
 
159

 
159

 
5%
 
5%
 
3,659

 
3,659

 
5%
 
5%
 
—
 
—
**
In excess of 100%
(a)
Key products listed do not represent all products in the respective therapeutic areas.
(b)
The Sustiva Franchise includes sales of Sustiva and revenue from sales of bulk efavirenz included in the combination therapy, Atripla. Includes alliance and other revenues of $272M and $324M for the three months ended March 31, 2014 and March 31, 2013, respectively.
(c)
Includes revenue from the co-promotional agreement with Otsuka Pharmaceutical Co., Ltd. Includes alliance and other revenue of $441M and $395M for the three months ended March 31, 2014 and March 31, 2013, respectively.
(d)
Includes Orencia SubQ revenues of $136M and $84M for the three months ended March 31, 2014 and March 31, 2013, respectively.
(e)
The three months ended March 31, 2013 includes pre-divestiture revenues of Bydureon, Byetta, Farxiga/Forxiga/Xigduo, Onglyza/Kombiglyze, Symlin and Myalept of $153M and post-divestiture revenues of $26M.
(f)
Represents all other products, including those which have lost exclusivity in major markets, over the counter brands and royalty-related revenue. Includes Plavix revenues of $48M and $91M and Avapro/Avalide revenues of $56M and $46M for the three months ended March 31, 2014 and March 31, 2013, respectively.


5

BRISTOL-MYERS SQUIBB COMPANY
DOMESTIC REVENUES FROM OPERATIONS BY PRODUCT
QUARTERLY REVENUES TREND ANALYSIS
(Unaudited, dollars in millions)
 
 
2013
 
2014
 
% Change
 
 
1st Qtr
 
2nd Qtr
 
6 Months
 
3rd Qtr
 
9 Months
 
4th Qtr
 
Year
 
1st Qtr
 
2nd Qtr
 
6 Months
 
3rd Qtr
 
9 Months
 
4th Qtr
 
Year
 
Qtr vs. Qtr
 
YTD vs. YTD
TOTAL (a)
 
$
1,971

 
$
2,045

 
$
4,016

 
$
2,037

 
$
6,053

 
$
2,265

 
$
8,318

 
$
1,765

 
 
 
 
 
 
 
 
 
 
 
 
 
(10)%
 
(10)%
Virology
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Baraclude
 
68

 
73

 
141

 
67

 
208

 
81

 
289

 
70

 
 
 
 
 
 
 
 
 
 
 
 
 
3%
 
3%
Reyataz
 
193

 
200

 
393

 
189

 
582

 
187

 
769

 
176

 
 
 
 
 
 
 
 
 
 
 
 
 
(9)%
 
(9)%
Sustiva Franchise (b)
 
251

 
275

 
526

 
259

 
785

 
307

 
1,092

 
228

 
 
 
 
 
 
 
 
 
 
 
 
 
(9)%
 
(9)%
Oncology
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Erbitux
 
158

 
168

 
326

 
180

 
506

 
176

 
682

 
158

 
 
 
 
 
 
 
 
 
 
 
 
 
—
 
—
Sprycel
 
115

 
135

 
250

 
134

 
384

 
157

 
541

 
145

 
 
 
 
 
 
 
 
 
 
 
 
 
26%
 
26%
Yervoy (c)
 
159

 
140

 
299

 
130

 
429

 
148

 
577

 
146

 
 
 
 
 
 
 
 
 
 
 
 
 
(8)%
 
(8)%
Neuroscience
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Abilify
 
328

 
378

 
706

 
378

 
1,084

 
435

 
1,519

 
325

 
 
 
 
 
 
 
 
 
 
 
 
 
(1)%
 
(1)%
Immunoscience
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Orencia (d)
 
214

 
238

 
452

 
246

 
698

 
256

 
954

 
229

 
 
 
 
 
 
 
 
 
 
 
 
 
7%
 
7%
Cardiovascular
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Eliquis
 
17

 
5

 
22

 
27

 
49

 
48

 
97

 
61

 
 
 
 
 
 
 
 
 
 
 
 
 
**
 
**
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Diabetes Alliance (e)
 
292

 
320

 
612

 
308

 
920

 
322

 
1,242

 
114

 
 
 
 
 
 
 
 
 
 
 
 
 
(61)%
 
(61)%
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Mature Products and All Other  (f)
 
176

 
113

 
289

 
119

 
408

 
148

 
556

 
113

 
 
 
 
 
 
 
 
 
 
 
 
 
(36)%
 
(36)%
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Total Excluding Diabetes Alliance
 
1,679

 
1,725

 
3,404

 
1,729

 
5,133

 
1,943

 
7,076

 
1,651

 
 
 
 
 
 
 
 
 
 
 
 
 
(2)%
 
(2)%
**
 In excess of 100%
(a)
Domestic revenues include United States and Puerto Rico.
(b)
The Sustiva Franchise includes sales of Sustiva, as well as revenue from sales of bulk efavirenz included in the combination therapy, Atripla.
(c)
Three months ended March 31, 2013 includes $25 million of net sales that were previously deferred until sufficient historical experience to estimate sales returns was developed. The following table provides a reconciliation of the net impact of reversal of previously deferred net sales.
 
 
2014
 
 
2013
 
 
% Change
 
 
1st Qtr
 
 
1st Qtr
 
 
Qtr vs. Qtr
Yervoy Revenues As Reported
 
146

 
 
159

 
 
(8
)%
Reversal of deferred revenues, net
 
—

 
 
(25
)
 
 
N/A

Yervoy Revenues - Adjusted
 
146

 
 
134

 
 
9
 %
(d)
Includes Orencia SubQ revenues of $94M and $70M for the three months ended March 31, 2014 and March 31, 2013, respectively.
(e)
Includes Bydureon, Byetta, Farxiga, Onglyza/Kombiglyze and Symlin.
(f)
Represents all other products sold in the U.S., including those which have lost exclusivity in major markets.

6

BRISTOL-MYERS SQUIBB COMPANY
INTERNATIONAL REVENUES FROM OPERATIONS BY PRODUCT
QUARTERLY REVENUES TREND ANALYSIS
(Unaudited, dollars in millions)
 
 
2013
 
2014
 
% Change
 
FX Impact
 
 
1st Qtr
 
2nd Qtr
 
6 Months
 
3rd Qtr
 
9 Months
 
4th Qtr
 
Year
 
1st Qtr
 
2nd Qtr
 
6 Months
 
3rd Qtr
 
9 Months
 
4th Qtr
 
Year
 
Qtr vs. Qtr
 
YTD vs. YTD
 
Qtr vs. Qtr
 
YTD vs. YTD
TOTAL
 
$
1,860

 
$
2,003

 
$
3,863

 
$
2,028

 
$
5,891

 
$
2,176

 
$
8,067

 
$
2,046

 
 
 
 
 
 
 
 
 
 
 
 
 
10%
 
10%
 
(1)%
 
(1)%
Virology
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Baraclude
 
298

 
298

 
596

 
311

 
907

 
331

 
1,238

 
336

 
 
 
 
 
 
 
 
 
 
 
 
 
13%
 
13%
 
(2)%
 
(2)%
Reyataz
 
168

 
231

 
399

 
186

 
585

 
197

 
782

 
168

 
 
 
 
 
 
 
 
 
 
 
 
 
—
 
—
 
(2)%
 
(2)%
Sustiva Franchise (a)
 
136

 
136

 
272

 
130

 
402

 
120

 
522

 
91

 
 
 
 
 
 
 
 
 
 
 
 
 
(33)%
 
(33)%
 
2%
 
2%
Oncology
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Erbitux
 
4

 
3

 
7

 
3

 
10

 
4

 
14

 
11

 
 
 
 
 
 
 
 
 
 
 
 
 
**
 
**
 
N/A
 
N/A
Sprycel
 
172

 
177

 
349

 
182

 
531

 
208

 
739

 
197

 
 
 
 
 
 
 
 
 
 
 
 
 
15%
 
15%
 
(5)%
 
(5)%
Yervoy
 
70

 
93

 
163

 
108

 
271

 
112

 
383

 
125

 
 
 
 
 
 
 
 
 
 
 
 
 
79%
 
79%
 
(1)%
 
(1)%
Neuroscience
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Abilify (b)
 
194

 
185

 
379

 
191

 
570

 
200

 
770

 
215

 
 
 
 
 
 
 
 
 
 
 
 
 
11%
 
11%
 
1%
 
1%
Immunoscience
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Orencia
 
106

 
114

 
220

 
129

 
349

 
141

 
490

 
134

 
 
 
 
 
 
 
 
 
 
 
 
 
26%
 
26%
 
(7)%
 
(7)%
Cardiovascular
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Eliquis
 
5

 
7

 
12

 
14

 
26

 
23

 
49

 
45

 
 
 
 
 
 
 
 
 
 
 
 
 
**
 
**
 
N/A
 
N/A
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Diabetes Alliance (c)
 
66

 
118

 
184

 
124

 
308

 
133

 
441

 
65

 
 
 
 
 
 
 
 
 
 
 
 
 
(2)%
 
(2)%
 
—
 
—
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Mature Products and All Other (d)
 
641

 
641

 
1,282

 
650

 
1,932

 
707

 
2,639

 
659

 
 
 
 
 
 
 
 
 
 
 
 
 
3%
 
3%
 
(1)%
 
(1)%
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Total Excluding Diabetes Alliance
 
1,794

 
1,885

 
3,679

 
1,904

 
5,583

 
2,043

 
7,626

 
1,981

 
 
 
 
 
 
 
 
 
 
 
 
 
10%
 
10%
 
(2)%
 
(2)%

**
In excess of 100%
(a)
The Sustiva Franchise includes sales of Sustiva and revenue from sales of bulk efavirenz included in the combination therapy, Atripla.
(b)
Includes revenue from the co-promotional agreement with Otsuka Pharmaceutical Co., Ltd.
(c)
Includes Bydureon, Byetta, Forxiga/Xigduo, Onglyza/Kombiglyze, Symlin and Myalept.
(d)
Represents all other products, including those which have lost exclusivity in major markets, over the counter brands and royalty-related revenue.



7

BRISTOL-MYERS SQUIBB COMPANY
RECONCILIATION OF CERTAIN NON-GAAP LINE ITEMS TO CERTAIN GAAP LINE ITEMS
(Unaudited, dollars in millions)
 
 
2013
 
2014
 
 
1st Qtr
 
2nd Qtr
 
6 Months
 
3rd Qtr
 
9 Months
 
4th Qtr
 
Year
 
1st Qtr
 
2nd Qtr
 
6 Months
 
3rd Qtr
 
9 Months
 
4th Qtr
 
Year
Gross Profit
 
$
2,768

 
$
2,940

 
$
5,708

 
$
2,890

 
$
8,598

 
$
3,168

 
$
11,766

 
$
2,843

 
 
 
 
 
 
 
 
 
 
 
 
Specified items (a)
 
85

 
70

 
155

 
69

 
224

 
102

 
326

 
45

 
 
 
 
 
 
 
 
 
 
 
 
Gross profit excluding specified items
 
2,853

 
3,010

 
5,863

 
2,959

 
8,822

 
3,270

 
12,092

 
2,888

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Marketing, selling and administrative
 
994

 
1,042

 
2,036

 
980

 
3,016

 
1,068

 
4,084

 
957

 
 
 
 
 
 
 
 
 
 
 
 
Specified items (a)
 
(1
)
 
(1
)
 
(2
)
 
(4
)
 
(6
)
 
(10
)
 
(16
)
 
(3
)
 
 
 
 
 
 
 
 
 
 
 
 
Marketing, selling and administrative excluding specified items
 
993

 
1,041

 
2,034

 
976

 
3,010

 
1,058

 
4,068

 
954

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Research and development
 
930

 
951

 
1,881

 
893

 
2,774

 
957

 
3,731

 
946

 
 
 
 
 
 
 
 
 
 
 
 
Specified items (a)
 
—

 
—

 
—

 
—

 
—

 
(16
)
 
(16
)
 
(48
)
 
 
 
 
 
 
 
 
 
 
 
 
Research and development excluding specified items
 
930

 
951

 
1,881

 
893

 
2,774

 
941

 
3,715

 
898

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Other (income)/expense
 
(19
)
 
199

 
180

 
5

 
185

 
20

 
205

 
(208
)
 
 
 
 
 
 
 
 
 
 
 
 
Specified items (a)
 
(19
)
 
(239
)
 
(258
)
 
(43
)
 
(301
)
 
(39
)
 
(340
)
 
88

 
 
 
 
 
 
 
 
 
 
 
 
Other (income)/expense excluding specified items
 
(38
)
 
(40
)
 
(78
)
 
(38
)
 
(116
)
 
(19
)
 
(135
)
 
(120
)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Effective Tax Rate
 
7.6
%
 
—

 
4.2
%
 
15.4
%
 
8.8
%
 
15.4
%
 
10.8
%
 
5.0
%
 
 
 
 
 
 
 
 
 
 
 
 
Specified items (a)
 
3.4
%
 
13.8
%
 
8.3
%
 
2.4
%
 
5.6
%
 
2.5
%
 
4.6
%
 
18.0
%
 
 
 
 
 
 
 
 
 
 
 
 
Effective Tax Rate excluding specified items
 
11.0
%
 
13.8
%
 
12.5
%
 
17.8
%
 
14.4
%
 
17.9
%
 
15.4
%
 
23.0
%
 
 
 
 
 
 
 
 
 
 
 
 

(a) Refer to the Specified Items schedule for further details. Effective tax rate on the Specified Items represents the difference between the GAAP and Non-GAAP effective tax rate.


8

BRISTOL-MYERS SQUIBB COMPANY
SPECIFIED ITEMS
(Unaudited, dollars in millions)
 
 
2013
 
2014
 
 
1st Qtr
 
2nd Qtr
 
6 Months
 
3rd Qtr
 
9 Months
 
4th Qtr
 
Year
 
1st Qtr
 
2nd Qtr
 
6 Months
 
3rd Qtr
 
9 Months
 
4th Qtr
 
Year
Accelerated depreciation, asset impairment and other shutdown costs
 
$
—

 
$
—

 
$
—

 
$
—

 
$
—

 
$
36

 
$
36

 
$
45

 
 
 
 
 
 
 
 
 
 
 
 
Amortization of acquired Amylin intangible assets
 
138

 
137

 
275

 
137

 
412

 
137

 
549

 
—

 
 
 
 
 
 
 
 
 
 
 
 
Amortization of Amylin collaboration proceeds
 
(67
)
 
(67
)
 
(134
)
 
(68
)
 
(202
)
 
(71
)
 
(273
)
 
—

 
 
 
 
 
 
 
 
 
 
 
 
Amortization of Amylin inventory adjustment
 
14

 
—

 
14

 
—

 
14

 
—

 
14

 
—

 
 
 
 
 
 
 
 
 
 
 
 
Cost of products sold
 
85

 
70

 
155

 
69

 
224

 
102

 
326

 
45

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Marketing, selling and administrative*
 
1

 
1

 
2

 
4

 
6

 
10

 
16

 
3

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Upfront, milestone and other licensing payments
 
—

 
—

 
—

 
—

 
—

 
16

 
16

 
15

 
 
 
 
 
 
 
 
 
 
 
 
IPRD impairment
 
—

 
—

 
—

 
—

 
—

 
—

 
—

 
33

 
 
 
 
 
 
 
 
 
 
 
 
Research and development
 
—

 
—

 
—

 
—

 
—

 
16

 
16

 
48

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Provision for restructuring
 
33

 
173

 
206

 
6

 
212

 
14

 
226

 
21

 
 
 
 
 
 
 
 
 
 
 
 
Gain on sale of product lines, businesses and assets
 
—

 
—

 
—

 
—

 
—

 
—

 
—

 
(259
)
 
 
 
 
 
 
 
 
 
 
 
 
Acquisition and alliance related items
 
—

 
(10
)
 
(10
)
 
—

 
(10
)
 
—

 
(10
)
 
16

 
 
 
 
 
 
 
 
 
 
 
 
Litigation charges/(recoveries)
 
—

 
(23
)
 
(23
)
 
—

 
(23
)
 
—

 
(23
)
 
25

 
 
 
 
 
 
 
 
 
 
 
 
Loss on debt redemption
 
—

 
—

 
—

 
—

 
—

 
—

 
—

 
45

 
 
 
 
 
 
 
 
 
 
 
 
Upfront, milestone and other licensing receipts
 
(14
)
 
—

 
(14
)
 
—

 
(14
)
 
—

 
(14
)
 
—

 
 
 
 
 
 
 
 
 
 
 
 
Pension curtailments, settlements and special termination benefits
 
—

 
99

 
99

 
37

 
136

 
25

 
161

 
64

 
 
 
 
 
 
 
 
 
 
 
 
Other (income)/expense
 
19

 
239

 
258

 
43

 
301

 
39

 
340

 
(88
)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Increase/(decrease) to pretax income
 
105

 
310

 
415

 
116

 
531

 
167

 
698

 
8

 
 
 
 
 
 
 
 
 
 
 
 
Income tax on items above
 
(35
)
 
(116
)
 
(151
)
 
(40
)
 
(191
)
 
(51
)
 
(242
)
 
(179
)
 
 
 
 
 
 
 
 
 
 
 
 
Increase/(decrease) to net earnings
 
$
70

 
$
194

 
$
264

 
$
76

 
$
340

 
$
116

 
$
456

 
$
(171
)
 
 
 
 
 
 
 
 
 
 
 
 
* Specified items in marketing, selling and administrative are process standardization implementation costs.


9

BRISTOL-MYERS SQUIBB COMPANY
SELECTED BALANCE SHEET INFORMATION
(Unaudited, dollars in millions)
 
 
 
March 31,
2013
 
June 30,
2013
 
September 30,
2013
 
December 31,
2013
 
March 31,
2014
 
June 30,
2014
 
September 30,
2014
 
December 31,
2014
Cash and cash equivalents
 
$
1,355

 
$
1,821

 
$
1,771

 
$
3,586

 
$
5,225

 
 
 
 
 
 
Marketable securities - current
 
1,178

 
978

 
951

 
939

 
1,834

 
 
 
 
 
 
Marketable securities - long term
 
3,242

 
3,223

 
3,623

 
3,747

 
3,558

 
 
 
 
 
 
     Cash, cash equivalents and marketable securities
 
5,775

 
6,022

 
6,345

 
8,272

 
10,617

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Short-term borrowings and current portion of long-term debt
 
(1,372
)
 
(764
)
 
(680
)
 
(359
)
 
(281
)
 
 
 
 
 
 
Long-term debt
 
(6,522
)
 
(6,442
)
 
(6,532
)
 
(7,981
)
 
(7,367
)
 
 
 
 
 
 
     Net cash/(debt) position
 
$
(2,119
)
 
$
(1,184
)
 
$
(867
)
 
$
(68
)
 
$
2,969

 
 
 
 
 
 


10

BRISTOL-MYERS SQUIBB COMPANY
2014 FULL YEAR PROJECTED DILUTED EPS FROM OPERATIONS
EXCLUDING PROJECTED SPECIFIED ITEMS

 
Full Year 2014
Projected Diluted Earnings Attributable to Shareholders per Common Share - GAAP
 $1.70 to $1.80

Projected Specified Items:
 
Downsizing and streamlining of worldwide operations
0.08

Upfront and milestone payments, net
0.12

Gain on diabetes business divestiture and other related impacts
(0.31
)
Pension settlements
0.04

Other
0.07

 
 
Total
—

 
 
Projected Diluted Earnings Attributable to Shareholders per Common Share - Non-GAAP
 $1.70 to $1.80

Gross margin as a percentage of revenues on a GAAP and non-GAAP basis for the three months ended March 31, 2014 was 74.6% and 75.8%, respectively. On a non-GAAP basis, the Company projects gross margin as a percentage of revenues for the full year 2014 between 75% and 76%. There is no reliable comparable GAAP measure for this forward-looking information on gross margin. See "—Reconciliation of GAAP and NON-GAAP Growth Dollars and Percentages Excluding Foreign Exchange Impact".
 
 
 
 
 
 
 
 
 
 
Research and development expenses on a GAAP and non-GAAP basis for the three months ended March 31, 2014 were $946 million and $898 million, respectively . On a non-GAAP basis, the Company projects research and development expense for the full year 2014 to grow in the mid single digit range compared to 2013. It is estimated that 30% to 45% of the research and development expenses in 2014 will be incurred on late-stage development programs. There is no reliable comparable GAAP measure for this forward-looking information on research and development. See "—Reconciliation of Certain NON-GAAP Line Items to Certain GAAP Line Items".
 
 
 
 
 
 
 
 
 
 
Marketing, selling and administrative expenses, on a GAAP and non-GAAP basis for the three months ended March 31, 2014 were $957 million and $954 million, respectively. On a non-GAAP basis, the Company projects marketing, selling and administrative expenses for the full year 2014 to decrease in the mid single digit range compared to 2013. There is no reliable comparable GAAP measure for this forward-looking information on marketing, selling and administrative expense. See "—Reconciliation of Certain NON-GAAP Line Items to Certain GAAP Line Items".
 
 
 
 
 
 
 
 
 
 
The effective tax rate on a GAAP basis for the three months ended March 31, 2014 was 5.0%. On a non-GAAP basis, for the three months ended March 31, 2014 the effective tax rate was 23.0%. On a non-GAAP basis, the Company projects an annual effective tax rate of approximately 18%. There is no reliable comparable GAAP measure for this forward-looking information on the tax rate. See "—Reconciliation of Certain NON-GAAP Line Items to Certain GAAP Line Items".
 
 
 
 
 
 
 
 
 
 
The GAAP financial results for the full year 2014 will include specified items, including gains on divestitures, expected charges associated with downsizing and streamlining worldwide operations, impairment charges, milestone payments, restructuring and pension settlements. The GAAP financial results for the full year 2014 could also include other specified items that have not yet been identified and quantified, including any gains or losses from acquisitions or divestitures, additional upfront, milestone and other licensing payments, charges for in-process research and development and licensed asset impairments, charges and recoveries relating to significant legal proceedings, restructuring activities and significant tax events. For a fuller discussion of certain litigation and other matters that could impact full year GAAP results, as well as the use of non-GAAP financial information, see Bristol-Myers Squibb Reports First Quarter 2014 Financial Results, April 29, 2014 including “2014 Financial Guidance” and “Use of Non-GAAP Financial Information” therein.
 
 
 
 
 
 
 
 
 
 


11
 GRAPHIC 4 bmslogo.jpg begin 644 bmslogo.jpg M_]C_X``02D9)1@`!`@$`M`"T``#_X0I)17AI9@``34T`*@````@`!P$2``,` M```!``$```$:``4````!````8@$;``4````!````:@$H``,````!``(```$Q M``(````<````<@$R``(````4````CH=I``0````!````I````-``&W=````G M$``;=T```"<0061O8F4@4&AO=&]S:&]P($-3,B!7:6YD;W=S`#(P,#`1L`!0`` M``$```$F`2@``P````$``@```@$`!`````$```$N`@(`!`````$```D3```` M`````$@````!````2`````'_V/_@`!!*1DE&``$"``!(`$@``/_M``Q!9&]B M95]#30`!_^X`#D%D;V)E`&2``````?_;`(0`#`@("`D(#`D)#!$+"@L1%0\, M#`\5&!,3%1,3&!$,#`P,#`P1#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P, M#`$-"PL-#@T0#@X0%`X.#A04#@X.#A01#`P,#`P1$0P,#`P,#!$,#`P,#`P, M#`P,#`P,#`P,#`P,#`P,#`P,#`P,_\``$0@`%0"@`P$B``(1`0,1`?_=``0` M"O_$`3\```$%`0$!`0$!``````````,``0($!08'"`D*"P$``04!`0$!`0$` M`````````0`"`P0%!@<("0H+$``!!`$#`@0"!0<&"`4###,!``(1`P0A$C$% M05%A$R)Q@3(&%)&AL4(C)!52P6(S-'*"T4,')9)3\.'Q8W,U%J*R@R9$DU1D M1<*C=#87TE7B9?*SA,/3=>/S1B>4I(6TE<34Y/2EM<75Y?569G:&EJ:VQM;F M]C='5V=WAY>GM\?7Y_<1``("`0($!`,$!08'!P8%-0$``A$#(3$2!$%187$B M$P4R@9$4H;%"(\%2T?`S)&+A7U5F9VAI:FML;6YO8G-T=7 M9W>'EZ>WQ__:``P#`0`"$0,1`#\`[[K-K+A]E=><:EKF-M>';"YSR-M&Z1[& M5.]?)9_H_2_,]546O%=(;96`^H.9=4&!UWK--5=5--[MSO3RO5]1CWLMNV?S M=W^B)Z.5BY.1NM?O?:Z'5L;8XMM=OQZW?:/?779/I-V/^Q^I79ZGV?TUG6X[ MVY#KI:*ZG[?6W.;L:STJ[:Q75^B]+?97ZCZJ_2I_T=U?JJS`"JO3=JSD;NM= MG6Z.XX=C\=UWJLWBNUN\O%5KFL<-FXNCZ7\Y^EK]%;^4]M>+=8\D-96YSB`28`)/M8'.=_94>0:@[D[LN,T"-A'; M^7]5P<7ZUY-F/TW.R<%M6%U:YE%+V7>I8Q]F[T/6I=32S8_9[O3OL]-;F=DN MQ,2W);1;E&H;A10`ZQW\FMKW5M<[^VN#Z=?C?LCZOV=.O];K=-E57V0/-H;6 M269GJX;B]F'MHW>IF,JIM_X;](CV_9_^;'7>H59ES\BNW+HHM^U6NVU^MNQJ MZ_TNW](UM>S_``ES'_Z.Q2RPQXA0X?5PUK^]PK(Y36IXM+O_``;>[''@@8.= MC=0Q*LW%<7X][=U;R"V6_O;7AKURS\G%L^LX#F[-T#MWXNG^"N.;6@!6HW>TOZDZGK&+TTT MRW+JMM%^X0#2:]U?IQN_PS$#KO76]$&+==3OQ;[A3=:'0ZH$.L];TMCO4J8R MNQ]OO]BY_IF9D6=0Z3-GJV^GU/[`'7_IZJO9;Z?J6TU^ MK^D6EU&RRW(Z5B];&-6[(R[:_1KL<]KZGXF50=WK5X[_`'W7-I^C_A:O\)8E M[0$HV+%2XAUEP\?_`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`O7JNE]3/4'9K35Z)PLI^+](.W;&UV>KH!LW^ MK]!1Z1U4]2;EDT^@<3*MQ2-V[<:MOZ30-V[]WT5R.1D4EO5A@W?Y<'5_\GU, M>1:23BLM/H3[\9S&7_:'V,^S^DS])_-I5WX[OMS<.Z>LCK;OL55;SO+'6TG( MEU7]7^M_<6>]*XC?>_ZW_H?]5__]#T M#K?JPPXA_6Q!`@06[F[66.)_1[KMGV>S;9^D_P`%Z?K+.QW/]"D-K_0^@[:X M/'HBGV_;/48ZK>[]+Z7VGU'_`&OU/Z+^B]=?/:2L8_D%UNULGSFKVZ;;_P!9 M^C?J_NW`Y6EI8/L[.0&;:MTV>UUE_I?9OIU5_H?_`$)6ZOE5)1Y?G/\`(?X+ M+A^0?RE_A/U3I/GW3KY524;(_5.D^:1CNOE9))3]5)+Y5224_52S.F>C^T^I MR;CE^I7ZGK``>CL_5?LGIRW['N^T_P#"_:OM?J+YH23H[2WV_P"ZZK3O';?] MG1^J=)\^Z6B^5DDU<_529?*R22GZ.Z4,?_G'UCTW7&^,?[0'BL51L=]F^SNK M<;OYK?ZGJK<7RJDGY-Q=_+'?^[X+,>QV^:6W][^7$_5.D^:6D^:^5DDQ>__9 M_^T/'E!H;W1O.$)) M30/S```````)```````````!`#A"24T$"@```````0``.$))32<0```````* M``$``````````CA"24T#]0``````2``O9F8``0!L9F8`!@```````0`O9F8` M`0"AF9H`!@```````0`R`````0!:````!@```````0`U`````0`M````!@`` M`````3A"24T#^```````<```_____________________________P/H```` M`/____________________________\#Z`````#_____________________ M________`^@`````_____________________________P/H```X0DE-!``` M``````(``#A"24T$`@``````!``````X0DE-!#````````(!`3A"24T$+0`` M````!@`!`````SA"24T$"```````$`````$```)````"0``````X0DE-!!X` M``````0`````.$))300:``````-!````!@``````````````5@```HP````& M`&(`;0!S`#,`,``Q`````0`````````````````````````!```````````` M``*,````5@`````````````````````!`````````````````````````!`` M```!````````;G5L;`````(````&8F]U;F1S3V)J8P````$```````!28W0Q M````!`````!4;W`@;&]N9P``````````3&5F=&QO;F<``````````$)T;VUL M;VYG````5@````!29VAT;&]N9P```HP````&7!E`````$YO;F4` M```)=&]P3W5T```"=@```)$P`8``'_V/_@`!!*1DE& M``$"``!(`$@``/_M``Q!9&]B95]#30`!_^X`#D%D;V)E`&2``````?_;`(0` M#`@("`D(#`D)#!$+"@L1%0\,#`\5&!,3%1,3&!$,#`P,#`P1#`P,#`P,#`P, M#`P,#`P,#`P,#`P,#`P,#`P,#`$-"PL-#@T0#@X0%`X.#A04#@X.#A01#`P, M#`P1$0P,#`P,#!$,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,_\``$0@` M%0"@`P$B``(1`0,1`?_=``0`"O_$`3\```$%`0$!`0$!``````````,``0($ M!08'"`D*"P$``04!`0$!`0$``````````0`"`P0%!@<("0H+$``!!`$#`@0" M!0<&"`4###,!``(1`P0A$C$%05%A$R)Q@3(&%)&AL4(C)!52P6(S-'*"T4,' M)9)3\.'Q8W,U%J*R@R9$DU1D1<*C=#87TE7B9?*SA,/3=>/S1B>4I(6TE<34 MY/2EM<75Y?569G:&EJ:VQM;F]C='5V=WAY>GM\?7Y_<1``("`0($!`,$!08' M!P8%-0$``A$#(3$2!$%187$B$P4R@9$4H;%"(\%2T?`S)&+A7U5F9VAI:FML;6YO8G-T=79W>'EZ>WQ__:``P#`0`"$0,1`#\`[[K-K+A] ME=><:EKF-M>';"YSR-M&Z1[&5.]?)9_H_2_,]546O%=(;96`^H.9=4&!UWK- M-5=5--[MSO3RO5]1CWLMNV?S=W^B)Z.5BY.1NM?O?:Z'5L;8XMM=OQZW?:/? M779/I-V/^Q^I79ZGV?TUG6X[VY#KI:*ZG[?6W.;L:STJ[:Q75^B]+?97ZCZJ M_2I_T=U?JJS`"JO3=JSD;NM=G6Z.XX=C\=UWJLWBNUN\O%5KFL<-FXNCZ7\Y^EK]%;^4]M>+=8\D-96YSB`28`)/ MM8'.=_94>0:@[D[LN,T"-A';^7]5P<7ZUY-F/TW.R<%M6%U:YE%+V7>I8Q]F M[T/6I=32S8_9[O3OL]-;F=DNQ,2W);1;E&H;A10`ZQW\FMKW5M<[^VN#Z=?C M?LCZOV=.O];K=-E57V0/-H;6269GJX;B]F'MHW>IF,JIM_X;](CV_9_^;'7> MH59ES\BNW+HHM^U6NVU^MNQJZ_TNW](UM>S_``ES'_Z.Q2RPQXA0X?5PUK^] MPK(Y36IXM+O_``;>[''@@8.=C=0Q*LW%<7X][=U;R"V6_O;7AKURS\G%L^LX M#F[-T#MWXNG M^"N.;6@!6HW>TOZDZGK&+TTTRW+JMM%^X0#2:]U?IQN_PS$#KO76]$&+==3O MQ;[A3=:'0ZH$.L];TMCO4J8RNQ]OO]BY_IF9D6=0Z3-GJV^GU/[`'7_IZJO9;Z?J6TU^K^D6EU&RRW(Z5B];&-6[(R[:_1KL<]KZGXF5 M0=WK5X[_`'W7-I^C_A:O\)8E[0$HV+%2XAUEP\?_`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`O7JNE]3/4'9K M35Z)PLI^+](.W;&UV>KH!LW^K]!1Z1U4]2;EDT^@<3*MQ2-V[<:MOZ30-V[] MWT5R.1D4EO5A@W?Y<'5_\GU,>1:23BLM/H3[\9S&7_:'V,^S^DS])_-I5WX[ MOMS<.Z>LCK;OL55;SO+'6TG(EU7]7^ MM_<6>]*XC?>_ZW_H?]5__]#T#K?JPPXA_6Q!`@06[F[66.)_1[KMGV>S;9^D M_P`%Z?K+.QW/]"D-K_0^@[:X/'HBGV_;/48ZK>[]+Z7VGU'_`&OU/Z+^B]=? M/:2L8_D%UNULGSFKVZ;;_P!9^C?J_NW`Y6EI8/L[.0&;:MTV>UUE_I?9OIU5 M_H?_`$)6ZOE5)1Y?G/\`(?X++A^0?RE_A/U3I/GW3KY524;(_5.D^:1CNOE9 M))3]5)+Y5224_52S.F>C^T^IR;CE^I7ZGK``>CL_5?LGIRW['N^T_P#"_:OM M?J+YH23H[2WV_P"ZZK3O';?]G1^J=)\^Z6B^5DDU<_529?*R22GZ.Z4,?_G' MUCTW7&^,?[0'BL51L=]F^SNK<;OYK?ZGJK<7RJDGY-Q=_+'?^[X+,>QV^:6W M][^7$_5.D^:6D^:^5DDQ>__9`#A"24T$(0``````50````$!````#P!!`&0` M;P!B`&4`(`!0`&@`;P!T`&\`G)E4WI.5&-Z:V,Y9"(_/@H\ M>#IX;7!M971A('AM;&YS.G@](F%D;V)E.FYS.FUE=&$O(B!X.GAM<'1K/2(S M+C$N,2TQ,3$B/@H@("`\"UN&UL;G,Z&%P+S$N M,"]S5'EP92]297-O=7)C95)E9B,B/@H@("`@("`@("`\>&%P34TZ1&]C=6UE M;G1)1#YU=6ED.C5#-3A&,3`W0S8P,T1#,3$X,3&%P34TZ26YS=&%N8V5)1#YU M=6ED.C5$-3A&,3`W0S8P,T1#,3$X,3&%P34TZ1&5R:79E9$9R;VT@&UL;G,Z>&%P/2)H='1P.B\O M;G,N861O8F4N8V]M+WAA<"\Q+C`O(CX*("`@("`@("`@/'AA<#I#&%P.DUO9&EF>41A=&4^,C`P-RTP-2TQ-E0Q,3HU-CHS M."TP-#HP,#PO>&%P.DUO9&EF>41A=&4^"B`@("`@("`@(#QX87`Z365T861A M=&%$871E/C(P,#2\^"B`@("`@(#PO&EF/2)H='1P.B\O;G,N861O8F4N8V]M+V5X:68O,2XP+R(^"B`@("`@("`@ M(#QE>&EF.E!I>&5L6$1I;65N#IX;7!M971A/@H@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`* M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`* M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`* M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@ M("`@("`@("`@("`@("`@("`@("`@("`@(`H\/WAP86-K970@96YD/2)W(C\^ M_^(,6$E#0U]04D]&24Q%``$!```,2$QI;F\"$```;6YT`",`*``M`#(`-P`[`$``10!*`$\`5`!9`%X`8P!H`&T`<@!W`'P`@0"& M`(L`D`"5`)H`GP"D`*D`K@"R`+<`O`#!`,8`RP#0`-4`VP#@`.4`ZP#P`/8` M^P$!`0&!YD'K`>_!]('Y0?X"`L('P@R"$8(6@AN"(((E@BJ M"+X(T@CG"/L)$`DE"3H)3PED"7D)CPFD";H)SPGE"?L*$0HG"CT*5`IJ"H$* MF`JN"L4*W`KS"PL+(@LY"U$+:0N`"Y@+L`O("^$+^0P2#"H,0PQ<#'4,C@RG M#,`,V0SS#0T-)@U`#5H-=`V.#:D-PPW>#?@.$PXN#DD.9`Y_#IL.M@[2#NX/ M"0\E#T$/7@]Z#Y8/LP_/#^P0"1`F$$,081!^$)L0N1#7$/41$Q$Q$4\1;1&, M$:H1R1'H$@<2)A)%$F02A!*C$L,2XQ,#$R,30Q-C$X,3I!/%$^44!A0G%$D4 M:A2+%*T4SA3P%1(5-!56%7@5FQ6]%>`6`Q8F%DD6;!:/%K(6UA;Z%QT701=E M%XD7KA?2%_<8&QA`&&48BABO&-48^AD@&449:QF1&;<9W1H$&BH:41IW&IX: MQ1KL&Q0;.QMC&XH;LAO:'`(<*AQ2''LP>%AY` M'FH>E!Z^'ND?$Q\^'VD?E!^_'^H@%2!!(&P@F"#$(/`A'"%((74AH2'.(?LB M)R)5(H(BKR+=(PHC."-F(Y0CPB/P)!\D321\)*LDVB4))3@E:"67)<`^(#Y@/J`^ MX#\A/V$_HC_B0"-`9$"F0.=!*4%J0:Q![D(P0G)"M4+W0SI#?4/`1`-$1T2* M1,Y%$D5519I%WD8B1F=&JT;P1S5'>T?`2`5(2TB12-=)'4EC2:E)\$HW2GU* MQ$L,2U-+FDOB3"I,%W)7AI>;%Z] M7P]?85^S8`5@5V"J8/QA3V&B8?5B26*<8O!C0V.78^MD0&249.EE/6629>=F M/6:29NAG/6>39^EH/VB6:.QI0VF::?%J2&J?:O=K3VNG:_]L5VRO;0AM8&VY M;A)N:V[$;QYO>&_1<"MPAG#@<3IQE7'P,QY*GF)>>=Z1GJE>P1[8WO"?"%\@7SA?4%]H7X! M?F)^PG\C?X1_Y8!'@*B!"H%K@%JX8.AG*& MUX<[AY^(!(AIB,Z),XF9B?Z*9(K*BS"+EHO\C&.,RHTQC9B-_XYFCLZ/-H^> MD`:0;I#6D3^1J)(1DGJ2XY--D[:4()2*E/257Y7)EC26GY<*EW67X)A,F+B9 M))F0F?R::)K5FT*;KYP0)ZNGQV?BY_ZH&F@V*%'H;:B)J*6 MHP:C=J/FI%:DQZ4XI:FF&J:+IOVG;J?@J%*HQ*DWJ:FJ'*J/JP*K=:OIK%RL MT*U$K;BN+:ZAKQ:OB[``L'6PZK%@L=:R2[+"LSBSKK0EM)RU$[6*M@&V>;;P MMVBWX+A9N-&Y2KG"NCNZM;LNNZ>\(;R;O16]C[X*OH2^_[]ZO_7`<,#LP6?! MX\)?PMO#6,/4Q%'$SL5+QHM\IWZ_@-N"]X43AS.)3XMOC8^/K MY'/D_.6$Y@WFENV<[BCNM.]`[\SP M6/#E\7+Q__*,\QGSI_0T],+U4/7>]FWV^_>*^!GXJ/DX^H6&AXB)BI25EI>8F9JDI::GJ*FJM+6VM[BYNL3%QL?( MR'EZ>WQ]?G]TA8:'B(F*BXR-CH^#E)66EY MB9FIN]^Z] MT4OYL_)FE^*7Q_W3V11X]-P]@92:DV-TYLH$&IWQVUNL346SL!%%J4O1PU*O M75[`KXL;1U$EP5'L8\B?0'] MQ.<$Y)Y7O=WCB\7='(AM8?.:YEJ(D`]`:N_I&CGRZUMM_P#R'^2WRB^-G2/R M:Q_R8[AZ,WOTS5[+ZI^9^V=I]E=C[0V#_=?LBB@SO1OR=R>V.L-R8*3&;*WC M!G*:'<&0Q,?W4`FD>&GD7'&&3*';N6N5N4^:-^Y5DY5LMPL+Y9;C;'D@@DF\ M2`E+JQ62='U2QE&,*2'2:`,P,M1B/NG-7-_.?*/+O.,7.%_MNX[>T5MNT<5Q M/%!X=P`]GN#1V\B:8I0ZB=XQJ6I*J1%I)P.M]K[$I]YXCI_YN3.5.5=XV2/^T";5"EY;^HN;6NM=/`R1AHS0FJCH>;19[:FX0;#S MUSESAL>_RXB+[Q.]E<^AM+RFA]6"(I"DHJ%HQSU8D/Y:.#(!'S=_F5$$`@CY MH=@D$'D$$4UB"/<:?ZZ=Q_TP7*W_`'+(?\_4K?ZT%M_X47F__N;3_P";KW_# M:&$_[S<_F5_^EH=A?_4WOW^NG/\`],'RM_W+(?\`/U[_`%H+?_PHO-__`'-I M_P#-T7+Y%=`_&SXK[>H\YW)_,5_F/X2NS4JT>T-DXOYD]D[A[%WYE99!!38? M9&QL125.X=Q5U35ND(:&'[>*1U\TL:G5[$W+/,7-'-UR]OLGMGRQ)'&*R2MM ML"0PKQ+2RL0B`#.34@'2#T$^;.6.4>2K6.YW_P!U^;8Y)#2*%=UG>>9N`2&% M07D)-!@:02-1`SU6ME>NOE_O3OOI?K_#?(CYN_%[9&]J?,=G;EV]W%\P>S-\ M=X[;^-.R915;Z[J[A@Q^?QFR.EVVV"*U>^EQ%:VQ*-+=$?VDTG8BQ@:`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`]HD4&A+=`.TVJ'8N0/;CW#:T\;8GV2';] MYAH2)=OF72L^D<7M7:I([C$Q%0J]'D^'5+M'=^U.T?Y:7R?QVV^Z8NCL3A,O MU/E-Z4F/W%C>\/B1NI7/3?8N.EEC>GJLSLBED&`KJRB(:BJJ:F:.8RN7]@#G M9[RRO-I]TN4Y9;$[@[+<+$61K7<8_P#;9)_N+.I."\(_1=D^!E0AJFO2AD^/?RV^$]\I\.= MV5?R/Z"QX,E5\0>\MVS'>.T\5#JD>B^/O>&6%57TJ1(0E-A-RM544<:$1U'D M<63#F3DWGO\`1YVLQM?,3<-QM8QX-K8 MC)9'9W;'R0^3.*QLU;UWO;#.M'NW9'6G4N&RV1.^MZ;5R(DIIJNOJ(\3#4QM M'*BDJ_M;<RL68":)LQRSW#*OA12+1@J`R%352;`VU64;M%_LJHQN.I):RNQVU/O& M;'[,Q,S`TV/Q&&BIS)Y(J8M.='L/[CS=S3S_`'>V\H[/;1VFT2S+'!86J^'` M&)H&DIF5A\3R2DTH7HN>A+MG)?*'MO9[ISKOEU+>[W#`\EQN-VWBW!5025BK MVQ*?A2*(+6H2K8ZJUH=J=F_)S=M-U?N5,CM[OO\`F.G&]W_*"6FEE&4^,W\N M'95>M)U?T935/HEP6Y>U('CHZK0D;5%=D*W[N`A1)[EJ2\VKE2S?=K4K)R[R MQJM;"H[;[>I16>[(X.EN:LN31$CT-FG4,1V6\!XN9N;=-YN-#W;?L M,+4M[,'\$ER*(U`-3O)K7%>A9J?BE2]X]V_S1NL^KY:3KSL+IO?/P@WY\8-P M8I(J"GZU[.ZL^.-*.O/X>`C046%J*2F.(JU*.HQ]5(=+,JV)UYO?8-A]IMUW M8&YVV^M]TAOT;)G@N+T^-7S+`GQ%X=ZC-">CMN24YDYB]Y]GV8K:;KM]SM$V MW.M%%O<6U@/`T^00@>$V"-#'!('5LGPW^2-)\INAML=E3XMMK[ZH*K)[%[AV M%4!XLAUWW#LNI_@V_P#9U?32LU13?8YB$S4HD_UK-XNWL%EMIA\,UM*-4,@/`U7#4P'##RZG#D#FU.=.6;/=VA\'_=>Z][]U[IHSFX" MHI8G[``3TQJ/DANX*_\`5SH4>O\`O'I;MC_F5W;O6/8Y$1F*;$WYM;=LBP@7 M:5X\#E:^1$4?4D`#V4;EL&^[/_R5MEN[7-/U8I(\_P"W4='.U\R]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U'K*RDQ]+4UU?54]#0T M<$M35UE9/%34M+30(9)JBIJ)F2&""&-2S.Q"J!HF&S>&W'BZ/.;>R^,SV%R,7GQ^7PU? M293%U\`=HS-1Y"AEGI*J+R(5U(["X(^H]WG@GM97M[F%XYU-"K`JP/H0:$?F M.J6]Q;W<,=S:SI+;N*JR,&5AZA@2"/L/3G[:Z>Z][]U[KWOW7NO>_=>Z][]U M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO> M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NFG-Y[![:QM1 MF=QYK$[?Q%(NJJRN;R-'BL;3+SZJBNKYH*6%>/JS#V]!;W%U*L%K`\DQX*JE MF/V``D],7%S;6<+7%W<)%`O%G8*H^TL0!^WH'J3Y2_&2OK4QM#\C.B*S(RRF M"/'TG;O7]16R3`Z3"E+#N%YWE#<:0M[^SM^4N:XXS+)RSN"Q`5J;:8"GK4I3 MHA3G3DZ600Q\V;8TI--(NH":^E`]>E/O?NWISK5=J/V%VIU[LE-]9BDV_LMM MT[PP.#&Z\U7ND5)C=OG(U]/_`!:JGDE4!8-?+"]KCVDL-AWO=#>#;=HN9S;H M7E\.-W\-1Q9](.D#YTZ6;CS%L&T"R.Z[U:VPN9`D7B2HGB.W!4U,-1..%>/0 MH>RGHYZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][ M]U[ICGW-MNESU#M:IW!@Z?<^3I*BOQNW)\M00Y[(4-(":NMH<1)4+D*NDI0# MY)(XV1+U"VMT]O)=I;2&T0@,X4E%)X`M2@)\@34])FO+1+F.R>ZC%XZEE MC+*'8#B0M=1`\R!0=/GM/TIZ][]U[KWOW7NF-MS[:7<$>TFW#@UW5+CWRT6V M6RU`-P28J.00R9./#&H_B+X^.5@K3",QAC8F_M1])=&V-X+:3Z,-IUZ3HU<= M.JFFORK7I,;RS%T+$W4?UI34(]2Z]/#5HKJTUQ6E.GSVGZ4]>]^Z]U[W[KW7 M_]'?X]^Z]U7S_,"[DWO@=G[)^-'1>0^U^27RWS==UAUU7P:I)>O-FQ4:U/;7 M=%?'$Z3PXWKC9TTDD,B,LG\2J:;QARI7W)'MQLEA<7M_S3S!'7E?9HQ/,#_H MTM:6]L/(M-*`".&A6K2M>HM]T=_W&UL-NY0Y:ET\W;[(;>!AQ@B`KF=D?'GXBY'I3KC'C&[,ZXZ3W1MO#Q,$^YJ_MMK962OS& M2D156IS.>R9I&VIV]7=B7<^;,3Y]`U_+PVW@= MY?RV/BYM'=6)HL]MG=/QKVEMW<6$R4(J,?F,'FML_P`.RN,KH&],U)74-2\4 MB_E&(]GGN5=7%C[H\VWMI,T=U#NDCHRFA5EDU*P/D00".@_[56EMN'M%R987 ML"RV*WMGH&2 MJE;^+?*'^6AO?(-1[YZGJ9U!?-[BZAITDH8BR.*2LQ]*:2$O+K]S'#=[3S5: MK?W)2+EKFJEO>4^&PWR):Q7`'X4N31SGN5WUM04Z@Z>SWGD^\;;K37-S5R?6 MYLJ_%N/+\S4FMB?QR6HJ@J#I=$T+5J];%W5W9>S>Y>N=D]K=>Y>+.[)[!VUB M=U[:RL5E^YQ68I(ZN!:B(,S4M=3:S%40-^Y!.CQN`RD#&;=MJOMCW._VC

U3B7;KJ%9(V'FK"HJ/(C@ MP.58$'(Z(1_*R_YD_P#(/_Q>?Y??^_;RON0_=O\`Y+7+?_BO[=_VCKU&7LM_ MR0>:?_%DW3_M*;H`_GSW-LGM'M?)=/[SR/C^*?PQP6#^3?S;KX2DM+O/YW,&W;UOV`VCOCY-=Z8X4GR2^7&;H>S>P<=-JDEZXV1 M#1?:]2=*8^29(YX<;USLZ6-)XV59/XE4U`D+E%;V$O&A5I2I'0T]KN7]QM;'DC\2/^R_OYJ7_`(>?Q*_^![@]K.L.](E#)B M.N?DK34[474_:TRC_)L7B>S:"-\!F9[11"O2GJJF4LRCVKVL_P!?>0[C8'[N M:=A1Y[0_BFL2:W%N/-F@/ZT0R=&I%%`>D>[C_6Y]Q+;F1.SE#F.1+>\'X8-P M`I;7)\E6X6L,IP-81W-2.K7?]^Z]U[W[KW7O?NO=$R^>=5\QZ?X] MYU/@UC=I5W=E7DJ2F-3NBLQ=-5X?:K4>1ER^3V?!N!?[LY#=Z545-%319)A2 MB*6632\B1H1Q[>IR2W,EN>?Y9EV$*32,,0TE5TK(4[Q'346*=U0!@$GJ/_QM_]E[MJ,D],6WEN/+9ZH@KWG--]E04E=52TN-19CXT@ITBB3]*J!Q[Z9;1 MLNP;!9+%LFV6UK9A:_I(J`BE:D@5;&:DDGS/7*#>]^YCYDOFFW_=KJ\OB]/U M9&-3 M)X3I'&C$5*(#&[$*<:F;NI72M:"IO^9[_*1W-_+NH]M?(7H3LC>&YNI6W)28 M6JRM?-'B.Q^K-S5OFDP%14YW;2XNGR>&RK0/#%D((*&2FJ_'#(C&:.1IB]J/ M>2T]RWNN6^8MK@BWGPBP4#5!<(*:P$?459:U*$N&6K`X($(>\GL9>>U,=GS5 MRQN]Q-L?C!"S'3/;2&N@EX](9&H0'"H5:BD'4";2_P"1I_-*[(^0N;R7Q-^1 MNX)]X[^P^VJS<_5?9.4=7W%NG"X1H1G]H;LJ@%;,YW$44ZUE'7N#4U-)#4BI M=Y(D>2)/?[VDVOEJ"+G'EBV$&W/*([B!?@C9_@DC'X48C2R?"K%=(`)`FC[M M_O1NW-5Q-R/S9=&XW2.$R6UPW]I(B4UQ2G\;J#K1SW,H?625!.R][Q9ZR^Z] M[]U[KWOW7NJ-/YS?\S;M/X&8KJ79726WMO3[_P"UHMRYNHW?N_'3YC#[;V]M M:HQ-&]+C,/'4T5/DQWM5M'N'-O-]OUS(-NL MRBB.-@K.\@8U9J$JBA>`%6)X@*0<;_O`^\6]>V<.Q[=R[:Q'=+X2.995+)&D M9445:@,[%N))"J/A)8$"S_)^_F"[[^??2&]\UVIMO"X;L?JO=E!MC/9?:]+5 M4&V]U4&9Q1R>'R]-CZJHK&Q>6C^WGAK*>.:2$%(Y4T+-XHR;WI]M]O\`;K?K M"#:+J23;+R$R(LA!>,JVEE)`&I<@J2`>(-=-2>>PWNEN?N?RYN-QO5I''NUE M.L;M&"L]^Z]T#G=WR#Z4^-^ MSJC?O>796U.M=K0"015VY,E'3U.3J(E#M08'$1";,;AR95@5I:&GJ*AAR$M[ M.]AY;WWF>]7;M@VN:ZNSY(M0H]78T5%_I.0/GT0V.M:_% M5Z:X)9*#)TU'D**=2"DD4T4]^Z]U[W[KW7%]>A_'I$FEO&7!*!['3K"D,5U?6QO;WL4J*\.M&M#3CUHD M?SFLW_,?V)V1@=C?+GO#!;EV/V'C,GN;9.T.E\EF[:5N3I6[$V'%S[Q> M]_@![J\R4'X;?_M'BZRX^[>2?9[E:I_%<_\`:3-U;=[AOJ<^O>_=>ZK,_F)? MRXL5\\Q;'N^WSV=WM<#V5Q$592BY5Q0^6#0X(R#D9ZY@67,/,&R[G;WUE MN]Q'?6TP96$CX9&J//(J,@X(P10]?1_^%/RBVQ\QOC5UEWWMO[:FGW5A4I=W MX*GE\AVMOW#VH-W[J1[*H)('M;MVWW>[;A9;980F2]N)5CC4>;N0JC]I MX^7'I!NFY66S;;?[MN,PCL+:%Y9&/!412S']@P/,X'7S6OE9\PNV?E#\@.S> M[,SNW=F)AWGN6NJMN;:I]QY6*@VEM"GD^TVMMB@IZ>L6D@CQ&$@ACE:)56>I M\D[`O*Q/4;E#DK9^4^7-JV&"SA=H(@'MF[^2K_+G4[*Z#^> M^[^_>U\KNK-4V]2M:%#2PK M.T2D.(B9,5/?7W-/U_,7MW9_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_ M=>Z][]U[HO7RO^0FW_BI\=.VOD#N2D.2H.M-IU.8I<.LPIFSN?JZBFP^UL`* MDJ_VPSFY>A% M9J>=*>?05YWYIM>2>5-\YHO$UQ6<_>_//%GM=WNC2WMR[%59F6VMHE!9BL8J%1%!X`NYH"6=JF M]N'_`(3(]8_W5CIZCY5;\_OM]FOERT/7>W_[JC(>/U&/;SY[^+M1B;@`Y,.5 MYN#Q[Q];[U>Z_5EEY0M_H-7PF9_$T_Z?1IK_`,VZ=9*K]SO9_H@KJE?^&5ZH/^>7\O7Y(?`#=^VZ'LRICW3L'*5$L76?:^UY\A)M>O MJ*)OO7PS4];:KVEN>D11.]!+Z74-)3RU"([KD1[>>Y/+'N-974FU)X.XH/U[ M>0+X@!QJJ,21GAK'#@P4D`XR>YGM9S;[7W]I'O#B;;'-+>YC+>&Q&=%#F*0? M$4/')1F`)'T"_C7VA3=U_'OI'MREF6=>Q^J]B;PG=23HK\[MO'5V3IWOR)J3 M(RRQ.#R'0@\CWSCYIVEMBYDW[9G6AM;R6,?8CL%/YK0CY'KJ+RAO*_=>Z][]U[KWOW7NO>_=>Z] M[]U[I`]K;_H>J.K^Q^TS'9]NDWC=MLVF*14ENKB.(,>"F1P@)^0)J>BS>]TCV39MVW MF:)GAM+:69E7XF$2,Y4?,A:#K4^^)'\_WY-]G?+KKK8?:VR>N:KJ/N#L?`]? M4NVMHX'*4FY-C'>F=I<%MW(XK/2Y:JGS\F)K*^$UJ54#?=PB0Q+`Y0+F#SE] MW/E7:N3-SW#9[^Z&\V5J\Q>1U*2^$A=U9-(":@#ITGM-*ZA7K"'D7[T'..\\ M][3MF][=:-L5_=I`(XD820^*X2-E?42^DL-88'4*Z0II2^?^9/A?G9E>EIZK MX1]C]>=<5V"PV\,[V37;EAGCWSD\+BL3!7XW&];YB?#9W`X;)3)35BSRU4=/ M+K:`PU4&F1CCU[73^W\.^JG/FV7-U'(\:0!"/"5F8AFG4,CLHJM`I84U:D;' M63/N[;^Y4_+S/[=;M:VDD4I8*:Z=+KGK4`_E%[Z MWKV'_-8^.&\=^[NW-O/=F:S_`&#+EMR[ISF3SN=R3R=3;^#_`'N4R=34UM2I M5B-+N5"\`6X]YI>\VWV&V^T/,]EMUE%!9QQPZ4C141?\8AX*H`'[.L#O8K]^Z]U5I_-0Q_S M[?I/*[B^%W9FP^N,%LO9F^-V]M2UT=52]JYC%[?Q\.7@HNM\Y/ALUAL5,N*H M:TR&]!6M.8A#5("WN6_:.3VZ&_0VW/.U7%U<3SQ1V]*&W5G8J3.@968:BM/C M6E=2'J%_>J+W//+L]W[>[Q;6EM;V\TMR347+JBA@+=RCHITAZ_`Y.G2XSUJX M_P`CW=NZMZ_S2^L=S[QW+G]V;DS6V.WZC,;@W)F,CG,UE9VZTW(YER64R=14 MUM=(60&\KL;@?T'O+/W\L[2P]I-UM+&UCAM8Y;8*B*J*H\=/A50`/R'6&7W< MKZ]W'WHV>\W"\EGNY(;HN\CL[L?IY,LS$D_F>M]GWSQZZ:]>]^Z]U[W[KW7_ MTM^+/9W#;7P>9W-N+)4>%V_MW%9'.9W,9&=*;'XK#XFDFK\GDJZID(CIZ.AH MJ=Y978@*BDGZ>WK>WGN[B"UMHF>YE=410*EF8@*H'F22`!Z],7-S;V5M<7EW M,L=K$C.[L:*J*"S,3Y``$D^0'5:GP7P.8^0?8?8W\Q;L/&5E%-W#CAUW\6MM M9B%XJO87Q8V_E)*G#9O[.=5DQV?[MST3;AK@=9%(:18Y#$Q42E[@7$'+>V[9 M[9[;*K+9-XU^ZG$U^ZT9:CXDM4_13^EK)%17J(?;:UN.:=UW;W7W6%E:_3P- MNC<4,.VHQ*/0_"]V_P"N_'M\,`T-.IGR;^>&RI,AO'XN_&O9^?\`E?\`)//X M#,[9R.P^K*FD?:767\*(NK^Z< MJ^WM\(['FSFB]CV?E>.1766X!\2?0P;3;0#]29C3!`"TR":$=.-H;8CPK?6I77=7!_2A45R"2]10JM0>@3^&ORQQWQ&V#TO\)_ MFSL?+_&3L'8>UL%USL'LK<]=3YCH+NB/#P?9T%9M+MJABBV_AL_5T\:R5&*R MC4LE.S*OD9W$8/>=^3Y><]QWSGOD2_3==MN)GFF@C!6[MM1J1);GO9`<"2/4 M#QH`*]!WD#GB+D7;.7O;OW$VV39]TMH4@AN)"&LKO0**8KD`(CD9:.325J!4 MDTZ,E\_.I=WYG:FP/E7T1CH\O\@?B=E:[LC9N+HVO_I5ZQR-`M-V_P!,5DM. MDSUM!O[9B/)1*J2.,I2T_ATM(S>PO[=;S907FX\H.:2!JF*1FG](%_N+LM_O>ROS#>PTYPV21;#=E&3 M(%[;6]^:RH!&S_B.@@!<]`KVPW[;MAWZ/EFPGKR3O\3;CLS'`C+=UY8?T6A< MF1$_""X)+8Z9OCG\D<9\5OA-\K^U)L:^Y-UM\Z_E=L_JO8M,))7F[GOD[:%E\*S_J_M\E MQ*?AAMX[96FE8G`TH#2N"Q4>?2?E/FV'DKV[YWWIH?&OOZR[E%;0CXI[F6Z9 M((5`R2SD%J9"!F\N@W^/7QORG97<.U/C)N[)IO;!=#;SH/EY_,/WZ&2IH.Z_ MFWV'IW)U[TT]9&!2Y;:?4U&$KZRD`>C,-'0P30Q3,;FG,G-$6U[+>?]2"TKP:*V%'9ITYO]P.6.28HOWS>EMPFQ#:PJ9;J M=JT"Q0KW-4XU'2@/%AU5=U;\A.]?B[WA\COEQ\I/A[VEUC\?_ESF>L\[)N7; M&3Q?9^Z.@:#JK9(V#BJSN_8VUHI,]@L;NG&)'D:BHI4J#B9'--)'))^F7-WY M;Y?YLV#ECDWE+G6TN^8]F2=-$BM!'>&XE\9A:RR=CM&U4`8CQ`-8('4+;+S3 MS+R9S'S;SUSGR%>V?*^^R6[F2-EN)+);:'P5-Y#'5T61:.S*&\(G003PMAW? MAN@_G=\;-V;4Q^Z-M]G=-]Q[5K<*NYMH96AS%-3S2+'48_+XRK@>58 MBIZR%)52>CKJ9/(BLI7W#]E/S%[?Y?*-]8Q7L-YL%_`4\2)@X!XJRD5TR1.%<`T9'45`(IT#GP M$[HWONS8^\/C[WI7"?Y+_%#/TO5/:U3*2DN^\$*+[OJ_NB@CD)FEP_:>S8XJ MLRM9CD(:H,JV4>SOW%V.PL[^RYDV".G*V\1FXMQ_OIZTGMCY:K>6JT_@*<>B M#VPYAW&^VV_Y6YDDKS?L]^Z M]U[W[KW6*;_,R_\`+*3_`*$/NR_$OV]5;X6^SKY9-'_S.2E_\2;!_P"]4OOK M:_\`R0V_YY/^L?7%R/\`Y+Z?\]@_ZN=?4Z'T'^L/?)`\3UVEZJH_G9YG:^(_ MEI?(V+<\M*IS5+L'#;=IZ@IY:S=$W9.T:S%14*."SU5,M#+4G3ZE@@D;@*3[ ME[V(@NYO=/E@V@/Z9F9R.`C$$@:OR-0OVD#J$_O$W%E![0%?U%A2,'B9 M#<1%:?,4+?8I/EUJI_R(]G[GW/\`S*.FLK@*>HDQVQ,!V=NS=]3")?#0[=EZ M]W%M2*2K>,%5BJ=Q;GH*=0W#22K[R\^\%>VEI[7;Y#`W3MBMJXX8<@ M<-G*!UGBI^9>1+V:^Y.0 M"I&I#BJDG2PHPJ0#0D$$<\>WG*GN)80;?S1MYE2%RT;JQ22,F@;0ZYHP`U*: MJU`2*J"%1\9?BQT?\0>M8.J.AMFQ;0VH,E49O)-)6UF6S6X<]60T]/59S<&: MR,T]=D\C+34D40+,(X88DCB1(U50DYJYNW_G3=&WCF&^,UYI"K@*J("2$15` M"K4D^I))))->EO)_)7+G(>T+LG+.WB"RUEVR6=W(`+N[$LS$`#T``"@``=&& M]AKH5=>]^Z]U[W[KW6D'_P`*1JFID^E M3USG^]N[GW'VE"Y*#:(J"IH"9[FI`X"M!7UH*\.MGC^51_V[K^(W_B(!/\+=6">XXZE+KWOW7NO>_=>Z M][]U[K3\_P"%.'_,TOB?_P"&!V9_[T6U_>:GW5/^21SA_P`],'_').L#?OB? M\EKDC_GEN/\`JY'U]^Z]UAJ/\Q/_P`L9/\`H1O=E^)? MMZJWPM]G7S.ND_C'N7Y+5GRI.S)*B;=/1W4>[N]*+`P0B9MSXG:?8.TL/NO% M0@!I_OJ3;&Y*O(4ZQAFGEHA"!>0$=3]]YKM>5H^4?K@!:7][':%R:>&TD,C1 MMZ4,B*C5X!M7EUR`Y=Y.O.;Y.=3MY)O=ML9;P(!7Q%BGB251YU$^6^WZW^1%53#:CU8"GRC(.&ZU8OFQ\>J?XJ?)#>O0 M$60.6J^NL+UO0Y[*!V>&OW7F.LMG[DW=/1ZU5DQHW+F:I*52+BF5+\W]Y;\B M*24C^CXCL%_HTZWJOY.7_;M+XI?^&?N?_P!^1O3WS^][?^GI\W_\ MUX_^K$772?V#_P"G0\D_\\\G_5^7JS+W%?4P=>]^Z]U[W[KW7O?NO=>]^Z]U M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U5I_.BV%N# ML+^6U\CL;MJFEK&N6)T0?[9RJ_:>H7^\)MEUNOM'S;#9H6EB2 M*8@<2D,TZW)EQSWR7N.QV4JI MN(9)8=1HIDC-0C'R#J66O!203@=<^_9SGJU]N^?-KYAOX6?;"KPS:15ECE%" MZCS*,%8KQ8`J,D=?11ZZ['V'VYLO;W8O6>[,'O?8^ZL?%D\!N;;U=%D,7D:2 M8?6.:(ZH:B!P8YH)0D]/,K1RHDBLHYH[GMFX;-?7.V;K9R6]_"Q5T<492/EY M@\014$4()!!ZZM[3NVV;[MUKNVSWT=SMLZADDC(96!^?D1P(-"IJ"`01T'_R M/^.'4ORNZDW%TKW3MT[BV3N-J.I=*:I?'YC#Y;&S"HQ>?V_E8E:?%9G'37\< MJ@J\;O%(LD,DD;F/+',^\\G[S;;[L5SX5_%49%596%&1UX,K#B/4`@A@""OF MWE+8^=]CN^7N8;3Q=NEH<'2R,IJKHPRKJ>!\P2I!4D%1=(].;)^/G4VP^ENN M:?(4NR.NE?+FP;=RML>V@`QT*?LHZ.NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N MH]724F0I*J@KZ:GK:&MIYJ2LHZN&.II:NDJ8VAJ*:IIYE>*>GGAJW.F M?Y1WP3Z$[OC[_P"N>I)J'?&.R%7E]K465W/G2;_JVW6@ M-_):_P"WFGQ=_P"UWO[_`-]-OWWT6]\_^G5\V?\`-.'_`+2(>N8'W>_^GP\F M?\U)O^T:;KZ(/OFKUU6Z][]U[H#/E!_V33\A_P#Q!G;7_O`[@]B#E/\`Y6GE MK_I86_\`U>3H-\Y?\JAS7_TK;K_JP_6CS_(6_P"WE_3W_AI=O?\`OLMS>\]_ MO#?].LWO_FM;?]7TZYR?=E_Z>_L/_-"Z_P"T>3K?Y]\Z.NG_`%[W[KW7O?NO M=?_3V/\`^:W\HNOTW'UG\(W?&Y:$8]G#PP8[!TU945;I!*A>>?:#E/<3:[KS[#;Q>+:5BLW MG98[=+EE[KJ9W[1%:(==*$O*R*@+*:8Z^]O.>UB[V?VYFN9O"O:37R6ZM)ABCI\=BNT.T,4O\*ZTV]58E$BDP&WT:H2G9J:HF5T5P7/O/)G M),LDVQV_]8.<"Q9KVY1OI(I#DM!`W=.X:I$TV*T95(-.C./8N>N?HHH>8+G^ MK7)(4*MA:NOULT8%%6XN%[;="M`88!JTU1V!`/5BG2G2G1OQSV10]<]([(V= MUQM"@"L,7MV&FIY M_DW/?K^>ZO6_$Y)H/X47"HOHJ`*/(=2OR[R[RYRGMT>T\N;=;VE@OX8P!J/\ M3L:L['S9RS'S/2H["V/UCVUM'+["[.VUL_?NS,]3M39?;.ZZ#&9O#UL95E5Y M*.O2:)*B`MJBF0++"]G1E8`A'MM_NNS7D.X[5=36]]&:J\99&'YBF#YC@1@@ MCI9NNV[/OEC/MF\6<%UM\HHTIK?A5WQN]Y*7$T0%SC_CYW1D7K,QL21>13XK-FLQ.IF9I0Q4"4_Z MUX.V-9[Z10;I:1Y8^MY:K19?G)%IDX`#CU$']3^;_`&]8S^VNZK?< MNJ:G:;V7"C^&QNVJT/\`1CFU1<236G55N.S^U^RNR.Q?B;US1[LZ#[0S&^*O MY@_"S8':^#EV9OCXU_,C8[R[F[*Z0(K+XC,]1=RJE3D<'78N>;!RTM76Q:/N M4CC,NRVUWM>U[9SCN;P[CM*6XVW9+D[IM,%RABFV_=8?U+BSSVO:W?=)"\9,)5I!36 M`.@>Z&[MSN$ZT[$^97=FU8-F;3^//R"[^J?CQU7O:H7#8W>WST^1V^,K6U&3 MS\58\5.=M_'C:LL8FEG"R43??5$+)+`Z$ZYAV&WN-TVWDC8KLSWFY;;9B\N( MAJ:+:;*)0%2F==Y)6@&&_35@0P/1#RSS%[V/]:\N)CJGFL[1Z,P+8BEN`J>&%`6J]6:_&WX5]`_ M&S)9/?&+DR?9G>.Z`9-\_(3MW/KOCM_=E7-$L57JW+DB1MW$3!=(Q^+CHZ01 MJJLCE=1BKFCGKF+FB**PF"6NP1?V5G;IX5M&!P[%^-A_'(6:M:$5IU,/*/MY MRQRC--N4)>\YDF_MKZZ?QKJ4D9_4;^S4_P`$85:4!!I7HXCUN-D1XY*NADCD M5D='G@9'1@59'5F*LK*;$'@CV"@DH((1@1\CT/C)$0074@_,=5I]C_`'#[6W MEE>[?@UVC'\1^Z,G.^0W)@,)3Q9?X[]MU)D\\M-V?TX*F'"PU=<08QE\.M'7 MTOE>8+-*;^Y2VSW&GN[&'8>?]I.\[$@HCN=-Y;CA6"YH6(''PY-2-0+51U$. M[>U\%EN$_,7MOO(V+F%SJD1`&L;HUJ1<6M0@)X>+%I=:EJ,W5=W>/R[W_P#& M_P"1?3GR3^1_3=;T#W1M*CCZ>[UJ-IU-3O'X]?*7XZY_*_$G,%RGZ+S1%HPX5RJBK"*>9.>]TY2YLV#F[FW8&VOF&!?I;PQ$RV. MXV+M4R6TXX7%J_ZR03!92A>,,QHIV.L/E\7N#$XO/8/(4F6PN;QU%E\1E*"> M.IH,<\,MM--;W$92>-BK*10J MRFA!'D0001Z]99P3PW4$-S;2J]O(@964U#*PJK`CB"""#YCIQ]M=.]>]^Z]U MBF_S,O\`RRD_Z$/NR_$OV]5;X6^SKY9-)_S.2E_\2;#_`.]4OOK:_P#R0V_Y MY/\`K'UQR]QMDX,.U.8ZJ5JF`BH#QZ%"!WP+]M?9BPY\V3]]WG M.4-I^NT?@A%>0::9;5*FDM6JC2<4-36@Z,>ZWOMN7MUO_P"X+'D:>]_063QV M=HXCJKA-,4FH+2C'4.ZHH*5.LE\FOY@':G\RWLK:^UODUVYM#XV]*[:RRLN<-]@VCEZ%R51(II(HV^$NR1AY)9*$@%B`HJ%":FKMF_REOC'\+>ANDJ[ M/?%#L_`=^9;>\?-?//,._1V_.&TR;=#`#X%J0="@TJXWO+/+LESR1O,6YSW!'CW8(UL14B,H,P*M21$W=G4Y8T(`K^9Q_.)W#\( MMSY7JOKOXZ;QW3O&F@Q4:]J=BXO+[?Z4CR&;PT6;I:7;=;0QK6=A5E'1SA:F M*"KQL<,\%E>ZHK%"7!Q""1VDJY M((-!4=!KWB]^[KVZO)]DVGE.XFOP%_QF=62TU.@<",KF<@'N`:,`@C42#U4G M\>_Y]'RN@Z[[_;>QH>[N_P#?&Z.N\)\:^OL9L.DI,)M3^(T6]Y-^99\3LVBH ML[N/$8B*@Q$=)CY*B>LJ*RH#--XQ.3,G,GW>>3VW/EP6&JPY=UVGF@[CIW'FBYF@3;X%A`2+4)O&;3 M$`\BJ%B"H6+L[5+4U=+#X*_S8/YH?9OS5Z[Z'[#PM'V+2[LW=28SL'KC/=7X MGKW,;`VX'L_[3[5R+ MN?,.VSM:O#"6AF2=IEFDX)'1G97\1NWLTE:EJT4CI?[:^]_O+O'N'M7+.ZVZ MW:3SA9X'MU@:"+C)+J5$=/"3O_4U!J!:58'HXW\Q[^>7V%\;-[[NZ5Z4^.^Y M,/N;!YC.[97MOO+`YG"[6RM;@ZG^'Y'*]=;2B6BDW?AHZA@]+DIZ^*GF0I)] MM)%(I8$>V/L#MO-%A9;[OO,L3VDB(_T]JZM(H<559I,^&U/B0(6&1K!!H/O= MK[R&Z\H[C?*EWR_P#C+V/O[Y`[PAWONW`=Y[AVOB\Q'@<#MYX-O':&RL_3XMJ/;F.Q>.DA MHDC+K=ZOXDJ%JNS-4A M5J*TKD`5Z'/W=.>.9>?.3]WW/FB_%S?1;D\:OH1*)X4+A:1JJT#.U#2M#0DT M'1"_YH/\[/N#JKOC/?%7X<8O"0;GV=F*/:>\>RLK@X=V9BMWW5B&*?9^Q-N5 MRS89&P];5I25-364]7)/7K)%%%&L0EFD/VG]B-EW?EZWYOYWED-I.ADB@5S& MHB%:22N*-W`%E52H"4)))HL9>\OWB=^V3F:YY)Y!AC%Y;R"*6X9!*YF-`8H8 MVJG82%9G5B7JJJ`NIG>GPG_"COJC:2=N5N^>K^X##CUS>7Z3J<;UQF=V10*G MW51CI,7@-E;-2KR$,=U-+A,_-42$:(0[Z1[8:?[L6\7AV:/;[NRJVE;H-,L= M>`.IY9:`_P`4L(4<6H.E"VWWL]DL1OLFY65_1-;6A6!Y0.)72D,56'\,,Y8\ M%J>G'^6%_,5^<'RKZX^=FW*MMJ;^^4&PZ3%[ZZ-VANS$8[9VV<94YV?,8+,; M'GIJ67!5$.%VQD<53&FBR%8)Q/4F.HJP'9U;]U_;/D+E#<_;ZZ3QK;E.X+17 M4D;-*[!`KK*"0X+.K-J*+2BU5,`%WV<]U_=OXWJG;6,P^)V M4F-_@60V$-P[OK\1EXJG$[IW?1UE1+FZ_)02.*L,II]!C71=LB?:&SY&LN5[ MA.0-QFN=E>\=F:75K$VB,,I#1QD`*$(&GSK4UZQA][+[W!O^;K9_#'+O)L&SC.?\8#UIJ((BJ<$*:BMC_P#,R_F[=8_`A:?KK;.#I>U_ MD-F,;%DZ?9'\2:@V[LC%5B:L=F^P,E2K+6Q/D%/DH\73A:NJA'D>2FB>&62, M/:OV8W7W$U;G=7!L^6D;29=-7E8?$D*G&.#2-VJ<`.0P$M^\'OMLWMCIVFSM MA?SVT>H>K MV,XL4L\,B[8_OC@-Z[ZSV/IYH6B%8S2T;2*5\S,K:9>W MS8/NY^WMS^Y][MYKW=T`UJ))I9$X']3PWBB0D9TX:GX:$5A+E_F/[T/N7:_O MS8;F"PV5R?#8QP11O0D?I^*DLSJ"*:LK7&HD&C#NK^:-_-L_EU]C[?VE\X^N M]L=H;5S.N2@R%?AMMX)=U8RDDB^_EV1V7UG24VVFRM&DZ>:"NQ]540!T\T$8 M=6*FS]IO9OW,VRYO.0=SEM+Q.(#._AL>'BP3DOI-,%'530Z6-#TEO?>;WR]J M-VM;'W'VJ&]LI,JS)&GB**:C#<6X$>H5%5=&9:C4HJ"=E7X>_,/IOYM]/8SN M'IS*SRT3S_PG=6U^0][EV3>X0)*:HY%J8Y8R2`Z$TQBA!`92"".LO.0N?=@]Q=@AW M_8)R8ZZ9(VH)(9``3'(`3FA!5@2K*05/IK2?\*WN$/?[_IZG,?^EM_^T>+J?ONW?\`3GN5_P#37/\`VDS=6X>X:ZG3KWOW M7NL-1_F)_P#EC)_T(WNR_$OV]5;X6^SK2S_X3M113_/3Y`03QQS0S?'SL"*: M&5%DBEBD[=ZO22.2-P4>-T)!!!!!L?><_P!Y8E?;OEQE-&&Y0T/_`%#3]<]O MNI*K>YO-*L`5.US@@\"/JK?H@'\T;XEY;X(_-+3ZXVQF*'Y!2,T<-/M MG=/7^%3(;KS$M-'_`,!L;G,.L69I8U!"P5BQ`ET8>\'O?9N5K"W> M2*ZE4V?F9(YFTQK7S9&K&Q]5)X$==`O;/W-V[G#VY@YOW&Y2.:TA87WD(Y($ MU2/3R5TI*H\E<+Q!ZI`_E=;2W#_,?_F4]W?S$.S<74G8'5&>,W6V(R:FHI*/ M<]91RX7J_;M.68TTDO7.QJ3^(U1B`T9:6DJ+`RDF>_=F\MO;#VMV'VUVJ4?O M&\CI.RX)C!U3N?/]:4Z%K_H8=?+K'+V9L;OW:]W>8_=;>(3^Z[&6MNK9`D(* M6\8\JP0C6U.$I1_Q=5,?SH_^WF?RB_[7FPO_`'T^P_QG_`$ZOE/\`YIR_ M]I$O4'?>$_Z?#SG_`,U(?^T:'K93^(&X?F;M;^4+\1\Y\)]E]1[^[`Q^"W?5 M;DVUVM69JE;);:I]Z[_E6EV:F-RV`H*G<=1DDB0)75U-"8R0I+$6Q[Z]MMN:2,(]N%.ES%#F74KD(%KE$8U^767G(=U[@67L1R+<^W>WV M-UNB12F2.Y+C5&)IS2+2R*9"U!1W44X9ZJ@Q?_"@_P#F#97?..ZWCZC^.E%O M/);KI-D1X3,;2W]AZBDW/69>/`KB\HV2[/IH\7-!E9/#.9S&(&#:RNDVF"7[ MM_MO#M\NZ'>=S:Q6$RZEDA8&,+KU+I@.H%F]TI]RBVD;%M*[@ M\XAT-%.I$A;1I;5<#20V#JI3SIUMO_':H^0M7U/MVH^4F.ZOQ7LY^5'YJ?8[1^-&-\[?JJ+8(+ M='N(SX2(&.&,1\)P4U8%6U4()''K&[W;]U_>'VROVN9MFV5^6KBY=+60"9W* MKW*)1XR$2%,M1=%00#PZ-Y\8OF;\J]M_'+?7RT_F2;;Z4Z,Z7AV7MK=O7='L MF'6FILQMK);CW'3QUVYH:J@BQ6/$T61>IGTSQ1`$@%\U\C\H77 M,^W\G>U]U?[AOAG>.8RE#`NFE2KJB&B$.9'H4"BJD]#SD[W`YVM.4]RYY]W+ M3;MMY>%O'+`(1()VUUH'C:205D!01I42%FHRKU4D?YNO\RC^8#W)DNJ/Y>G5 M^'ZXP='!-7C)5V*VWN?<^*VZE4M,FY-_[OWK'5;!VO#4NR".EIZ-I!*QABFJ MW`)F3_69]KO;G9(MX]R=V>ZN&(&D,\<;/2NB&.*DTA'FQ:E.YE0=09_KZ^[O MNCO\VR>U>S1VELH+:BL!9) M:5:A8Y#`TGCDTJN7>3ON_P#N:EU8P7>TRN%#&."2`M2OAL\*12QL0"14KJH=)-#2\ M#X*_S3^K/F;\?^P^T(-J[AP/9?26V:O/]L].;;I9]X;FEIZ/%5^3IYM8P99"`K,&M MP*-*LFDA%H&#]C?A9J(/F9_PH/\`DWELUFNOOC]U;+\9Z>@F%/59OLG"P9_N M(*\:2Q--M[.T!VKM!ZFGE5C#)2924*0R5`O?WD'R/]V[E6&"#F'0^))0^8:,>17K&CW`^]-SC/<7&U'76PL?\7,%4BGZ_ZFZ]G^0W?5-U6NZTR':M9M+%5V]S34 M]5B,CLK9&U\;FI*B$-/2^2IFCDDB:*G$:M[8/8'D:RW/<9.;;@:KF\F%G:&X M\/3;B1A%4AEEED9:'#44$`ZFJ1OF3[R'N%?[5MD7)EL=%K8P&^O1;>+JN3$I MFH"K0PQJ^H96K$$J52@)NOB)_.3^0>'^"W>GR@^7.Q\9N^@V+NW;'7O16[,- MCZ?8U3W7V+N*FRTN2V=5T=%2G"1TFSH M6Y_<#E_E/DR_>&2XADFNXV)E%K"A73*"3JK*256-V)U:3J"MT.N1/?\`YI@] MMN9>MN2>*VGC@LY440F[GD#:HB`-%(@H=Y$4#3J72SK3HLWQP^7'\[C^9 M=N/?&X_CIV5UQU'L79>0IZ;)S-MO9V!V+B,CDXYJS';;I,CG]G]C;XW!DQ0Q M>23FHCB0HTS1>6(,*N9^3?8;VLM;"UYFVNZO=PG4E1KE>5E6@9R$DAB1:X'` MDU"UH:`_E+GK[Q7N_=[E=\I[O:6&VV[`,?#B2%6:I6,,\4\SM3)^(`4+$5%6 MCY1_S"OYS?PHW/U3LGY.U&T\7AJ7>>+W*G9&T=D[3K!]O+S9-NYQ:!+=;A9/J(H8BMW&A&N(R*/ M#I3XE$<4HJ"<$=;B.'RU#GL1BLYBYUJ<9F<=0Y;'5*_IJ*'(TT5923K_`+3+ M3S*P_P!?WA1/#);S36\JTE1BK#T*FA'[1UGM;SQW,$%S"U89$#*?4,`0?S!Z MYRN5M]_4!$G: MBQ7'D-1X1S'SK1'.5(8A.N>OO3]W3<>7)[SF;D:U>YY<8EY+=:M+;>9T#)D@ M'$$5>,88%07ZJ]^$/\Q+Y&?`_=YRW56XOXOL3+5L%1O3J/<\U56;%W3&A5): ME*19/+MS<7VZZ8\G0F*H&E5F$\*F%I9Y]]M.6?<*R\'=[;1N"*1%<1@"6/Y5 MX.E>*/4<2NEN[J&O;GW6YL]M+_Q]DN_$VQV!EM9"3#)ZFG&.2F!(E&X!M2C2 M=Z7X)?S$>A/GSL6?/=99&3;^_MOTM-)O_J3<533C=^T99BD7WT/B\<6XMJU% M2VBGRE*OB8E4F2GG)@7G_P"X/MIS%[=[@MONL0DVZ0GP;A`?#DIY'^"0#)C; M/FI9>[KI+[:^ZW+'N=MK7.SRF+V,#N(XO-':\G<>?Q53NM]U;@%4M`U+U?LZG>*EKJ$Y']BFKJP5@ MR+&\%*(S%++EY[??=QLY=LAWWW!NY(MM0, M*/E;,IU[D<;\;*7=#T07S"E?9D^WXIJ>J>%>*)YH\@"=!C$IT^WI6 M^ZTEV=H,&:Z?&5KTQUX5\76017\0!3SK3IB)?O>O9#>A<8*Z_`9;`24XT\(H M"#3\!(?RI7'56/RV_G!?-+Y)]1X_X]=GR8WKG(;:W97/V+E-BT.=V%N?>55A MC]E1;9WGBOXBRXQ<#E8YY:NEIUIH9ZI8O)`C4ZWEODWV5Y&Y7WF7F3:0]U'+ M"/!64I-'$&R7B;3W:UH%8ZB%K1CJZA;GGWY]PN;MBBY5WDI:2PSMX[0J\,DI M3`CE75VZ&U%E72&8+504SM'?,+^87)_+G^/O2N+H.E>U>]MRU?4&V/M=VO#D M:7KS$QX/"X;!?Q/LCL4TF9FBS60K'29J58GGJ->IYHO(C-B9R5[;#W-YDWV: M3?;/;[47LE8ZJ9FULSZ8(:J-(&-50!2@4T(ZS-Y]]U#[3\K,P.`KL#'1Y/%9"AS%7%D-XUE?$JM#(U5DIHY$D;]M;)IE#W<] MG^3.1O;H[AL]M,V[QW4*F>21F=P]58%12,#S&E`00,\:Q)[+>]W/7N#[GC;= M[NX5V66TF86\42JB,E&5@YU2EAD$M(003@8I?I\S_EA1?#GIV7M:IZF[1[DJ M9LS!M_&;2ZMV_49BL6NJ,=D\F,EN;(Q15$.UMK4U/BI!/D)(I]$KQHL3LX'O M';D;D^3G;>QLZ;Q:6*A"[23N%%`RKIC7!DD)840$5`))`'63ON#SO'R#L#;V M^QWNX.9`BQ6R%SJ*LVJ1J$1Q@*=3D&A(`4D]:PW5G\\[YB_)+YM?'#9^(&S. MI.G]W=V[!V?FNN,!@Z'<=1G=M[IW+C\'D:;S>/>[U#832+.[E`CQH74I&A"@5`J',A(J*]8<;+ M]Y'G[F[W$Y2L(/I['89]Q@B>!$$A>.214822R`N6H30QB(`T.G'6RU\Y_F52 M?"?J:G[)EZ>[/[GK\GDJG$XS;W7.%J*NCH)Z7&U&4FRF]-Q1TM=!M';L5/3, M#5-3U+L_"1,`[+BUR!R0_/>\-M8WNTL8T4,SS,`2"P4+$E09'J?AJHIQ(Q7+ MWW)Y_C]N]C7=VV&\W"5W*JD"$A2%+%I9*$11@#XM+&O!3FFN'\9OYV/S&^5' MS^^.FQYZK9O6O36].R:':N7ZMVOMZ@RD.4PF8IZFF=L[N[<--7;EK,O2FTL< MU%+C8!*H/VX&I3D[S5[$1RI5E(/9&A"!3P(8.:? MBZQ,Y/\`O$<_VL]O9\OW%V(VMHXU8,C@COE<&0L.(*&-:_A\NMLCN M3_F4/:O_`(C??/\`[S&4]X>;'_R6MH_YZHO^KB]9O[__`,D'>_\`GDF_ZMMU M\_/^3M4Y*B_F,_'>MPN,&;S5$_:59AL(U;#C%S66I>E^Q)\9B&R52KT^.7*5 MT<`&:A;2IN80S:1EM(J:#)I3KEU M[!O-'[L\J26\/B7"FY*)4+K86DY5=1PNHT&HX%:GK8%W_BO^%%W:.'S79>`S M/3G1%-3M75^%Z(VS5];UV[Y*.)G:EQ\.6SVW-]XO(5[P(`/O-Q4HD)@*_PPM0>9X]91;I!]Z_>8+C=[6X MV_;$%62SC-N9:>2AGCF5FI_'.M3Y#@"P?"3^?=W?M/N&CZ2^?F,Q=7@Y]R-L MK-=E1[8IMC[UZQW+!7-B*A]^;=QE-0X2OPF/R49BR`BHJ*MH`))CY]'A(LY\ M^[QL-YLC[][=2N+@1>*L'B&6*="-0\%V)8,5RE697PO;75T#?;K[S?,=CO\` M'R[[GPHUL9O!>X\,0S6\@;2?&C4!&16P]$1TRW=33UL\?)N2.;XR_(26*1)8 MI>B>V)(I8V5XY(WZ_P`^R21NI*NCJ000;$>\4>5`5YJY;5A0C<+?_J\G68_. M)#YZ#IW>%5@=MRYNL!I,/'F\I%%3-52_MP"36W"GWT#]]HK2?V[O8+^Z,%B M]Y9K)(%+F.,W,8=](RVE:MI&32@ZYK_=XFO+;W-L;C;K,7&X1V-ZT418()9% MM92D9KP^R,/_`,*-MY[;R_;.)W-U)U8*2&JR]!T%L/\`T:9# M=\='$KU*8^B?/;9WKCUS_=DL;J'9YK6\NZD* M;N;QQ'7AJ.AXF45\U@``S6F>LCMWM_O9;A:3[Y!>6-EI!9;*'Z=I:#.D:XYE M9J>37!).`*XZ!'^7U_/M[2K.VL#T3\Z*'!/0;BST>T*7MZBP,.RL]LO=UOWF]ZDWRUY:]R8XS%++X0N@@A>*0G M2!<1BB:-7:S*J&,Y8,*Z=L__`!_'O#KK.+K_U+;OGIOSXD]9_-'>^U^[_P"6 M]%O+L/=L&(W;1=^;D^4^Y^M]I[UVWG$7;N(R]7N&K-)M[8M+]]CY,0U)55-- M1TTU/XM8C:,OEE[>;=SENO(UA=[#[GF#;82T9M$L(YY(G3O90@J\IHPDU*K, MP:M*@TPS]S=SY&V?W"W&RYC]I!<;K.%E%[)N4EO%-&_Z:L9#1(1J4Q:6944K MIK0@E2T/Q!VME**DR>+_`)%*Y/&Y"F@K*;[P.B5205;9Y`01@@@Q`@@\0)_P#V85?^Y0__`%JZ<_UOK?\`]EG;_N=1_P#6[KW^R987_O0W5_\`I>^W M?_LW]^_KQ/\`^S"K_P!RA_\`K5U[_6^M_P#V6=O^YU'_`-;NNC\-,&H+-_(< MJ5502S/\^=N*JJ!Z6V1_*[H:?N"C[!Q\6&WQLWYD9KLW;O566V;4 MQ;DW#F*G=VUJW-[62JZZQ]&P\O;=[,J-^6Z7 M1-%NKW$=LT1$CN98R\=8%'B.BN:4"G+`=&N^=7RD^#':_1VU.X*/XE0_,OJ/ M9OR)[.ZAS:;7WUE^MHMA]P9W+4DLFYJO;VU(*A-R4G<%0OWE%FI4,M09XKVF MK60@_P!O^4N?]GW^\V5^\S[9! MK>G^CN_=K4^_^GOY-6W^U]J5;BF&X=J_S$=O95*>JAC4/C,K2U>]*;-8/*4: MV22CKJ>FJ8;6,8`'L1;OO6_\NW;;=O?O?)9W@SHDV9UJ#^)2(BKJ>(9&93Z] M!C9=AY^HU"/PL#*'1AP*.JL/3H1_]DRPO_>ANK_\` M2]]N_P#V;^RO^O$__LPJ_P#_V3+"_ M]Z&ZO_TO?;O_`-F_OW]>)_\`V85?^Y0__6KKW^M];_\`LL[?]SJ/_K=U[_9, ML+_WH;J__2]]N_\`V;^_?UXG_P#9A5_[E#_]:NO?ZWUO_P"RSM_W.H_^MW15 M_D)E/AY\70N#[T_E!8O;&5KZ5,N^P:#YT?WZW8^(A#2?WCRNR=EY[<>0QF!I M2@_R[(0T\&H@([,0/8NY;BYVYLK<)H\)\< M>F\=CNJ*OHO&1;%PT^+Z>K]T9#>5=UQBZZ)J[&[3K=P90+6U%7BJ&ICCDA;T MT3@TR72%3[Q0YPF>?F??)9=X&X2FX8-^2)XGKM+U3Y_-=_EL]1?*WH+L7?VV-CX M';WR,Z_VOE]X[,WM@,738S,;M;;E#/E:O8VZVH(8O[Q46X:*FDIZ1ZD/-0UK M121NL?FCEFGV?]T=YY0YBVS;KN_DDY9N9ECEB=BRQZR%$L=3V%"06"T#K4$$ MZ2(%][O:/8N=N6-VW.SVV*+FRUA:6*9%"M+X8+&&32!X@<`JI:I1RI!`U!M- M?^7Y\Q=]_"GY)[$[1VSF:^'9U;F\3@>VMJQU$HQ.\>O:ZNC@S=)7T6H4\V2Q M%-.];C)V&NEKHD8'0TB/F][C\D[?SWRON&TW4"F^6-GMY*=T;.X86#2*ES'7ME@)HX8<"R@EXSQ5P#P)!V_/Y_ M!HZ[^6SO2LC$%5%_I$ZEK:"ITI*%\^Y88TJJ:0@Z&EI*EU#+8F.0CZ$^\+ON MZZX_=&Q0U!^FN`1]B<#^8_:.L\/O/>'+[1;A(*,/J[8J?MD&1]H)_(]5+?\` M"9[J[;F?[C^27;64QE'6[@ZXV1L7:^UJVIBBFFPQ[%R>Z)\Y5X_R*S4M;4T. MRTIC,EG%/-+'?1*X:8OO3[M=6VR"L80'U`,I:AQ4`\ M0.H.^Z!LUI=;_P`W;Y-"K75I;0QQDBI3QVD+E?0E8@M1G26'`GK;]BVQMN'< M-3NZ';V#BW76XR+"UFYXL301[AJ\-3S_`',&)J3_`-U_]]MUK[+_O1_\`*[[)_P!*M/\`J_/T9_=$_P"5`W__`*6[_P#: M/;]:_P!_-O\`C9VO\5/G9V;ONMILO1[9[7[)SG=?4?85.)VHZV3.YS^]-904 MN3(9(=Q[)W!6-3SP,PF1$AG"^*>)FR-]FN:-GYO]OMJV^-D:ZL[5+6XA-*C0 MGA@E?-)4%0>!JRUJIZQ>]\^4=\Y)]RMXW*1)%L[Z[>[M9Q6AUOXA4-Y20N=) M7B`%:FEE)OX_E_?S]>H>X:';?6'RZ>@Z=[8,5%B8>RPGAZGWO7+&L"UV5J`6 M;KK+U\BAI5J0<1Y&9EJ:=62!<=/<;[NV];))=;MR8&O=GJ6\#C<1#C11_HRC MRT_J4P58U8Y/>UWWGMBW^.TV;GHKM^]T"BXX6TQX58_Z`S>8;]*M2'4$*+D. ML?B9\=NMN\.R_E#UEL^CP_9G>F&HH-\;CPV8KYL#N.EEJ:3,29>BPJ5DNWZ: MMS]92P5575TT2M62KYF)>25Y(2W7G'F;=-@VKE/=;UGVK;W)B1E`=#0KI+4U MD("556/:.W@`!/VSSV"Q[QN48$TB.Q205#Z@E=`+D!F91W'N M.22=1O\`X4A_]EU]?_\`BLNQO_?B]L^\RONP?]._W+_I:R_]6;?K!?[VW_3R MMK_Z4\/_`%?N>ME[^6ON6@V9_*_^-N\,KJ&+VI\?VW+DBA`;[#!0YG*5FDMZ M0WV]*UK\>\6O=*UDOO=CFBRA_M9MQT+]KZ5'\SUE][17D6W^S?*-_/\`V,&U M^(W^E0.Q_D.M'#KF#<_SZ^>VS(NQ9^2?R!PS;QJQ/*\M#@MR[F@DS%) MCY/U04FW]K*]/1(ME@@IXT4!5`&?.YM:>W7MY?-MD0$&U[:WA"G%T0Z2?4O) M0L?,L3Q/7.':5O/<[W-V]=UE9KC=]T3Q37(220:POH$CJJ#@`H`P.OI.[?P& M$VI@<+M?;6+HL'MW;F)QV"P.%QL"4N.Q.&Q-)#08S&T--&!'3T=#14Z11HHL MJ*`/?+NYN9[RXGN[J5I+F5V=V8U9F8DLQ/F2223Z]=<[6UM[&VM[*TA6.TA1 M41%%%5%`554>0```'IU7;_-QZ`P'R"^`_?V+R>,@K-P=;[-RO<6QJ]HT:MQ. MY.N*"JW#.U!*PO$^9V]35V-E%[-#6-^0")+]FN8[GEOW$Y=FBE*VUU.MM*/) MDF(05_TKE7'S4=13[Z,_)CUJT_ M\)__`)!9SJGYTX?JK^(3KLSY#;8W!M#-8MI&^Q.Y=KX7*;SV?FS#J"?Q"D?$ MUE!$_P!1'DY!R2/>6WWC.6[?>/;^?=_"'UVVRI(K>>B1EBD7[#J5S\T'6%_W M7N:;G9/)U\O$C1I8GI_$-+(#Z2'HWG_``IP_P"9I?$__P`, M#LS_`-Z+:_L&?=4_Y)'.'_/3!_QR3H=_?$_Y+7)'_/+X0]_O\`IZG,?^EM_P#M'BZG[[MW_3GN5_\`37/_`&DS M=&QS?\P+X/;;S66V[GOEET!B1[!UO[<<_74$-S;\G;D]O(H96$$A#*PJ"#IR"#4?+H<7/N MC[87QV_P#1J[1_ M^N?M[_6Q]Q/^F*W/_LGD_P"@>F?]=GVQ_P"F]VK_`+*8O^@NC2;2WOL[LC9V M+WSU_NC`[TV;N3'25^`W1MC*4>:P68HM4T!J<=DZ"6>DJHTGA>-BC'3(C*;, M"`$KRPO=KO9;#<;22"^B:CQR*5=3@T92`1@@_8:]#2QW&PW>PAW+:[R*XV^9 M-221L'1QD55E)!R",>8(X]:;W_"=7_LOGOS_`,0!O[_W[W5WO-O[S'_3NN7? M^EE#_P!HUQU@']U'_IYW,_\`TJYO^TJWZNW_`)WWPR7Y3_$3+[UVMBS6=L_' M9,KV/M'[:'R5^9VFE)$>QMIQA5>:;[W!4"9&GB0&26MQD,2_YUKP/["\\'E' MG.&PNY=.S;GI@DJ<+)7]&3TPY*$G`61B>`ZR*^\9[?CG3D2?<;*'5OFTZIXJ M#N>*@\>+U-44.H&2\:@<3UI(]4]^=U[(ZW[<^//6V8KQM'Y+_P!R-N[TVO0P M3U5=GJS;FXXLEMVFPHAD$E+7Y*LG-%4"-6-;23M`X92+9X[QR[L5_NFS*\4A(`0.FERU>(4#4*_"PU#/7.O9.9^8MNVC?>5=HN&^AWCP8Y8P"2 MYCDU1A*<&8G0U/C4E3CKZ%'\NSXH4'PR^)75O2_V].N[HL8-V=GUT#))_$^R M]T14]=N=_N$]-33X=UBQ=+)QJHJ"&_-_?-OW+YPDYXYRW;?-1^B+^'`#^&", MD1X\BV9&'\3MUU.]J>2(O;_D;9>7M(^O">+<$?BN)`#)GS"8C4_P(O6DW_.C M_P"WF?RB_P"UYL+_`-]/L/WG=[&?].KY3_YIR_\`:1+USN^\)_T^'G/_`)J0 M_P#:-#UN(?RGO"CWM_Z>GS?_`,UX_P#JQ%UGO[!_ M].AY)_YYY/\`J_+UK)?S^OBA-T)\NJ3OC:5#+C]D?)"EGW:U31(\$&)[7VZU M'2[XIXY8K&"HS`GHLR'+!Y:JMJ2O$9ME5]W3G`2!K_:R(Z'):W>I MB/S"T:*GDJK7CUAY]Y_DAN6.>H^9K&,IMV[J9:C`6YCH)A4<"]4EKQ+.].'6 MU-_++^5^-GCC(L&?QH/3P9:LH'^D.J,GU0]9J^SW.PY]Y M`V/>Y)`VY*G@W/J)X@%APN!A8ZF@R&3F3@EA[FWVZI[;>S7,_/T MHT;QN9\*VKQH"T41'_-PRRGU1%/4!>Y]?=3WSY2]N(3KV/:1XUW3A4A99@?^ M;8BA'H\C#H%/^%*W?F6;>707Q;PU8:/:^&VM5=Q[IQE(YCILAF M.O\`I.@[][SF><[ARQR9;R:;..$W4BC@SLS115']!4D(']/Y=6,_\)[>E,'U M[\$J;M&+'Q)NGO??V[-PY?*M$HK)\!LO+UVQ=M8GS6U-C\?48;(542WLLM?* M?[7N,OO([[<;E[@MM)D/TFWV\:*OD'E42NU/4AD4_)%ZEC[K'+MMM7MJF\B( M?6[G=2NS>92)C#&M?X5*.P'J[>O1;/YY/\Q?XT[HZ%WS\+^M\S2]O]O[MW#L MZ'+U.TEBS&V.N9]L[NQ>?GBJ=PT[24F2WC528G[!*"@-1)3_`',OW+PNJQ2B MCV"]LN:;3F';^>=T@-ELL,-D%$.5C&K7K>@.D:01D!'[R'NQRA> M\L[E[>[1<+?[]/+$&,7?'`8Y5<@N,-*=.@(FHKJ.LJ0%+5_(2_EU_(7H3=^Z M?E/W5CLCUEB=[=:5&R-F=99A9*3=F=H5XX8TC,[WWA_'&W!R=9+,O8*` M`L2=+/W9/:CFKEB_O>=>88GLX+FS,,5NV)75W1_$E3C&!H`16HYU$D*`-577 M_"A%$3^8GFF1$1I>G^KWE9456E<4N7C#R$`&1Q'&JW-SI4#Z`>Y9^[<2?;2" MIP+V?_"O4,?>F`'NM<$#)L+?_`W6US_*PZKVGUG_`"]OC#@<#B,=!!N[J?;W M8.YVCI(;YW<78^.CW1G*W*LT8;(3.;K[D\U MW%Q,Q:&\>&/)[$A/AH%]!VZL?B)/$GK-SV6V6QV?VLY.M;:!`L]BD\F!WR3K MXCEOXCW:7)14\$?DJ6II(XT>:5%84^Q?.UKR_[@_5\ MPWI\*_MVMVGD8G2[-&R,[L2=),80L31=0)(4'H'_`'A>0;OF7VT^BY9L1XVW M7*W*V\2A=:*LBR+&B@#4!(9`H%6TD`%F`ZU=OY8O\T'?'\NW=VYL+D=JMV!T MKV!D:"KWYLE)TQFY,/FL9&]#%NG9]?4K]M#F8J%_#54=4!3UT<4:-)`\:3+E ME[K>T^W^Y=E:SQ7GTV^VRD0RTU(RMGPY`,E:Y5ERA)-&!*G#/V<]Y=R]J;^\ MMY;+ZKEVZ=3-#73(CKV^)$QP'`PR-VN``2I`8;@^*WE\"_YPGQ_K-K1Y'&=J M;+CK\1G,ULZJJZW:79W7&XZ)G-!65E#2U5-N#;=>JRS4PK*:26AK8))HHYIX MG<'"J:Q]P_97F-+LQ/:7VED60`203(>(!(*..#:6`=2%)52!UGI#N'ME[]P.U<#2_8X+; M6&Q>W\+1>6:?[/$X:A@QV.I?/422U$WV]'3(FMV9VM=B3<^XVNKF:\N;B[N' MU7$KL['`JS$LQH,"I)X8ZE2TM8+&UMK*U33;0QJB"I-%0!5%34F@`%2:]//M MCI1U[W[KW7O?NO=4+_S)OY(O4_RDI=P]M?'>DP?4'R$:&IR57C*6!,9UQVG7 MJ'F>'<..I(_!MC<^0>X7+TD8CFE:]9#*6-1%D-[7>_.\+R$+P5-'D,?.:? M,;;W%C2_VV8P&7IPT-3`QDI:VDDNK,C(_O-F_L.7.?>6VMK@1WFP7T(96!J" M"*JZ-Q5U.5.&5AFA!'6`VW;CS1[<\U+=6QEL>8]OG*LK"A#*:-'(O!T889YNY]I8GJN?'T=6XJ-G[SW5N)-C=EX MFEJSHJ@<304^7-#4629X3!.-)86PCY+]MFVOWRM>4MT'BVMC,UP"1B2*-/%@ M8CAW$QZQD`ZES3K/WGOW43=_N^WG.>TGP;S<(%MBH.8I9)/!N%!X]JB70V"1 MI;%>J*/^$^?16"[9^'@JXEGIDWK793$[4VS6-$ZM M&U1BHLU65M,Q]4552Q2J0R`^\@?O(+;+1YU!%1XQ98XS3U76SKZ,JD9'6]K[Y]] M=*NOG)_S=,1CL)_,A^65%BZ6.DIINQJ7+R11*%1LAG]I[;SV7J2%`'DKV')TDKEG%J5J?1)'11^2J`/D.N3?OK!%;^[?/$<*! M4-V&H/XGBC=C^;,2?F>MXCY<113?RX_D+'-%'-&WP_[#+1RHLB$KU+DG4E'# M*2KJ".."`1S[P(Y,)7W.Y:*D@_OJ'_M(7KHYSRH;VFYI#`$?N&?C_P`\S=:B M/_"??_MXUM3_`,17VG_[I:?WF;]X_P#Z=E>?\]EO_P`>/6"GW7/^GL67_/%< M_P#'!UOI>^>?73/KYO?QICCB_FA]-Q11I%%%\V=KQQQ1(L<<<:=RTZI''&@" M(B*`````!8>^GO-1)]IM\)-2=AD_[1CUR3Y0`7WEV!5`"CF*/`_YZQU]'NM5 M7HZM7571J:=61U#*RF)PRLK`JRL#8@\$>^8L>'0CC4==:9`#'(",:3_@Z^^FWND2?:SFPGC^[6_P# MKDW[0@#W>Y,`&/WHO_'CU]##N3_F4/:O_B-]\_\`O,93WS:V/_DM;1_SU1?] M7%ZZH;__`,D'>_\`GDF_ZMMUH#?R6O\`MYI\7?\`M=[^_P#?3;]]]%O?/_IU M?-G_`#3A_P"TB'KF!]WO_I\/)G_-2;_M&FZ^B#[YJ]=5NM!+^?9UCA^N?YBN M_,AA***@I^T=C;"[.K*>!/'"V8R5#6;7S-:B`!?+D\GM*6JF8?KJ)I&/)/OH MI]WC=9]S]L]NCG;V>WVGW7W.6WC"K>V MT-P0.&M@8W/^V:(L?5B3UL^?%+LW+=O?R9,#O3/5)]]^[];;A=2%KC]PW,;$\28(YH:GU)$8)/F>M7?^0M_ MV\OZ>_\`#2[>_P#?9;F]Y9?>&_Z=9O?_`#6MO^KZ=8:?=E_Z>_L/_-"Z_P"T M>3K?Y]\Z.NG_`%\]/^=CUAA^KOYCW?-+@*6.BQF]GVEV8*6&-8HTRN]=K8K) M;EG0+8$U^Z5K:EC^7F/OI+[$;M-NWMAR\]PY:6`205.>V*1E0?E'I7[!URO^ M\1LT&S>[7,R6J!8;@Q7%!_%-&K2'_;2:V/S/6T'_`+-CO?\`X8Y_V9K^(S?Z M1/\`97?X+_'?W/NO[W_>_P"B/^\.O5Y?O/XO_EGDU:O)ZK_GWB=_4ZP_U_?Z MJ^$/W9^]M6CR\.GU&C[-/;3TQUF5_7CO[FT:_/Q:_2Z_6NKN MKZYZ_]7;H_F']%Y;>_7V`[WZ\VCC-[]L_'&7,[II]@Y7'4N4Q7=O3V8HHZ7N MSH+<>+K*:MI,QB^P-HTIFH(98)C'GW*]>#9MS M"QF96*M:W*FMK=HP(*M#(:.016)Y`:C'44^ZO+<^X[7:\S;58)<[YM)>00LH M9;NU<4N[*12"&6>(50%329(RM#GHL_6_Q\[`V%U_M+Y*?RG^VZ.HZ;[)PE!O MZ/X?=S93)YKI+<%'F[9#)4W6^X:BJJMS=';RBE,M-+1)-+C(\BC15"0QP^," MG=.9-MW'1K/\`NN[9GM'#]S"WVN[;/8_O[9KJ+=^5#6EW;58*/2>/XX&%>X.-(.-5<=#3E M;W5V;>]P_JYOMI-LO.2TU6=W16<^MO+B.X0T[3&=1&=%,]+#Y)?.[I#XX9G' M=>5$NX.V>^]RA(]F?'?I[%MO;MG<-34QL]'+5X2@?P;3PDFG4^0RLM+`(0SQ M^4J5]H>5_;[?N9X)=R41V?+L7]K>7+>%;H!QHYS(_HD88UH#2M>E_-WN7RYR ME<1;4[2WW,\W]E8VJ^-F]X34+5FT\=0RY'(R?)3O7%S4F0SE)1T-.\E9BL"]) MC/&H9I@Z,"+X>8>5N4)X=M]N=L.ZBMIT74F_/GY%7]&?$[9VV\+#@H_BS_+7VA7K6]J]Z28JDBA_@ MN]>[8H7R1J*@FJKZRMH?%5.\.CW)ES*FVM->[=RX1=[A([%_K][D%+> MTU&NJ*U)":1VHJR50!J]11:PR;HMLG+5BMCN?-`:SVV*-`G[NV")JW-YI`&B M6[`,FINYV>/2Y*TZ"GI7IW8?1>R.P\KFL?4TGPO[]^2GR(^#_P`DZ.&W.X,Q1?%3Y!4D@#18O*;&SE4,55Y1RB4FJCF/DE"6-]]WO<>8+_;88)0W/ M.W;79;K9$C_<@/;*=PLS_$LJ#Q%CR6[UP*]$G+VP;9RUMVZSW$17V]W3=[[: M+\`T%L8[IAMM\/)6A<^&TAH%_3;+4Z/1\=?C34=JR]BTF![&S?Q6_F8?%O/T MO6WK>/:W9NU.V=J!*R>HGC@R7\4CJF,PT M1Q^P!S-S2NSC;'N-LCW?VKW:,SVUO,3XEFU=-Q;V]P/U()+>2JA02GAE!IR3 MU)/*G*#;VV[):[M)LOO!LLHM[JYMP/#ODIJMKJZMC^G<1W,5'+$+)X@?NP!T M:G`_/;L;XZ9[&]:_S'NM:+J"2NK(L1M;Y4]M\MX=I9:I)K#"2HJ!$%U-*2,@1AB1D"G1"X^R/F_P#.JT'2 MV"SOP:^,>09ED[L[&PU+4_)WLK#%UM/U=UE6>;&=78;,4;'PY?,O+7B-XZBE MB#`H)#.U\A>W_=OMQ'O_`#6O_$6%B+&!O2><4:=E/&.*B5!5S3/49#=_<;W* M[>7K:7EODY_^)DAD`]B/-1%#960[+FXAA6BQM+ M_N/$]/$*ZV#L.@OM?(O+E[STG*>PVC/L&S/'=;K=2L99[^_/?:VT\[5:18//6377O?NO=>]^Z]UBF_S,O_`"RD_P"A#[VOQ+]O56^% MOLZ^632?\SEI1^?])L/_`+U2^^MS_P#)#;_GD_ZQ]<7(_P#DOI_SV#_JYU]3 MH?0?ZP]\D#Q/7:7I"=I[MP6P>LNQ-\[GJ8*/;>SMC[KW/GJJI95@@Q&"P5=D M\C)*6(&A:2F?C\_3V8[19W&X[KMFWVBEKJ>XCC0#B6=PJ_S/19O5];;7L^Z[ ME>.%M+>VDD,I4+R3Y3< M&4@QV,H*>-0"[RU=6D:`?4D#WUIN;B';[*XN[F2D$$3.['R5%+,3^0)/7&"U MM9MRO[:RM8ZW%Q,J(H\V=@J@?:2`.MZ3^>SBWPG\KS<6%DE$\F(W9TIBWF!8 MB9Z#<&/I&E!;U$2-%?GGGW@!]WV43^[%M.!0/#=-3[4)ZZ2_>4A-M[,W=N6J M8Y[1:^NEU%?Y=5Z_\)@_\_\`-#_ECT%_T/W#[DG[UWP\C?;=_P#:MU%GW-_B M]P?LLO\`M:ZVRO>'?6<'6M!_PIF_[)[^-O\`XF7<'_O$5GO*?[J__*RJ^PS.'JFR&UMWX.28KY::>GKJ5G*DJ& M(,$[1N_,G)FZ6NZ;9/<6.Y!0RFA76C9%584DC>G!@R-\Z=9#[ULO*W/6T7>T M[M;6VX;67*,*A]$BX.ET.J.5*\5*NM:8KUIV?S-_Y(F\?B5@=P][_'[,Y3LW MH+$M+D-U8+,+"_875N-EJ$1*ZNEHXH:7=^TJ,RA9:^&*GJJ)+-40-$LE4,V/ M:KWYLNYC@2TYB?$;K7P;AJV4GB:`"6(5RX"L@RRE07Z,Y_P`)YOG7V+/V+6_"3L#- MUVY=B9#:>!Y;74:F%H^YXE)SX;)J<+P1E.D#6>BV_\`"D/_`++KZ_\` M_%9=C?\`OQ>V?8G^[!_T[_V_Z>5M?_2GA_ZOW/6QE\%- MJUN^_P"4-U#LC&`MDMY?%/H(!:MW#@=RXBD`)N`3/6+R>/>,WN#>1[? M[S[U?R_V4&[I(?L1T8_R'66'MK92;G[$[#MT/]K<;))&OVNDBC^9ZTK/Y<6Y MJ'K;Y_\`Q4S.ZB<528KO79^$RS5NJF.,GS.5_NPSUHD`:`4-9D@90P&D(;V] MYT^YUK)NGMSS?!:=[OM\C+3.H*OB8]:A<=<]/:6\CVCW0Y)N+WL1-RB1JXTE MV\//I0MG[.OI2>^7/777HI7STWKB^O/A3\J]V9B6**CH.@^T*./S:=$^2SNT MLI@,+0@/Z&DR&9RD$"`_J>0#\^QE[>6,NY<]\H6<()=MQ@./)4D5V/Y*I)^S MH#>YNXP[5[><[7UPP$:[9<#/FSQ,B#_;.R@?,]:/W\E79&7WM_,G^.?\+ADD MI]I9#>&]\Y4(I9*+$8#8NXSYIB%*I'492JI:8$V&NH4`W(!SV]];^&P]KN9O M%8:IECB0>K/*F!]BAF^P'KG+]WG;I]Q]W>4_!4E('EF<^BI#)D_:Q5?M8=69 M_P#"G#_F:7Q/_P##`[,_]Z+:_N*_NJ?\DCG#_GI@_P".2=3#]\3_`)+7)'_/ M+X0]_O^GJ[=]Y_>[#;[&Q/*UJYAA2/5XL@U:%"UII-* MTK2IZCK=/ND;!N.Y;AN`YPNX_'G>33X,;:=;%M-=0K2M*T%>DE_T#)=/_P#> M4_97_HO]K_\`UZ]K/^"JWK_ID;7_`)S2?]`](?\`@/-A_P"FUO/^<$?_`$'U M?9\5OCM@_B;\<>N/CSMO<&4W7ANM,'E<;2[BS5-24>2RLF6SN9W)6U-124/^ M2TR_?YF58XU+:(E4%F8%CCQS?S-<_/_$`;^_\`?O=7>\P?O,?].ZY=_P"EE#_VC7'6$7W4?^GG!O-Z]MX^51:2KS'+$(+ MBXJ-#1##,M#J\291ID!4*-3E2:BF+7+?W:['8?=.7G`WL+\KPS&XM;8!M:3$ MU57J-/A0,2T9#%F*H&`H2=A+WC=UE-U\[W^='_V\S^47_:\V%_[Z?8?OI7[& M?].KY3_YIR_]I$O7*C[PG_3X><_^:D/_`&C0];B'\G+_`+=I?%+_`,,_<_\` M[\C>GO"CWM_Z>GS?_P`UX_\`JQ%UGO[!_P#3H>2?^>>3_J_+U*_FQ_$M?E]\ M+>R]F8C&BO['V)3GM3JPQPK)6R[MV?1UD]1@J0Z#(TF[=N5%=C$0%5-14Q.W M^;'NGL]SC_4OGK:[Z>73MEP?I[CT\.0@!S_S3<*Y/HI'GU?WPY''/GM[N^WP M0ZMVMA]3;8R98@24'_-6,O&!PU,I/#K5U_DE_P`P?;OPVW5WYLOM3*BDZQWA MUGN+L;#4U54+`B=H]78+(Y>@PU`)1IBR&_MOI48Y0+O45U/0Q`$D>\L_??VW MN>=[/EV^VB'5NL%TD+$"OZ$[JI8_*%Z/Z!&D/6&?W=O=.UY`O>9]NWN?3LUQ M9R3H":?XQ;HS*B^C3IJC]6=8UZN$_D$]1;FW?A_D9\_^TXVK.Q/DUV-N'&X+ M)U"/Y#MN@S]3G=Z9#'O("5QN=WW5_:",$B,8%`+"WN%/O%;S:V4W+/MSM!T[ M;M5LC.H_C*!(@W])(AJKY^*>IZ^[%L5Y?PZ&]#5NN\7;JC'_?:N7E9?Z+ MS'33R\$=59?\*0=HYC$_-KK[=U5#+_!=W]`;8I\35$,86K-M;OWM2Y:BC<@+ MY:5?:XPI\JQRS!A]HU*2/Z0]>C;_'CJCY>?,C^3_\`%?IOX;]K M;8ZXH=O[_P"XMB?(I,GN/+;8RN1Q%3OK-;BPE%'G,'BLIDDPL.-W/]QDL=#X MY*^*JIA=XUDC8&\R[QR7R1[T\W;WSOL\MU));6TUEI19%5A$J.=#LJZBT=$< MU"%6X&A`ZY5V3GOG_P!AN2M@Y`WN&TCBNKJ&^U2-&S*9GD0:T5FT!9-4D8H7 M#)Q`(-J'P"_D[_&_X308G>N6I*?N?OV"."HE[/W7BX1C]K5_C_>CZVVO-)64 MFVEC=BJU\KU&5<7M/%&YA$1^XOO7S/SVTUC"YL>722/`C8UD'EX\@H7_`-(* M1C^$D:NII]L/83E+V[6#<9T&X)9;_Q#G6'_`%IS7OH1]VW_`*=I#_SVS_X5ZYH?>G_Z>M/_ M`,\%O_@?K<"_E\?]D*_#_P#\5NZ<_P#>#P?O"SW(_P"G@UO_`$[;D/\`Z5%K_P!64Z-+EMS;;P-7A:#.;@P>&KMR9#^$[=HLMEJ#'5>? MROB>?^&86FK*B&;*Y#P1L_A@6230I-K#V$H;6ZN$GDM[:22.)=3E5+!%X:F( M!"BN*F@Z&D]Y:6LEO%&M+,9:A*P M@)[FWVX]]N9.2A;[9N>K<.7%H!&Y_5B7_A,A\@.$;U7R4IQZ@+W1^[QRKSZ; MG=MIT[;S0U29$7]&9O\`AT0\R>,J4?S82<.M.VOHOE3_`"Q?E6:=JC)=6=X= M592">.HH*IJS;^Z&/0"2*1?'/$6CE2*>-DCS7CDY1] MUN4-05+O8+Q"*$4>-Q@_..:,\",@Y!*D$X$2Q\Z^SG.V@N]ES'9.#535)$.1 MZ"6"5>(."*A@&!`^B%\7>\:#Y*_'?ISOC'8_^$1=H["P.ZJK#B0S+A\O5TJQ M9[#QSMZJB'%9N"HITD-C(D88@7M[YJ5:==5^3.8XN;^5-@YFBB\-;VU20KQT,1WI7S"N&4'S`KT/7L/=";H@? MSJ_F*=+_`,OZFZEK.X,!OS.4W;6Y,MA,?+LG%XW(C!8[;L6)EW!GLM_$LMBA M)#0)G*8I34YEJ:@,^A?1S(OM_P"V>^>XS[RFRW%O&]G$K'Q69=;/JT(NE6R= M#58T48J<]1A[E>Z_+WMVS?Q-0M5C"`;$`W'L!WEG=;==W-A?0-%>0NR.C"C*RFC*1Z@CJ1;&^L]SLK7<=ON$FL M9XU>-U-5=&%58'T(->E#[3=*NM(C_A2!M/9N"^:77FX,##24VZ-Z]$X#*;YC MIA&LM96XK=6Z]NX++UX3U&LGP6+BI`S>HP4,8^@'O//[L-Y?7'(NY6UPS&T@ MW!UBKY!HXW=1\@[%OM<]AT_P"$S>:H*?Y$?([;\K1#)97IG!9:B#$"9Z3![VH: M6O$5^2HDS].6`_H#^.`_]ZB"1N6N6+D`^$E\ZGTJ\1(_XX>A+]S^XB3FOFVU M8CQGV]&'K1)@&I_O:UZW+?>$'6?_`%\Z7^<3_P!O*_E=_P"'IMW_`-]WLWWT MQ]D_^G6\G_\`-!_^KTO7*'W[_P"GO<[_`//1'_U8BZW>OEG_`-NYOD)_XI_V M+_[Z/)^\#.3?^GF\M_\`2ZA_[2%ZZ+\\?].GYI_Z4,__`&BMUJ&_\)^/^WC6 MU/\`Q%?:?^Q_W"T_T_K[S.^\=_T[*\_YZ[?_`(\>L$_NN?\`3V;'_GBN?^.# MK?2]\\^NF?7S>OC1+'/_`#0NFYH9$EAF^;&UI8I8V#QR1R=R4[I(C"X9'4@@ MCZ@^^GO-0*^T^^*PHPV&3_M&/7)/E`AO>78&4U4\Q1T_[*QU]'VK_P"`E5_U M#S?]:V]\Q$^-/M'76F3^S?[#U\Y#^6M_V\N^+_\`XL#B_P#W.K_?3?W1_P"G M6;KZ%_U?_$;[Y_\`>8RGOFUL M?_):VC_GJB_ZN+UU0W__`)(.]_\`/)-_U;;K0&_DM?\`;S3XN_\`:[W]_P"^ MFW[[Z+>^?_3J^;/^:H>LMH9!8W5_MZZH@S&]C3OI_3(M)O*%B#R-7^ MP]]"ONWV4EK[:03.M!<7L\@^8!6*O[8CUS/^]-?QWGNM<01L";6PMXF^1(>: MG[)1UL=?"_8V3Z\_DG;;P.8@FIJ^N^)7<>\6@G5DE2D[`Q&_]\XK4C`,FO$[ MA@:QY%_>,7/.X1;E[[W5Q`P,:[S;1U'K"T,3?\:0]99^WVVS;5]W>TMIU(E; M8[J6A])UGF7_`(RXZUE/Y"W_`&\OZ>_\-+M[_P!]EN7WE5]X;_IUF]_\UK;_ M`*OIUA[]V7_I[^P_\T+K_M'DZW^??.CKI_U\_?\`GL;QQV[?YD_%_RLB,IL18=&_N^V4MG[7;&TJD M&>2>0?Z4RLJG\PH(^1KUR[^\I?Q7WN[S`L+`K!%;Q'_3+"C,/R+$'YBGEUL0 M_P"R^;V_Z!_O]#G\.J_[Z?[*W_?G^#^/_+O)_>/_`$S_`,+\5K_<_P`._9T_ M75Q]?>-7]9+#_@C?WWXH^A_>WA:O+X/IM7V:L]95_P!5MQ_X%[]P>$W[P_.3+7FR/NYC MVA8[6_'XI;?X;2[/F2M/IYFR21&QH.H9Y?/^M]SW>OU,*B@`,JK4CHQGS9^/\`TUWU\?NR*+MOK[;^\VVCL7>FZ=H92OIV M@W#M#<>)VWD:_'YO:NY*%Z7.;?R,%72QL7I9XQ*%T2!T)4AGD/F/?.7N8]K? M9MRD@\:XBCD4&J2(SJ"LB&J.I!.&!IQ%#GH6>XG*_+_,W*^[Q[[M<5P8+:62 M)F%'BD6-F5XY!1T8$#*L*\#48Z+Y_*9Z.ZIV%\.NC^U]L[,QM-VEW7UAM?>_ M:W9.0:ISF_-\[CSM(F2R%3G=V9F>NSE11?>2EX:,3+20?V(U))(D]XM_WC<. M=M_V>ZOF.TV%W)%;P"B11(ATJ$C4!`:<6IJ/F>@K['\M[)MG(/+F]V>WH-ZW M&SCFN;AJO--(XU,7EY\[C10B-&-2F(@J9#%)#-[7>VNV3;/ M97'/?TOB[KXPL]JB(J9K^44\4*>*6R-KJ>TR%14$=%_NKNT.]W]K[>"\\'9_ M`-]O$P-!#ML)U>"6'PO=NNB@[A$KG25;I4?R[>NL"+N+*)!:&62HIK*A1E"3W+W. M';DV_P!OMLNO&M-M=GNY02?J=QD_W(E).6$1_1C)R`K9-:]+?:G:9]S?Q< M5'FMD]B?,'YI;5W%CWTK(]!E.TLO#]S1S%7-)D\=/HJ*2=1KIZF*.5"&0'VM M]PMWOM@YOY*WK;)O#O[;9-LD0_-;=30CS4CM8<&4D'!Z0>VFR;=S)R1SWL.[ M0"3;KO?MVCD7^BURPJ#Y,IHRMQ5@",CHC.WM]]E_&O=]/VGO-\CG.]OY=LN- M^/?R]AI*>=LA\B_Y?6\ZU*WJ/Y$4-$IFJ,[G^KH?%7U#*SSQRTM>M7,@?Q^Q M_<[?M?--DVT6(6/E_F4->;<21ILMXB%+BS)X(D^4'`$-&44TKU&]KN6\3F7E0K8[H`#JO\`9)36UO@,EWMQ1VXD%91(PK3K8QGIMD=I[)2.LH]M M[^Z]WWM^EJA39"CQ^XMK;KVSG*.&MI)):2LBJL;EL3DZ&=)$#H\,J MM?[1?DH\MMN5O(14$I)&Z$@Y%&5E((Q0@]98,FW;UMP$D<-UM5S$#1@LD^=^:KOV[]OWE MWB02[G#=F[9`L;W/T]QX,7C.@5G"QC2031N+`G/6/7MWR!R?9^YWN5'%LD;0 M[3/9BR1RTB6OU-MX\W@(Y98RTI+`@57@A48ZL@^:7R/E^,O1^4W9MW%#=7;. M\LQB.K>AM@QZ7J]^]S[ZF?%;)P,,!>,S4=-5EZ^O]2:RXI7J6_<+FT\G/'TM/&>4]TYWYG/-G,%SN,4/@[9&J MPVL/E#;1#3#&!Y47N:G%V8^?3G('*8Y-Y:M=KFG\?=I&:>[G/Q3WPCT-.O>_=>Z][]U[HA?\QRD^:]3\;LO)\$,IB:#N"CS%-59 M>EJ:7!S[DS&QQC,K#FH]VK734D\+5`#O##*D#"H:(-(?MB_(B< MT0CW"B=ME9"%(+A%EU*5:41]YCH&!I@$@L-(-(R]V4]PWY1G/MI,B[\L@+`A M#(T.E@ZPF3L$M2I&K)`(4ZB*_.W[#ZR[>ZVV\ MWMO*C(05#2FIC&9I*62H;SQEUE0NKVU`D<^^EFV[KLN]VBS;1N-O=63+2L3J MZT(X=I-,8H>'#KE/NNS[[L%ZT.];9/>!7.:BM>/6W1TG_P MI'^.%3U[M^#OCJSN+`]E8_"4-+N2786)VGNG:N,TD\03;G""4-=%O! M44+ZI*%WI4*S!`H)(4M1A$ONI]X#>/ MXM!6@WWOVFB>6'"S817,V,Q;L:V.MT5%2M.U.D4H(][/?#;=SVV[Y.Y-NO&A MF&FXN5^`IYQ0GBP;@\@[2M54L&)`^]@_N_[IM6ZV?/'/-IX$\!U6MJU"XD_# M-,!4(4XQQGO#T9PI4*RN_GU_._J3.]5]A?!G;^W^Q,GW!C][=0DI,W55*U>/;W>;?=]MY_N; MFV396@F5%\2LK,28LJ!1`"&/Y>QW.R;K[;VMK=OORW$#2-X9 M6%54"7#DU[JVWV.:#NY>L*';F;V=M. MHW,,;E]J9#=M*]'EL3!/!EG@R,>\5:)Z.&JE#4Y3Q$NON3_?KV^W?GRQV*YV M*ZM?$L/'+K)($U+((S56(*U7P\ABH[JUP>HD^[G[E;+[=;AS#:\PVEWX6X_3 MB-XHC)I:-I11E!#4;Q<%0Q[:4R.MZ%6#*K"]F`87!4V(N+JP#`V_!Y]X`'!I MUTD!J`1UIG?SYOG5U)\ETVA\=NKL!V/4[IZ*[?WN-^YO<&TYL#@!D,115&TG MH,"*FHDR^3$M>LS^:2EIHO%$K)K$@*YP?=Z]O]YY5-[S-NUS:BTW"RB\%4D# MO1B)*O0:5Q04#,:DUI3KG]]YGW)V/G`6'*FS6MV;W;;^;QG>(HFI08M*5.IJ MM4U*J*`$5KA;_P`@WYU]3=&;>K_B1V'M[L>EW]W/WS19+86;P^U)LUM:HJ-U M[>VMM*#'9VHI:AX!CB(I4J?'!DZ>58I9$>. MGFA&W-GM_MGN]R-RCN27<=KOWT43PRD5#:XE9X7`[BFK(*U*,"0""RL`>3?< MG=?9/W!YUVM[*2[Y=^OFCGA!HR^'*RI/&350^G!#4612%)!"LMI'R\_X4!?% M7?\`\9.TNO\`IK97:N>[%[5Z^W3U_38_>VV<)M_;VUH=Y8*NV_DLOGJ^EW-F M#D'QE'D'D@IJ-)UJ9E57DB0LPB7DS[N7-^W_O1R[M>VLD`6:-$2,2H49G8 M2/JTAB0J@ZC0$J,]`+_PGU^!/;&+[7J?F=V9M?+;+V+A]G9S;?4U/N"AJ,7E M=[YG=<46.R>Z,;05<<55_=/%;?\`N8(ZID6*MJ*M?`SK#*0(OO'^XFSS;.G( MVU7:3[@\Z/<%"&6)8\K&Q&/$9])*UJH7N`+#H,_=;]L=\AWM_<'>+*2WVV.W M>.V#@JTSRT5I%4Y\)4U*&I1V;M)"MT&W_"E7J[=>.^2O2O<;XJO?8^Z>FJ7K M^GSJ4TCXRGW5L_>&[\Y6X:HJT4Q4]=/B-VT\\,;+?1(`] M.T212RN4)X`E958`\16E=)H)?PP_GCXGJ+XK]`_%_KKXO=E=R?(':..INOL; M@<-E*&BVSN2&/+U+XVMQ55C*/?8*;>N M;N8N;-SYLM;'ER9C,SLI+H=(U!@Q2,*&&&\2I%.VO1Q[??>/@V+DKE?DW:N3 M+S<.:($$"HC`1R#4=)4J))"Q4Y7PZ`@]U.@P_FW?RE.X-I]@YKY??&S8&>S. MQNQ)T[`[+ZSVG&IS6TJG,22U1J,>LC8VI:4%$I5 MAD!M[->\>RWFVP3MBN85[4#,V%D"T6CTUK3)?4.B;WS]C M=^L=TN.?.4=KEDVV[/CW%O%W2VD[=TA54R\1:K:DKX;:L!`IZ-U\0_\`A1/U M=0=:X39?S&V=V'C.T=I8VGPF2W[LC"X_<6)WO+BX5I?XOFL-4Y7"Y7;>YZSQ M?Y9#''4TLE3KD5H%<0Q@SG/[M&[2;I/?>V7M'MOM8T_./.N]6HW*.-E0ZM, M,"L*.VN0*7D9:J**`%+`!BU1'7NQ[U;I[OK;\C\A;%>':I)59QHU7%PRFJ*8 MXRX2)6HYJS$L%+%`M#0^"77VZ^YN[X*-OD!V-@4I]ONK'[@[E9['L+ M-_5RUDJK-V^/,>WQ"#32B@E8]5#1F9J5`6?_`&"]GI?;3:[[F#F-5_K1=Q49 M5[_IX!W^$"M=4CL`TFFHJJ(M:$MK\?SH_G%UA\Z^U.HZ[I+;?8<6W>JMI[GP M63RV\MKOMZIRN9S^=I*J6/'8I:NOK(Z&AIL3'ZZD03-)*RF)=%VR/]C.0=V] MO]HWF/?KJV-S>31NJQ2:PJHA'$]Q]F]RMZV*3EVTNQ M:64$B,TL>@L[N#VK5C0!1EM)J2*"G5QG\B#YW]1U?3'47P5K\!V+B>Z,'+VC MDJ2NFVM)4[%R^*?-[E[#:J&XZ2IEDP\T.+K'@9*VG@B>IB"1RLTT:F$OO!^W MN\IOF]>X$=Q;/L4@@4@24E5M*0TT$=U6`/:Q.DU(`4GJ??NT^Y>Q/R_L7MM+ M:W:Q\-N>LVC3;4Q]#!M>"IP*TE.(-R[ER%9$:#[BKR M$5XZ6FK*A8`SE!Z`\J>VGM9N7N-)>26NZVMK:6KQB0R$F0AZFJ(!F@!RS**T M%>-(?]U?=_:_:Z*QBO-FN[N]NXY#$(E`C!2@I)(Q&FI8857:E33A73M_E@?- MRF^"/R&2H@O%,6$ET"MFO[K\AO[@\J6NQ6&Z0P7<%S'*C2$E#H1XRK::D5#D M@@'(I3-1@1[-^XJ>VG.-WS#N6T3W%G]R[4QFX\-MSL?;./W3A\5N[%'";DH*/(H6CI\MC?-4QT]2 MA4\QRRPRI9XW>-E8\Z]_V:YY=WGA4]E'1WT6#Y?\` MRKV3\,^DLUWGO_;.^=V[?P^5PV%;#=?8:#,YR:NSM2U+1RS"MKL9CL;C(Y%/ MEJ:B>.-"50:I)(T85\E\H7_/&_0?.=MN]O\`EVXYDW2SN9[6-T31`@=R7-!6I557U9F`&!DD`_/6^\_RW M^5?<7R&Q.QL[M#$]C9W&5>)V]D%>NR-!B\%MO"[7QYR-330+3-7UE+A$GF2+ M5'%)*45G50[=)>0>7EY-Y0V3EJ;<(YIK6-@SC"EG=I#I!-:`M05R0*D"M.N6 M'N/S*W//.V_\U0;;+!!=RJ51LLJI&D:ZB!340@8@8!-`2!7K9?\`Y)W\S78] M;L'X_?`/<7579>-[%P]+O3#8/?.*QE)E-B9"AAR&Z-^P5>>8U=+F]NNE!424 MKO\`;5-.9XT8R(LI$>+'OO[5;A'N/,?N+;;O:MMCF)GB9BLH-(X2$P5?(#`: ME-"10TSE_P#=W]X=MDVSE;VPN]DO$W:-9D295#0LH:28%\AX^TE2=++4`U`; M&S3[Q6ZS"Z^?M_-'^#68ZF_F09#IKJS%05&-^2NYMN;UZAP5"8[4<_:^Y:G# MU6W6I:=I'Q]#A]]PU\-.I4*F.6%OH#;HW[2\_P`&\>V$>^;O,1+M43Q7+GS% MN@8/4\2T10GU?4.N77O/[;S['[MR\O[+`#%N\TMZ?X^=,[:^/'2'5G2&T8T7`=8[)P6TZ6=8Q&^2J<;1QKE38+M0EPJY9:$E)5'FT9)J/Q(S`=VFD;>]WM6ON?RS'!9.D?,=D MS26SMA6U`!X7/DL@"T;\+JA/;JKJZ?!SYM_(W^3MV[O;J7OGIG>`Z]W?7T]9 MOGJ_.Q';^?QVA"P3F*63'Y:FCATU"&**499\_]FS6&\\O;Y!^\H5(BG3O1D;)AF44=:'(J`\;%NTU(ZPR]N/<7FSV#WW<=C MYFY?G_=4[`S6[C0ZNO:)H'-4:HP:$I*H6CC2K=7@[K_X4?\`P^I=M+4]?=5] M^;UWQ6QK%C-GY'`;4VS2-DI;)3T>0S\&Z]Q/$DL[!0U)15SF_"7L/<"6?W8> M=7NBNY;OMT%@I[I%>20Z?,JAC3R_B9!\^LC;W[VO(268?:]EW.XW%A18F2*, M:CP#.)9*5..U'/RZ9_B-N/YY=C=I;Z_F:_.'.=B]%?'#JGKC>V9Z_P#C-MR# M-O61UN5IQE,IE$@EA6"BB0![G.V]O=LVC; M_:KD&WMMPYGO+J)9KYRG8X<4`G^%2S=I6,^''&6#%I">D_(MW[F;MO6Y>\/N M/V\I65I,\&WQB0:XRAJ3;CN8*O<'D7Q))`I4+&HZUU_YJWR?V;\U?ESG> MZ>IMM;XQ^R#LK9NT<:V[L(F,S.0FV]25/WN0?'4-7DXJ*EEJ:UDB5IFD9(]; M!"VAGVO50;0I\+LN;(X/=%)55=%4+D*N2&:&GJ5 MI:HQR/IC<0R,,/\`WJ]O=ZY;W_=^:+JXMI-HW'<)6B*25D!D+2A7C(!%!4%E MU+4#(U`=9N>PON9L/-/+FR\HV=M=1;UMFV1+*)(Z1D1!(BR2`D'4:$*VEJ$T M!TD]%*_X4E[;SM!TU\6NZ]N5^3Q.6ZQ[KR^'H,OBZF>DJMT:"52'20W!O[&/W7KJWDWOFW8KJ-'AN[!6*L`0RQN492#Q!6< MU'`CH#?>XM+F+8.2^8;25TGL]Q959205:6,2*P(X,K0#21D'IG^,7_"BSJ6/ M8.$VU\P>O>QMI]K8/$45+F-U[&V[C\WMC>3N,]UR5N5K-L\CDK'*Y62*I^#4%99%7@&)5J"A! M(J4_)OWK]C&UVUGS[M5W!O<<8#RPQJ\LD@I:2%+R&5V3W-G(6R;?[(\A7/];=\A5WG>>0@G3K*(@BA!`:1J(. M"@LQ.-(KU`?N-O\`N?O][C6G]2^7YVC2W2WB#*->A7=S-.REDB75(?B1[P-YOY@?FKF??.86BT?5W+R!>)52:(I/F50*"?,BO71; MDGEM.4.4N7^64E\0V5JD;-P#.!5V`\@SEB!Y`TZ,![#G0HZH/_X42=-/O_X/ MXCLRAI'FR71O:6W,_5SQQEWAVKO..?9&80V4LD3YW*8B1SP`(;GWD1]VG?!M MW/LVU2/2+<+1T`]9(J2K_P`860?GUC']ZSE\[I[^+]?E*Q,/@-U)F\+28#(&M:3-0 M]:=B+CZ^@QC2UUWO=SK[9[?#;R[:]_R:SG0DFM`C5[Q;SZ6 M5H8MK5$VS/C'V16[U>D<4N/W/N_;&+VM!7-':- MJC,8J'+Y:KI(93MVO;7P-Z>V[ M\&/]D/5:BIZXJ>L\#[KW"WNYY_P#]<(D#&"MBB<256+R--#]U3G0T; MYRW4W*7OOR'<6-CN(220*],&:UG7(UQU!(!)4D461&;0V:CGS9P\Z?=V]Q;; M<-PVQGCC9TU9$%Y;OAO#DH0"0`X!JT/R^*W#N?(9>K9W*TT4&,+U#6#"*]Q MCF/NQ\TV\ES+NO,FV6^U1*6,VJ0X'FRLD84?Q$O0?/K*%OO91F/\($=6/IUK>?S>JB2L_F.?)^LEI9Z"6LW+M"LEH*O MQBKQ\M7UELBHEH*L0R30_=T3R&*70[IY$.DD6/O)[V74)[8\J(KAE6*0`C@: M3RBHK0T/$5%:=8D^^[F3W9YRD9"K--$2IXJ3;PG2:5%1P-"14=;^.>Z]H>V_ MC7E^J\G/]KC^R>D:S8=95B/RFDI]V[%DP,M6L9($C4J5_D`OR5]\ZK?):R6M^)0/4QRZZ?G2G73VYVJ/?>4)]DF;3%>;<82>-!+#H)_+57KY^_6 M^;^1/\I7YL[>W9O?KFKHM[]59O-X[([;SBU>/V[V-L[+T%=M_+R["O MPF>P]>9J#)4R5"0S^)VC9HWB]]&]T@Y:]X^1+FSL-S5K"\C5E=*,\,JD.NM* M@AD84=&()%0#0@]SJSOG?V+GV[A\E/D:;=(V=69B!Z! M\]AL/MC%SU&7J\69S)3U%:^/HZ>11-4!HD:-L>]O^[GM_+5Y'O7/'.-HO+UN MX=E`,?B!370S2,`H:E"%#LP[5H2",E]R^]!N?-5C)L/M_P`CWCQB'<]N=87;``FB(0L/B`[A44U#(I44ZQ,V=;WD3G_`&R?>[&5I]JW2-IT M3N8F"8&15;X6/:=)KI8T-:&O6[1O#^H#:R":@5*,!I+_$CMNDZ$^7'2W?VZMK; MGR6UNO\`M7$[SSV+PE")LU)AXJ^22N3&1UC4='4U]/2U#/'')+"DKH%+H&U# M.[G+9GYBY,WWERSNXEN[FS:)&8T753&JE2`2,D`D`UH>'7.WD;?4Y8YZY>YH MO;*9[*UO5E=4%7T:N[36@+`&H!(!(I45KUN7?*GYT]Z=M_!G'=^?R]NBLQW+ MM_L.7?>R][T^\=J9Z+?6Q]O08[(X*JW!A.N<7D(*_=/PS^3O5W=AVI6/N/J7=J93)[.S\-9@*W(XRII*W![DP51]W2FJQ55D<% MDJJG25X7,$KARC:=)SGYJV*QYXY4W;8OK%^EO(=*RH0X5@0Z.*&C!752145& M*BM>N>W)_,-_[?\`..S_ M_"E/XNT>P:C(]>=,=U9[LJ;'R?P_:^ZZ79^W-JT>6:`^/^+[IQFZMP5\N-AJ M2+FFQSRRH+6C)N,0[#[KG-C[BL6Y;Y81[6&S)&9'D*U_#&T:#41_$X`/KUFQ MN/WN^3(]K:7:N7]QEWTNP\MCJO;L.]HIZQ:UMC=5T=6J5%?35%+''CXJJ MGUT.(H4%Y7FCB@EFGGCW'Y5]I>58>5^7)XY=\AMQ#!"K!S%04\6X(P"#5RIH M\CG@%)80-[?^UW.'O/SA/S=S1;RP\OSW)FN9V4H)JFO@VP.6!%$#+5(D'Q%@ MJMLK?S7>P?EGTW\8EVO\/>@,7V;M7=.TMX=:]CRXG%Y?/[AZOV97[8@P.%K- MG[!V]/2U>2@&.J:Q#4A*NGQIIH?)3LDFI,6_9_;>3M\YK-WSKS&]I>0S1SP: MF5$GE$A=A),X(4Z@ITU4OJ:C`BAR\][MTYYV#DX6?(7*Z7EE-!+;SE59WMXF MC"(8H$(+#27&JC+'I6J$&HTG/AI\CMR_![Y5]:]Z2[3K2TD820M5& M:-T:.1;,0IS1J4.9.\?>ZY0CVN1]AV"_EWED.E)ECCB M5J8+NDKLR@YHJ@L,56M153_+V_EI_('^87\AY_DW\FL'N#!])YC?59V;V#NK M=>.J<-7=SYG(Y>7.U.U=DXVJC@J:C`9FMD\59D(E2AHZ#7%3R-.(XUE[W)]T MN7/;;EI>5>5;B.3?DMQ!#'&P86RJN@22L*@.HRJ'O9Z%AIJ>H4]K/:'FGW4Y MJ;G'G"VECY=DN3<3R2*4-V[,7,<*FA*.<.XHBI55):@&\S]G1_9_P_[2F^P^ MV^S^Q\$7V?V?B\'VGVVGP_;>'T>/3IT\6M[P"UOK\36?$K6MND M/AQ^'X6@>%2E*"E*4I3A2F*<*=?_U]_CW[KW15?F3\=IODITEE=I[=RXVIVO MM#+8CL_HC?Z!5J]@]S[%G;+;'W!#,4E,=%45JM09`:7\F-K*A-))'L7\DH'>G"CJIKT"N?^5&YNY=GL;2?P-[@=;BS MF\X;N$ZH7!]">Q^-8W84Z"_K;Y&0_)WX-=D;_P`AB/[J=AX7K;MOK[NGK^8E M:_KGN79&V,QAM_[/K87=YH4I,M$:BC+DO+CZFGE/Z_9MNG++FR?C3_*2Z![P["J6AVQU]\8]D9B>DA=%K\YD MVP]+1X';&(5P5ES>Y\Y4T]!1H19JBH2]EN0;\XQG*_,>ZO2SM=FA<@?$[:`$C7U>1RJ*/X MF'ET0/K[I/?W??8.-^-79^N7M#Y%9O;7S3_F@9>D>5/[H=9P5<4-YSO.[21[MS"PK^E;@UL-I!\@0%#) M4,$1V!*MUL>DX[#8XLQHL5B<51$LQ,%#CL;CJ&"Y))\5-1T5'31?[3''&OX` M]XQ?JSR_B>9V^99F)_:23^9/66GZ5O%4Z4@1?D%50/R```^P#JK?^4KN_:6Z M.H?D0FV=T;=W$\'S8^4V5F7!9K&Y9HL7N+LW)Y/;^2D6@J9RF/SN-85%',;1 MU,!UQEEY]RS[QV5Y:;SRR;JTEB!V&P4:U9>Y(%5UR!E&PPXJ<&AZACV-O[&] MV'FH6=[%*1S%N+'0ZM19+AF1NTGM=>Y#P89%1U+_`)B'75=U_7[*^=>Q]K_W MJR?1V%S.Q_DAL.GHXZP]R?#K>;^/M+;%?0R?LY6LZ]$K;CQL+.UY_2T\'<'F-IND-*&#<811G*CX5N5&L>0<,"2QZ2>U M6[1['?7GMQ)>>-ML<"WNT3DU%QMDQJJ!C\3VK-X9\S&4(4*.EO\`$C_LO[^: ME_X>?Q*_^![@]H.M*C`P5]%B/%_=K! M52&6GDCCJ9XBDH;VKW\?U#Y(M.44[>9MX6.ZOS^**W'=:VA\P6_MY5-""54U M%.D?+9_UQ>?KWG63NY4V-I+3;A^&:Y/;>7@\F"T^GA854@.PHU>K7O]^Z]U[W[KW3/F]O8#,HLM0R`BQUT ME?!40/#QU"CCC\@^RF_W?=MT(;<]TN+EAYRR/)_Q]CT=; M=LFS;0"NT[1:VJGB(HDC_P".*O2]]EW1GU$GQ]!5.)*FBI*B0*$$D]-#*X0$ MD*&D1FT@L3;Z<^[K)(@HLC`?(GIMHHG-7C4GY@'K&F*Q<;K)'C:".1&#HZ4= M.CHZFZLK+&&5E(N".1[V9I2"#*U/M/6A!"""(5!'R'4_VWT[U!EQF-GD:6;' MT,TKD%Y):2"21R`%!9WC+,0H`Y/T'MP2RJ`%D8#[3TVT,+$LT2EOF!UW#C<= M3R++!044$JWTRPTL$W-I-S/N#VQ%"C7$Q M4CT(+T(^713#R3R;;W(O(.4ML2[!J'6UA#`^H8)4'Y\>A[``````````L`!P M``.``/8=Z$_#I.;LV;M#?N$JMM;YVKMO>>W*THU9M_=>#QFXL)5F(ZHS4XK+ MTM90SF-C=2T9L?I[56=]>[=.EUM]W+!=+P>-V1A]C*01^WI)?6%AN=N]GN5E M#<6C<4E19$-/56!4_F.D=U_T3TCU-/4575O3_5_7%75H8JJKV+L+:VU*NIB8 MW,514X+%4,\\9/\`99B/\/:W8;VWA'X8YY47] MBL!_+H/;ARCRKN\IGW7EJPN9SQ:6WB=C_MF0G^?2OV/U=UGUC22X_K;KO8W7 MU#/I\]'LG:6`VK2SZ0H4S08*@H(I2`HY8$\>T5_NVZ[JXDW3<[BYD'`RR/(1 M]A&%V2X;26C125N`;?2X]Z:21Q1W)'S)/5EBC0U2-0?D`.I?NG5^O>_=> MZP3TU-5((ZJG@J45M:I/%',BN`5#!9%8!@K$7^MC[LKLAJC$'Y8ZJR(XHZ`C MYBO47^#XC_G5X[_SAIO^O7N_CS?[^;]IZI]/!_OE/V#_`#=.```````%@!P` M!]`!^`/;73O7?OW7NN$D<.15='4_561@593_`$/O8)4@@T/6 MB`P(85!Z@_P?$?\`.KQW_G#3?]>O;GCS?[^;]IZ;^G@_WRG[!_FZS04%#2N9 M*:BI*:0J4+P4\,+E"0Q0M&BL5+*#;Z7'NK22.*.Y(^9)ZLL4:&J1J#\@!T'W MJ]^=Q]DY9,+LCKO;F0W+N"N;2TQIJ*/]B@H(6=/N\MEJUXJ2CIU. MNHJIXXU]3CV9;'LVX+,0!D]:KW\IFAWK_,4_F5]T?/[MRA=\ M'U3$]7LW$S:ZG%;>W%N>FKMM=:[2QK2Z89H-C;$HZZ=W10YR(@JG`DF+'+CW MBDL?;/VMV+VYV:3_`!B\-)6&&=(R'GD;S!EE*@`XT:D&%ZPL]CH]Q]U_=[F' MW0WV.MM9"L2G*I)(#';Q+7!$,(=B1G7I5U_WEF(_ET6[=RCRKM$PN-JY:L+:X'!XK>*-O\`>E0'^?0TD`@@ MBX/!!^A']#[(NA#TW?P?$?\`.KQW_G#3?]>O;OCS?[^;]IZ:^G@_WRG[!_FZ MDT]'24FO[6EIZ;R:=?V\$4.O3?3K\:KJTZC:_P!+^Z,[O36Y/VFO5EC1*Z$` MKZ"G2>WAL;9786(&W]_;0VQO?`K74.3&$W=@<5N/$C)8R<5..KQCLQ2UE']Y M0U"AX9=&N-N5(/M39;A?[;-]3MU[+;W&DKJC=D;2PHPU*0:$8(K0]);_`&W; MMU@^EW.PAN;;4&T2HLBZE-5;2X(JIR#2H\NDIOWHOI/M1X)>S>G^K^PYJ:-8 M::?>^P=J[JGIH4TZ(J:?.8JNFIXUT"RHP%A[6;=S!OVT!AM6]7=LI-2(II(P M3\PC"OY](MSY:Y=WHJ=XV&RNV44!FACD('H"ZDC\NG_8_6W7?6.+?"=;;"V9 MU_AI'623$[)VOA-JXV25%*K++18.AH::255-M3*6_P`?:>_W3<]UE$^Z;C/< MSC\4LC2-^UR3TIVW:-JV>$VVT;9;VMN?PPQI&O[$`'2U]H.C'KWOW7NDUO+9 MFTNP]K9W9&^]MX3>&S]SXZ?$;BVSN/&TF7P>:QE2NF>BR.-KHIJ6J@>P-F4V M8`BQ`/M58WUYMMW;W^WW4D%[$P9)$8JZL.!5A0@](]PV^QW6RN=NW.TCGL)D M*R1R*&1U/$,IJ"/MZ;,/UEUS@-C8SK'"[#VAC.N,-C(<+BMB4FW,3%M&@Q,` M(BQ]/M\4G\+2E7424\5F9B3(6/F7KJK\Z M],P;/M-KML.S6^V0)M,:!%A$:B)5'X0E--/E3H*1\._B2N0&5'Q?^/0R0?R" MM'3/70J!):WD$@VY?R6_M?6_/U]G']=>%Z?4S4_P"/]$O]0N1A M+XW]3=J\7U^D@K_U;Z'W$X?$X''TV)P6+QV%Q5%&(J/&8FBIL=CZ2(?2.FHJ M.*&F@C']%4#V'9IIKB1IKB5I)FXLQ+$_:34GH3P6\%K$D%M"D<"B@50%4#Y` M4`_+IQ]M=.])[=&T=J;XP]1M[>FV-O;OP%65-5@]T87&Y_#U)2^DU&,RU-5T M4Q74;:D-K^U-I>WEA.MS8WDM[8V.XP-:[A9Q3VK<4D M174_:K`@_LZ0&P_CUT)U;DI,SUGTEU+U[F)5D23+;*ZZVCM?*/',H66-LAA< M1159BD46*Z])'X]F.X/74_:O^29MW_-"/\`XX.I6YMG;0WI1+C=X[5VWNS'(Q=* M#HE=K:F6ERE+50*S:1+^&1%4WO>2'$ MTE)&YO\`U!][N]PO[]@]]>S3./.1V<_M8GJMGMNW;(P(P)(*0E/&INQ^@_/O7B2!BX5!3]G6#^#XC_G5X[_`,X:;_KU[MX\W^_F_:>J_3P?[Y3]@_S= M3HXXX8UBAC2*)`%2.-%2-%'T544!5`_H/;9)8DDU/3@`4!5``'2%WCU7UAV( MBQ]@]<;"WU&H`5-X[/V]N=%`&D!5S>.KE`"BW^M[,+'=]VVPUVW=+BW/_"I' MC_XZPZ+;_9=FW44W3:;6Y'_#8DD_X^IZ#C"?$GXK;:R4>8V]\:^A,)EH9%F@ MR>*ZAV!05\$R/Y$EIZNFV_'/!(LG(9&!!]F<_.7-UU$8+GFG<9(2*%6N9B#] MH+T/13;\C;RZBZG[&(/876'7F M^R``#O+96V]T$`*%`'\;QM=8!18?X>S*QWK>-L_Y)N[7-O\`\TI7C_XZPZ*M MPV+8]V_Y*NS6ES_S5ACD_P"/J>D)MWXH_%W:&2BS&U?CAT3MS+P2)-!E,)U+ ML+&9&GE0L4DIZVCP,53`ZEC8HRGV8W/.'-E[$8+OF?<)82,JUQ,RG[07(/Y] M%EIR1R983+<67*6V13@U#);0JP/R(0$?ET/JJ%`50%50%55``4`6``'``'L. M<QJ5T'N<.3)4 MYSV';]BG->8]AN4N;0_BELC*K75O7S,)_P`8C&3I\15``/6/W/<,G(G,>Y9N;8[)UCYKYFW&Y@AD/_$3;(W/UEVQKV^)I9%)H=", M5:IIU$^S.S?A'M&NVOOJDSWR1_F1?)W/U/=7L^L.I\!)2XBGGRE5%34]/!-4TT4B2,ON.=[V"^Y\O8[O;WCVOVOVF,6 MMM=71\.'PD)U2**!IY[A]4A$:EB2JL017J3]@YDV_P!NK"2RW))=W]V]YE-W M=6EH/%G\:0#3&Y!*V]O;)IB5I&"JH9T4@D="9!\/_DE\RJJGW+_,&WY%L[JJ M26"NQ/PDZ'W)DJ#9)C1R\-/WKVG02T6?[1K]&GST%`]+B(YT#PN5+)[*FYUY M7Y(1K7VWV\S[N`0VZ7:*9?F;2W-4@'H[ZI"#1AY]'"\A\W>X#I>>Z6YBWV0D M%=HLI&6'Y"\N5H]PWJB%8@153Q'0E=I?RR^D,G6X7?WQHJ\A\,>]-G86GPNT M.T.@:+'[>QU1C:"&&"AP/8W74<<&SNR]LB.!$F@KX5J944*:C2-)*]I]U-^B MCGV[FI%WSE^=RTD%V2[!B:EX9LR0/DT*'2#^&N>CC>O9[ER:2WW/E!WY?YDM MXPD5Q9!8U*J``D\&(KB/`!5QJ(QKICH/:+YH=Q?&>:'KK^91U?C<3L[(N3QR14Z:B9/R M-LG-2MN?M=NSO>KWMMMPRQWD=,DV[U"7*KY:2)``*@L:=%4?N#O_`">R[5[N M[,B6#]B[I;*TEC*&[0+F.A>U=A\6L&(DFA517JOO<77>XNKF+RL.VW.VW>W.\\PP-#8;HJ;7OT3+H:WO%'^)[D4(!0L0&9B`JNL@ MRQZBV[VFZV6Y78^6;A9MRVAGW?EV56#K=6+G_'MK$@)#A02J*"6:-HF[5'25 MP?RFR_>O<'S$VK\4LK+2=E?S%-W_`!)VEUWFRROD^J.O8?C!19+OWL;-T]+, MLU+6=38&HFQK%'CD3-3Q>(L\>DK+CE&'E_9>2;SF^(':^68=QDF7\-Q,;\K: M0H2*$7#@/D$>$#7!KTBMN=)^9=^Y^LN29RN[\US[9%`_XK:`;<&O9W`-0;9" M8\$$2E=-2*=;(?3'4>R>A>J=@]-=21O4Q]XP;YO-_S%O&X[YN=%&68^;,:LY_$Q).3T)OLJZ..O>_ M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_= M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW MOW7NM?\`_G5?'S^8/\O8MC]%_&[J^AR_0F+@I-Z[WSY['V-MNMWGOM:FOIL5 MM^NQ&X=P8BO3![.HHEJX[H\-76UJN?521$9&>Q7,GMOR6;_F#FC=F3F)R8HD M\&5Q%%0%G#(C#7(>T\"JJ1P<]8O?>&Y6]T^>UVWEOE'9EDY80":9_'AC,LU6 M"H5=U;1$.X8(9W!XQCH\'\JKX;93X1_$/:76.\:+&TO:NY,QF>P.UFQE539& MGCW5G)(J2BQ$>4I"]/71[=VQC:"B9XGD@:HBE>)F1PQ`7N]SO%SYSI>[K92, M=HB18;?4"I\-,EM)R-]^Z]U[W[KW7O?NO=>]^Z]U[W M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO= M>]^Z]T"7R+W!WKM?IW>&<^->PMJ]F]ST,.-.SME[USXVUMS+239>@@RIKLJU M7CD1Z'"R5%1%$U52K/+$L9E35?V?Q>^>POC_LZDWAV5G1G,Q1[=[/ZLH,'0F&AH\70T&, MI:K?U=5)24.-Q\,2F:>:9]&IW9R2#V2ZW$=Q;*@H`H509F- M`J@9))I4DGK:D^`FY?GEEME9O;_S@ZZL;AYZ4T=&Z/%4P)/)42JE-&D8)Q%]Q;7V]AOX+GD'>[J[B MG:1IEFC*B(E@4",R1LP-6!!4D!15B3UFK[87GN9/MUQ:^XVP6=E+;I$D+P2* MYF`4ARZ+)(JD40@A@"6("`#JP#W'/4H=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U__T=_CW[KW7O?N MO=%E^9=%T-D?BWW?C_D[EZ+;_15?L3*478.>K::MK&PF/JFA@QN7Q5)C*/(9 M6JW'CKY]O;2^._9&5V#O/'[8IY(MD1UYRHV[>IH^:N?;C MGWE&\;FF>V0F(/9-!;;:"H0!Y+R!9HBY!NBI\/!\72ID'6'^Y[#!)R?[X>#J81'H[7P+J/DC3[*W M'3_"'`_RK*VG@S57#V365F_OE\_=U9NB*IDCKZKN=^P.J,1VLVX:G(+*Y_C- M)3)Y&?P1(GI`"]PUY7:_M6Y]N.;E8Q@P`0[=]*(Z8%MX-PUOH`H/TV8TIJ). M>I$]LFYM3;KM/;FVY*91(1<$S;I]89`>XW?CVR7.LM4_JJHK72H&.C[_`'W\ MX;_GE_Y:G_H=_*+_`.US[CSP_93_`)2^:?\`G%8?];NI.\3WZ_Y0^4/^\3WZ_Y0^4 M/^?S_M>.^KB_M^UC]GOJ8/H;OFWZS6-&B*RUZJ]NG3-JU5X4 MS7ATGO)/>_Z2Y_>%GR9]#H/B>)-?^'HIW:]4&G33CJQ3CU0IMOK_`+'W;W?T M_G_BIW-\-^J,SBOD12R]>[+Z=K_FSNOXY[J[AHZ#(U.ZZ3JMMP?&++[+P^/R MNSXZBGW=+M7/+MY<*X.12&/[>1,A[K<=LL]AWNWYOV/>[R!]L/C2W(VN.]CM MB5$9N-%\LK,LE&MQ<0^-XH_2+'4#C):;7NU]S'L-UR3S!L%C<)NH\"*U;=Y+ M"2Z"L9!;:]O:)%:+4MT;:;P/"/ZH4:2+=_Y?FT_Y>N&^<'R_W)\?.TML[M^0 MN[Y9JK=?6V(V_NRDP?4-)C\M1TW;^)ZUW;N#;&WL'OC;F>[7<5,U3BM44%.M M)&B)"`7ACW'O/XM'A5T``+QN[ M]P-UD7U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO= M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[ MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=> M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>] G^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=?_9 ` end